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The Alternative Lengthening of Telomeres (ALT) mechanism of telomere 
maintenance is utilized in 10 to 15% of human tumors. ALT positive cancer 
cells have distinct morphological hallmarks such as heterogeneous telomere 
length, ALT-associated promyelocytic bodies (APBs) and extrachromosomal 
telomeric DNA. It is currently unknown how ALT is activated. The 
mechanisms through which ALT maintains and elongates telomere length are 
also unclear. 
As the Small Ubiquitin-like modifier (SUMO) protein modification of the 
promyelocytic leukemia (PML) protein is required for the formation of PML 
nuclear bodies, the SUMO pathway, particularly with regard to the formation 
of APBs, was investigated in an ALT context. While p53, an important tumor 
suppressor and a pro-apoptotic factor, is also modifiable by SUMO, such 
modification has not been investigated in an ALT context. Thus SUMO-
modification of p53 in ALT cells was also investigated. 
Western blot analysis was used to show that p53 was ubiquitinated in a 
telomerase-positive human breast cancer cell line MCF7 while SUMOylated in 
an ALT cell line JFCF-6/T.1R. Results from the cell cycle and western blot 
analyses indicated that the tumor suppressive functions of p53, both 
endogenous and exogenous, were highly regulated by SUMOylation in human 
cancer cells. In addition, the use of arsenite as a source of oxidative stress 
inducer showed that under conditions of stress, the de-SUMOylation of p53 
led to its transcriptional activation. Thus cellular conditions appeared to be 
critical in the SUMO regulation of the activities of p53. 
  xxiv
Through the use of a PML coiled coil domain deficient (PML C/C-) mutant 
which cannot be SUMOylated, our immunofluorescence data suggests that 
the coiled-coil domain is critical for the formation of APBs in ALT cells. The 
stable over-expression of PML led to a slight increase in telomere length while 
that of PML C/C- resulted in a moderate reduction in telomere length in ALT 
cells as observed from southern blot analysis. 
Wild-type PML and PML C/C- were also stably over-expressed in non-ALT 
MCF7 cells. We demonstrate for the first time that APBs were detected in 
MCF7 cells when PML was over-expressed stably. We also report the novel 
observation that the stable over-expression of wild-type PML and PML C/C- in 
MCF7 cells led to an ALT-like heterogeneous telomere phenotype. Our data 
suggests a possible switch in the telomere maintenance mechanism in MCF7 
cells stably transfected with PML as the telomerase activity measured by the 
TRAP assay dropped drastically. This underscores a novel role for the PML 
protein in the activation of the ALT pathway in a telomerase-positive 
environment. 
The cell viability assays showed that U2OS cells stably transfected with PML 
C/C- were more susceptible to anti-cancer drugs while MCF7 cells that 
exhibited ALT-like phenotypes were more sensitive to doxorubicin. Thus our 
study implicates the mode of telomere maintenance mechanism in the 
susceptibility of cancer cells towards anti-cancer drugs. 
This study provided a better understanding on how SUMOylation in ALT cells 
can be altered, leading to p53 functional changes, according to cellular 
conditions. Importantly, this study contributed to the current understanding of 
  xxv
how ALT can be activated in a telomerase positive background and how the 
telomere maintenance mechanism can affect susceptibility towards anti-
cancer drugs. 
 
Illustration I Project overview 
Telomerase activation and the ALT pathway help to maintain and elongate 
telomere length to allow unlimited proliferation. In the present study, the 
SUMOylation pathway in ALT cells was investigated. The SUMO-modification 
of tumor suppressor p53 and its effects in both ALT and non-ALT cells were 
also studied. The over-expression of PML and its SUMO-defective mutant 
was also performed to determine the effects of such an over-expression in 
ALT and telomerase positive cells. 
 
  1
1 CHAPTER 1  INTRODUCTION 
 
1.1 Post-translational modifications 
Post-translational modifications of proteins usually occur after protein 
synthesis and involve chemical modifications of target proteins. Post-
translational modifications are deemed as a highly efficient way of altering the 
functions of proteins. They are critical for many cellular processes due to their 
ability to bring about rapid changes in the functions of proteins and their 
complexes. Post-translational modifications include the addition of functional 
groups, such as acetyl and alkyl groups, to proteins. Post-translational 
modifications may also involve structural changes of a protein, including the 
formation of disulphide bridges between cysteine amino acids and proteolytic 
cleavage (of a peptide bond). Post-translational modifications of a protein may 
also involve the attachment of other proteins or peptides, such as ubiquitin 
and the small ubiquitin-like modifier (SUMO). Subsets of a pool of proteins 
may be modified post-translationally according to the cellular conditions and 
microenvironment as part of the cellular response and regulatory processes. 
1.1.1 Small Ubiquitin-like Modifier (SUMO) 
The Small Ubiquitin-like Modifier (SUMO) protein is a 10-11 KDa polypeptide 
that has a strong structural homology to ubiquitin (Melchior 2000, Ulrich 2009, 
Johnson 2004). However, SUMO has distinct sequences from ubiquitin; there 
is an approximate 18% sequence homology between these two proteins 
(Johnson 2004, Melchior 2000). SUMO has distinct surface properties and an 
unstructured flexible N-terminal extension that is not found in other ubiquitin-
related modifiers (Ulrich 2009, Melchior 2000). In mammals, there are 
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currently four known members of the SUMO family; SUMO-1, -2, -3 and -4. 
Similar to ubiquitin, SUMO is produced as an immature precursor that has to 
be C-terminally processed for the exposure of the di-glycine motif for 
conjugation. However, the presence of a singular proline residue at position 
90 in SUMO-4 prevents its processing, and this results in its inability to 
conjugate. While its biological function is unclear, SUMO-4 may have 
specialized functions through non-covalent interactions (Ulrich 2009). SUMO-
2 and -3 have nearly identical sequences and they are significantly different 
from SUMO-1, sharing only 50% similarity in sequence. 
The functional relevance of SUMO-1, -2 and -3 is determined by their cellular 
distributions. In vivo differential regulation of the SUMO protein members 
resulting in changes in expression and conjugation patterns also affected their 
functionality (Saitoh and Hinchey 2000). The majority of SUMO-1 in cells is 
conjugated to substrates while free SUMO-2 and -3 readily attach to target 
proteins in response to cellular stress. The functions of SUMO-1, -2 and -3 
were also implicated by their interactions with their downstream effectors and 
SUMO-specific isopeptidases (SENP) (Di Bacco and Gill 2006). Similar to 
ubiquitin, SUMO-2 and -3, but not SUMO-1, can also form polymeric chains 
as their N-terminals contain SUMOylation consensus motifs. However, 
despite their detection, the biological functions of these poly-SUMO chains 
are unclear. The dynamic process of SUMO conjugation and deconjugation 
makes functional analysis of SUMOylated proteins a challenge. In addition, 




SUMOylation is the process of conjugation of SUMO to its target proteins 
whereby an isopeptide bond is formed between the C-terminal carboxy group 
of SUMO and the amino group of the lysine residue within the target protein. 
SUMOylation occurs on lysine residues within a loosely defined consensus 
motif, ψKXE, where ψ denotes a hydrophobic residue, K is the modified lysine 
residue, X is any residue and E is glutamate. 
SUMOylation is a dynamic process of conjugation and deconjugation that 
results in a small portion of the target protein being modified at any given 
time. The conjugation of SUMO to a target protein is mediated by a series of 
enzymes responsible for energy-dependent activation, transfer and substrate-
selective conjugation of the modifier (Ulrich 2009) in a multi-step pathway. 
1.1.2.1 SUMO-activating enzyme (E1) 
The SUMO E1 enzyme is a heterodimer with subunits Aos1 and Uba2. Uba2 
carries a conserved cysteine which is the active site for catalysis. The E1 
enzyme activates SUMO in a three-step reaction. Firstly, a SUMO-adenylate 
intermediate is formed by the attack of the C-terminal carboxylate of SUMO 
on ATP with the release of pyrophosphate Secondly, as the SUMO C 
terminus is transferred to the catalytic cysteine on Uba2, a high-energy 
thioester intermediate is formed with the release of AMP. In the final step, the 
SUMO thioester is transferred to the SUMO-conjugating E2 enzyme. 
1.1.2.2 SUMO-conjugating enzyme (E2) 
The E2 conjugating enzyme Ubc9 contains a conserved cysteine residue in its 
active site that receives the SUMO thioester from the E1 activating enzyme. 
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Attack by the SUMO thioester on the ε-amino group of the substrate lysine 
residue results in an isopeptide bond between the C-terminus of SUMO and 
the target protein. In vitro, this reaction can take place in the absence of an E3 
ligase because Ubc9 participates directly in substrate recognition of the 
SUMO consensus motif. 
1.1.2.3 SUMO ligase (E3) 
Most of the SUMO E3 ligases contain a RING finger-like domain termed SP-
RING motif. This cysteine-rich motif is required for its ligase activity. While the 
SP-RING motif probably does not contribute any catalytic residues for SUMO 
transfer, it probably acts as a binding platform for the coordination of the 
interaction of the E2 enzyme with the substrate. The PIAS (protein inhibitor of 
activated STAT) family is the most prominent among the SP-RING proteins. In 
general, the E3 ligases appear to play a part in conferring substrate selectivity 
to the SUMO conjugation process. 
1.1.2.3.1 PIAS 
PIAS (protein inhibitor of activated STAT) proteins were named after their 
ability to interact and inhibit STAT proteins (Palvimo 2007). In mammals, four 
genes encode the PIAS proteins; PIAS1, PIASX, PIAS3 and PIASY. There 
are however five distinct mammalian forms of PIAS with some generated by 
alternative splicing: PIAS1, PIAS3, PIASY, PIASXα and PIASXβ. Mammalian 
PIAS proteins have high sequence homology; the initial 60 amino acids at the 
N-terminus and RING finger motif are highly similar. It is currently unknown if 
PIAS proteins display SUMO isoform selectivity or if they have a role in the 
formation of SUMO-2 and -3 polymers. It is interesting to note that PIAS 
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proteins display selectivity of their own SUMOylation; for example, PIASX 
proteins were modified by SUMO-1 and not SUMO-2 (Rytinki et al. 2009) 
while PIAS3 was equally modified by both SUMO-1 and -2 (Palvimo 2007). 
However, the functional and biological significance of such selectivity in self-
modifications is not known. Given their similarity in sequence homology and 
redundancy in interactions, it is possible that the local concentrations of PIAS 
proteins play a major role in determining the specificity of targets. 
1.1.2.4 SUMO-specific proteases (SENPs) 
SENPs are SUMO-specific isopeptidases. There are currently six known 
members and they contain a homologous 200 amino acid sequences known 
as the ubiquitin-like protease (ULP) domain that harbors the catalytic active 
site. Besides being involved in the cleavage of the SUMO precursor to the 
mature form, SENPs are also involved in the deconjugation of SUMO from 
target proteins and in the processing of SUMO polymers. The C-terminal 
hydrolase activity of SENP converts the SUMO precursor to its mature form. 
The removal of SUMO from target proteins is accomplished through the 
isopeptidase activity of SENP and this occurs in a single energy-free step. 
SENPs appear to be specific towards different SUMO isoforms in addition to 
preferential activity towards either SUMO maturation or deconjugation. 
SENPs exhibit different intracellular localization and are frequently found in 
specific substructures, suggesting that sequestration may be important for 
their substrate specificity and non-overlapping functions. 
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Illustration 1.1 The SUMO pathway of processing, conjugation and 
deconjugation 
“SUMO is depicted as a grey lollipop symbol. The high-energy thioester bond 
between the mature C terminus of SUMO and the E1 (Aos1/Uba2) or E2 
(Ubc9) enzyme is represented by a wavy line (~)” (Ulrich 2009). 
 
1.1.3 Regulation of SUMO conjugation 
Post-translational modification by SUMO is recognized as an important means 
to control the activity, stability and localization of proteins in a reversible 
manner. There is probably a dynamic regulation of SUMOylation as there are 
usually low levels of SUMO-modified targets at any given time. SUMO 
conjugation could be regulated at the level of attachment and removal of 
SUMO to and from target proteins whereby any changes in the rate of 
conjugation and de-conjugation would affect the levels of modified proteins at 
steady-state. Conjugation factors such as the E3 ligases are probably also 
involved in the regulation of SUMOylation. Post-translational modifications 
may affect the localization of the E3 ligases thereby regulating the spatial 
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specificity of intracellular modification. Phosphorylation appears to be an 
important means of regulating SUMO modification as phosphorylation of 
substrates usually led to a reduction in its SUMO conjugation (Desterro, 
Rodriguez and Hay 1998, Muller et al. 2000). As various molecules can 
modify lysines, there is likely to be competition amongst the modifiers for the 
same lysine and this in turn serves as a form of regulation, particularly if the 
lysine residue in contention occurs in the consensus SUMO motif. 
1.1.4 Biological functions of SUMOylation 
SUMO acts predominantly by modulating the interactions of its target proteins 
with other cellular factors. The presence of SUMO on target proteins can 
provide an additional binding site for another protein, thereby recruiting 
downstream effectors or localizing the substrate to a specific cellular 
compartment. SUMO-modification of its substrate may prevent its protein-
protein interactions through the blocking of binding sites or through a change 
in the protein conformation. SUMOylation may also affect other post-
translational modifications of its target protein. 
1.1.4.1 SUMO and transcription regulation 
Many substrates of SUMO are transcription factors and hence the effects of 
SUMOylation on gene expression are relatively better understood. In most 
cases, SUMOylation of transcription factors represses their transcriptional 
activity. Thus when the SUMOylation sites are mutated, there is generally 
hyperactivation of transcription. There are various mechanisms for SUMO-
mediated repression of transcription. The activities and functions of many 
transcription factors are regulated by their association with promyelocytic 
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leukemia (PML) nuclear bodies (Johnson 2004). Transcription factors could 
be sequestered into PML nuclear bodies upon SUMOylation, resulting in them 
being unavailable for transcriptional activation (Ulrich 2009). SUMO could also 
recruit histone deacetylases (HDACs), resulting in chromatin modifications 
and transcriptional repression (Ulrich 2009). In addition, SUMOylation of 
HDACs enhanced their repressive activity (Yang and Sharrocks 2004, David, 
Neptune and DePinho 2002). PIAS proteins could also repress transcription 
activity through their interaction with SUMO-modified transcription factors 
independent of their E3 ligase activity (Sharrocks 2006). 
1.1.4.2 SUMO and the maintenance of genome stability 
The effects of SUMOylation in the maintenance of the genome has been 
studied extensively in lower eukaryotes such as yeast, as the ease of genetic 
manipulations has allowed phenotypic analysis of mutants deficient in 
components of the SUMO pathway. There appears to be an emerging role of 
SUMO in the maintenance of higher-order chromatin structure and in 
chromosome separation. Mutants such as the ubc9ts yeast mutants were 
sensitive to DNA damaging agents and accumulated abnormal recombination 
intermediates spontaneously during DNA replication (Maeda et al. 2004). The 
use of mass spectrometry in the analysis of SUMO conjugates has linked 
SUMOylation of topoisomerase II to the fidelity of chromosome transmission 
(Takahashi et al. 2006) and the SUMOylation of RAD52 to the regulation of 
recombination events at the ribosomal gene locus (Torres-Rosell et al. 2007). 
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1.2 Promyelocytic Leukemia (PML) 
The promyelocytic leukemia (PML) protein is a growth and tumor suppressor 
that is inactivated in acute promyelocytic leukemia (APL) through the fusion of 
the PML gene with the retinoic acid receptor α gene. PML is a potent tumor 
suppressor in APL and in other cancers; PML has also been implicated in the 
repression of gene expression and the promotion of both intrinsic and 
extrinsic apoptotic pathway (Jensen, Shiels and Freemont 2001, Ruggero, 
Wang and Pandolfi 2000). There are three cysteine-rich zinc-binding domains 
in PML, a RING-finger domain and two B-boxes (B1 and B2). Together with a 
predicted α-helical coiled-coil domain, these four domains collectively form the 
RBCC motif. The RBCC motif is important for higher order protein interactions 
upon which the functions of PML are dependent on. Therefore, the RBCC 
motif is essential for PML nuclear body formation and for the tumor 
suppressive activities of PML. 
The PML gene consists of nine exons and its expression is regulated post-
transcriptionally through the alternative splicing of the C-terminal exons which 
result in the production of at least eleven different isoforms. PML isoforms are 
divided into seven groups (Jensen et al. 2001) and all isoforms maintained the 
RBCC motif. All PML isoforms contain the three lysines that are modifiable by 
SUMO; lysine at position 65 of the RING finger, 160 in the B1-box and 490 at 
the nuclear localization sequence. However, the nuclear localization signal in 
exon 6 is not present in all PML isoforms and this results in both nuclear and 
cytoplasmic isoforms of PML. Thus while the RBCC motif is conserved in all 
PML isoforms, the isoforms differ in their C-terminal regions. 
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1.2.1 RING finger motif 
The RING finger motif is a cysteine-rich zinc binding domain. The conserved 
RING structural elements consists of two zinc atoms bound via a cross-brace 
arrangement of Cys and His ligands. Mutations of these ligands in PML 
disrupted its nuclear body formation and led to loss of its growth suppression 
and apoptosis abilities (Jensen et al. 2001). The requirement of an intact 
RING finger for PML nuclear body formation could be due to specific protein-
protein interactions that are mediated by the RING motif. In addition, the 
RING finger motif in PML specifically interacts with the SUMO E2 conjugating 
enzyme Ubc9.  The SUMO-modification of PML is thought to be a prerequisite 
for the formation of nuclear bodies and thus the ability of the RING finger motif 
to interact with Ubc9 is critical for the SUMO-mediated nuclear body 
formation. 
1.2.2 B-boxes 
There are two B-boxes in PML while in other RBCC proteins, there is only one 
copy of the B-box motif. The B-box motif can only be found in the RBCC 
family members and this suggests that it is an important determinant of the 
overall motif and its function (Reymond et al. 2001). The B-boxes, B1 and B2, 
are two distinct cysteine-rich motifs adjacent to the RING domain. Both bind 
zinc but differed in terms of the number and spacing of conserved Cys and 
His ligands (Borden et al. 1996). While substitution of the conserved zinc 
ligands in B1 and/or B2 disrupted the formation of PML nuclear bodies but it 
did not affect the oligomerization between PML (Borden et al. 1996). The B-
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boxes work in tandem with the RING finger to exert the growth repressive 
functions of PML (Fagioli et al. 1998). 
1.2.3 Coiled-Coil domain 
Coiled-coil structures are formed from the inter-winding of α-helices which 
result in rod-like structures. Coiled-coil domains mediate homo- and hetero-
dimer interactions, higher order multimer interactions and high molecular 
weight complex formation. This domain is also critical for the formation of PML 
nuclear bodies and the full growth suppressive effects of PML (Fagioli et al. 
1998). 
1.2.4 PML nuclear bodies 
PML nuclear bodies are subnuclear structures consisting of PML aggregates 
and a diverse range of proteins. PML nuclear bodies are discrete punctuate 
structures, and range in size from 0.2 to 1 μm in diameter. There are about 
one to 30 PML nuclear bodies per nucleus. These nuclear bodies are highly 
dynamic, transiently recruiting and releasing proteins to and from them, thus 
acting as a depot and organizing centre. As more than 50 proteins are known 
to localize to PML nuclear bodies, these structures are thus involved in many 
cellular pathways such as transcriptional regulation and DNA damage 
response. Besides facilitating post-translational modifications, PML nuclear 
bodies appear to localize proteins to their sites of action. 
1.2.4.1 PML nuclear bodies and SUMOylation 
As mentioned above, PML has three characterized SUMO binding sites which 
are essential for SUMO attachment for the formation of nuclear bodies. In 
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addition, PML contains a SUMO-binding domain, also known as SUMO-
interacting motif (SIM), which aids in the formation of nuclear bodies through 
its interaction with other SUMOylated proteins. Accordingly, many proteins 
found in PML nuclear bodies are SUMOylated as there is SUMOylation-
dependent recruitment of proteins to the nuclear bodies. SUMOylation of PML 
is cell cycle regulated; PML is SUMOylated during interphase, deSUMOylated 
before the start of mitosis and is reSUMOylated before the start of another 
cycle. Throughout the S phase, PML is tightly co-localized with SP100, 
another main constituent of PML nuclear bodies. The number of PML nuclear 
bodies increases significantly in the G2 phase of the cell cycle. The 
deSUMOylation of PML correlates with a complete loss of PML nuclear body 
structure, strongly indicating that SUMO modification of PML is a controlling 
factor in the nuclear body formation and structure. 
1.3 Cancer 
According to the world health organization (WHO), cancer is one of the 
leading causes of death worldwide. Cancer accounted for 7.4 million deaths in 
2004, making it for the leading cause of death in that year. The projected 
worldwide cancer burden is expected to continue to rise with an estimated 27 
million new cancer cases with 17.5 million deaths in 2050. Globally, cancer is 
the second leading cause of death after heart diseases in developed countries 
while being the third leading cause of mortality in developing countries. In 
Singapore, one in four deaths are from cancer, making it a leading cause of 
death locally. While ethnic and gender differences are contributing factors in 
cancer occurrences, the most common forms of cancer include those of the 
lung, stomach, colorectal, liver and breast. 
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While the onset of cancer may occur at any age, the risk of cancer occurrence 
increases with age. Regardless of the age of onset of the disease, the costs 
associated with cancer are hefty. In addition to the emotional and physical 
burden of the diseased state, there is a huge financial burden of cancer. 
Financial costs of cancer include the costs of treatment, rehabilitation fees 
and health insurance premiums. There are also indirect costs of cancer such 
as morbidity and mortality costs. 
In view of the high mortality rates and financial considerations, it is hence not 
surprising that a lot of efforts are concentrated in the area of cancer research. 
While drugs for cancer treatment have been developed, there is no cure for 
cancer as yet. However, decades of research have led to better knowledge of 
how cancer can arise and how certain forms of cancer can be prevented. 
While current knowledge purports cancer to be highly complex, there are 
established hallmarks of cancer that evolve around such complexity. 
1.4 Hallmarks of Cancer 
Cancer is a diseased state whereby cells do not respond to the controlled 
regulations of normal cellular proliferation. It arises through the accumulations 
of multiple genetic mutations and each mutation predisposes the cell to further 
mutations. There are six main hallmarks of a cancer cell; self-sufficiency in 
growth signals, insusceptibility to growth-inhibitory signals, evasion of 
apoptosis, perennial angiogenesis, tissue invasion and metastasis and 
unlimited replicative potential (Blagosklonny 2003, Hanahan and Weinberg 
2000). Each of these physiological changes is deemed essential for malignant 
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cell growth and is seen as novel characteristics acquired in tumor 
development. 
Cancer cells are considered immortal because of their ability to propagate 
indefinitely. Cancer cells do not respond to death signals and are able to grow 
even in the absence of growth signals. The ability of cancer cells to at least 
maintain their telomeres accounts largely for their unlimited proliferative 
capacity. 
 
Illustration 1.2 Acquired capabilities of cancer 
“It is suggested that most if not all cancers have acquired the same set of 
functional capabilities during their development, albeit through various 




1.5.1 Structure of telomeres 
Telomeres are hexanucleotide tandem repeats of TTAGGG at the ends of 
chromosomes. There is about 5-15 kb of telomeric sequences in human 
chromosomes. The complete telomere structure includes the telosome. The 
telosome is a supramolecular complex consisting of six proteins; telomeric-
repeat binding factors 1 and 2 (TRF1 and TRF2), protection of telomeres 
protein (POT1), TRF1-interacting partner (TIN2), transcriptional activator and 
repressor (RAP1) and POT1-and-TIN2 binding protein (TPP1) (de Lange 
2005). Each of these molecules has a role to play in the maintenance of the 
structure of telomeres which is critical for its functions. 
Of the six proteins in the telosome, TRF1, TRF2 and POT1 interact directly 
with the telomeres. TRF1 and TRF2 bind specifically to double stranded 
telomeric DNA while POT1 binds to single-stranded G-rich telomeric 
sequences (G-strand overhang) (Broccoli et al. 1997, Baumann and Cech 
2001). TRF1 regulates telomere length while TRF2 and POT1 protect 
chromosome ends, preventing chromosomal fusions (Cesare and Reddel 
2008). However as TRF2 has also been shown to have a role in regulating 
telomere length (Smogorzewska et al. 2000), the distinction in the functions of 
TRF1 and TRF2 is less clear. Interestingly, the over-expression of TRF2 led 
to a faster rate of telomere shortening and cells entering senescence with 
shorter telomeres, suggesting that it is telomere structure and not length that 
affected its function (Karlseder, Smogorzewska and de Lange 2002). 
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Due to the inherent nature of DNA replication, there is a 3’ overhang of G-rich 
sequence (Makarov, Hirose and Langmore 1997). This overhang is able to 
fold back into double stranded telomeres to form a telomeric loop, also known 
as t-loop (Griffith et al. 1999). The t-loop is important for the maintenance of 
the structure of telomeres and for the enhanced stability of telomeres. 
1.5.2 Functions of telomeres 
The role of telomeres at chromosomal ends is essential to prevent DNA from 
being recognized as double strand breaks so that genome integrity can be 
maintained. The structure (Karlseder et al. 2002) and a sufficient length of 
telomeres are required for adequate protection of the genome (Verdun and 
Karlseder 2007). 
Telomeres also function as a biological clock. With each round of successive 
DNA replication, 100 to 200 base pairs are lost due to the end-replication 
problem (Shay and Wright 2000). The removal of the terminal RNA primer 
leads to the formation of the lagging strand with a subsequent loss of 
telomeric sequences. As a result, daughter telomeres end up with a shorter 
sequence compared to their parental counterparts (Shay and Wright 2000). 
Critically short telomeres can trigger the activation of p53 and ATM to bring 
about cell cycle arrest and cellular senescence. It has been reported by Jegou 
et al. that telomeres shortened from an initial length of 10-15 kb to 
approximately 5 kb or less at senescence (Jegou et al. 2009). Thus the 
progressive shortening of telomeres confers a lifespan onto cells whereby 
only those with sufficiently long telomeres can continue to proliferate. This 
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characteristic progressive telomere shortening is seen as an anti-tumorigenic 
function of telomeres. 
In normal cells whereby cell cycle and proliferation controls are in place, 
critically short telomeres eventually lead to cellular senescence. However, in 
cancer cells, the cellular proliferation and apoptosis pathways are highly 
deregulated. Thus cells can bypass senescence through the activation of 
telomeres maintenance mechanisms to achieve unlimited proliferative 
potential. 
1.5.3 Telomere Maintenance Mechanisms 
The activation of telomere maintenance mechanisms is critical in the 
transformation of a normal cell to a cancer cell. It is generally required for the 
rescue and bypass of cells that are in crisis due to the presence of extremely 
short telomeres. When cells exit the crisis stage with an active telomere 
maintenance method, they possess unlimited proliferative potential and 
become immortal (Verdun and Karlseder 2007). The activation of the enzyme 
telomerase is the most common method of telomere maintenance in cancer 
cells (Reddel et al. 2001). There are also alternative methods of telomere 
maintenance that are independent of telomerase, termed alternative 
lengthening of telomeres (ALT) (Bryan and Reddel 1997). 
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Illustration 1.3 Telomere length maintenance and immortalization 
“When the telomere lengths of proliferating normal cells become marginal, the 
cells undergo senescence, which includes permanent withdrawal from the cell 
cycle. This barrier to proliferation may be breached temporarily by loss of 
function of key tumor suppressor genes, but the telomeres eventually become 
critically short and the cells enter crisis. Escape from these limitations on 
proliferation may be provided by activation of a TMM, telomerase or ALT. 
Telomerase activation often results in stably short telomeres, or in telomere 
lengthening and stabilization in the normal length range. ALT results in a large 
increase in average telomere length, but there are very short and very long 
telomeres present within individual cells” (Reddel 2003). 
 
1.5.4 Telomerase 
Telomerase is an enzyme that adds G-rich telomeric repeats to chromosome 
ends. It is activated in about 85% of human tumors as a telomere 
maintenance mechanism. Telomerase is a specialized reverse transcriptase 
that adds G-rich telomeric repeats using its internal RNA template to the 
chromosomal ends. This action thus allows for the maintenance of the 
telomere length. The enzymatic component of telomerase in humans is called 
hTERT while the RNA component is termed hTR. TERT is the reverse 
transcriptase catalytic subunit while the hTR consists of the RNA templates 
for the de novo synthesis of telomeres. 
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As reported in two studies, the over-expression of hTERT in fibroblasts 
resulted in telomere elongation and cell immortality through the avoidance of 
telomere-shortening mediated replicative senescence (Jiang et al. 1999, 
Morales et al. 1999). In addition, the reported ability of over-expressed hTERT 
to bring about the maintenance or elongation of telomere length indicated the 
presence of endogenous hTR and that the expression of hTERT is a rate-
limiting step for telomerase activity (Zhang et al. 1999). 
The up-regulation of telomerase in the course of cancer development takes 
place after telomere shortening and chromosome instability. In most 
telomerase positive cells, the telomere lengths as measured by the terminal 
restriction fragment (TRF) analysis are relatively homogenous with an 
average range of 10 to 15 kb. 
1.5.4.1 Telomerase inhibitors 
The expression of dominant-negative TERT mutant in telomerase-positive 
cells led to a down-regulation of telomerase activity and eventually apoptosis 
(Hahn et al. 1999, Zhang et al. 1999). This suggests that telomerase inhibitors 
could be useful in cancer therapeutics. Studies have also shown that 
telomerase contributed more to a malignant phenotype than the maintenance 
of telomere length alone (Zhou et al. 2009, Shammas et al. 2008, Vidal-
Cardenas and Greider 2009). Thus the potential of telomerase inhibitors as 
powerful and effective cancer therapeutics could be due to its other anti-
cancer properties in addition to the inhibition of telomere maintenance. There 
is a further discussion of the use of telomerase inhibitors in telomerase-
negative tumors in the subsequent text. 
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1.6 Alternative Lengthening of Telomeres 
As mentioned above, besides the conventional method of using telomerase to 
maintain telomere length, there are alternative methods of telomere 
maintenance. All other methods of telomere maintenance that do not use 
telomerase for telomere maintenance are classified under the alternative 
pathway. It should be noted that the alternative methods of telomere 
maintenance might not engage identical pathways even though there might 
be similarities among the pathways utilized. While there is an Alternative 
Lengthening of Telomeres (ALT) pathway that is believed to account for the 
majority of non-telomerase dependent telomere maintenance, there are other 
telomerase-independent pathways used in different organisms that do not 
exhibit the hallmarks observed in ALT. 
1.6.1 Hallmarks of ALT 
Due to a lack in knowledge of the exact mechanism(s) of ALT, there are no 
definitive assays or molecular markers that can be used to define and detect 
the ALT mechanism. However, ALT cells exhibit certain characteristics that 
are strikingly distinct to them. These hallmarks of ALT are thus used to define 
ALT cancer cells as such. The main hallmarks of ALT cancer cells include the 
presence of heterogeneous telomere length, ALT-associated nuclear bodies 
and telomeric circles. 
1.6.1.1 Heterogeneous telomere length 
While cancer cells that employ telomerase as the telomere maintenance 
mechanism have a relatively homogenous telomere length, ALT cells have a 
heterogeneous telomere length. Telomere length in ALT cells range from less 
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than 3 kb to more than 50 kb, thus displaying both very short and very long 
telomeres. The average telomere length in ALT cells is about 20 kb. Besides 
the fact that no telomerase activity can be detected in ALT cells, telomerase is 
not expected to be able to bring about rapid telomere elongation as is usually 
seen in ALT cells. With the use of a telomere-specific probe in fluorescence in 
situ hybridization, chromosomes with undetectable telomeres as well as those 
with very strong telomeric signals were observed within individual cells 
(Henson et al. 2002). When immortalization of cells in culture activates the 
ALT pathway, there is a tight temporal correlation between the onset of 
immortalization and the exhibition of the ALT heterogeneous telomere length 
phenotype. As such display of a wide range of telomere length appears to be 
unique to cancer cells displaying the ALT pathway, the heterogeneous 
telomere length is used as a main characteristic of ALT cells and as part of 
the criteria to define ALT cells. 
There is a dynamic telomere length distribution in ALT cells and the lengths 
can change drastically during proliferation. Murnane et al has shown that the 
rate of chromosomal fusion in ALT cells was proportional to the high 
frequency of telomere length fluctuations (Murnane et al. 1994). Murnane et al 
also reported that there was a great variation in the telomere length of the 
short arm of a chromosome to the long arm of the same chromosome in an 
ALT cell, with about a 100-fold difference in telomere length. In a telomerase-
positive cell, there was only a two-fold difference in the ratio for such 
variations (Murnane et al. 1994). 
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1.6.1.2 ALT-associated PML nuclear bodies 
Another hallmark of ALT cells is the presence of specialized promyelocytic 
leukemia nuclear bodies termed ALT-associated PML nuclear bodies (APBs). 
APBs are PML nuclear bodies containing telomeric DNA, telomere-associated 
proteins such as TRF1 and TRF2, and DNA repair and recombination 
proteins. Within a given ALT cell population, APBs are detected in only about 
5% of the cells. This is probably due to their formation during specific phases 
of the cell cycle (Grobelny, Godwin and Broccoli 2000) as is observed with the 
PML nuclear bodies. Yeager et al showed that the occurrence of APBs in cells 
immortalized in vitro took place at the same time the characteristic ALT 
heterogeneous telomere phenotype materialized (Yeager et al. 1999). There 
is an excellent correlation between the heterogeneity in telomere length with 
the observation of APBs when 100% of the tumors analyzed in a study by 
Henson et al displayed heterogeneous telomere length as well as APBs 
(Henson et al. 2005). 
As DNA recombination proteins, including RAD51, RAD52, MRE11 and NBS1 
(Wu et al. 2003, Wu, Lee and Chen 2000, Yeager et al. 1999), could be 
detected in APBs, APBs have been assumed as sites where telomere 
recombination takes place. Yeager et al first reported that telomeric DNA, 
including its extrachromosomal counterparts, was found in APBs (Yeager et 
al. 1999).  Live cell imaging studies by Molenaar et al showed that 
chromosomal telomeric DNA associated and disassociated with telomeric 
DNA present within APBs in ALT cells in a dynamic manner (Molenaar et al. 
2003). The observation by Nabetani et al of the co-localization of 
phosphorylated histone H2AX (H2AXγ), a marker of DNA double strand 
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breaks (DSB), with APBs suggested that some telomeric DNA in APBs is 
recognized as DSB (Nabetani, Yokoyama and Ishikawa 2004). This is 
consistent with observations of the presence of linear DNA in APBs. Thus it is 
possible that APBs serve as a depot for the localization of DNA and proteins 
that are involved in ALT and facilitates ALT-mediated telomere maintenance. 
However, it has also been speculated that APBs are involved in the removal 
of by-products generated by the ALT mechanism and are thus probably not 
important in the ALT process (Bryan et al. 1997a, Reddel et al. 2001). 
APBs were detected with the onset of ALT and disappeared when the ALT 
pathway was inhibited (Henson et al. 2002). In addition, various studies have 
shown that the absence of APBs due to the knockdown of proteins such as 
TRF2 (Potts and Yu 2007, Stagno D'Alcontres et al. 2007) led to telomere 
shortening, suggesting that APBs is required for the ALT pathway. Hence 
APBs are established markers of on-going ALT processes and are thus a 
hallmark for ALT cells. 
However, it should be noted that there are other alternative telomere 
maintenance processes that can occur in the absence of APBs (Fasching, 
Bower and Reddel 2005). The combination of the existence of heterogeneous 
telomere length and detection of APBs are used to determine definitively the 
ALT status of a cancer cell. 
1.6.1.3 Extrachromosomal telomeric DNA 
Extrachromosomal telomeric repeats are readily detectable in ALT cells but 
not in telomerase-positive cells or normal human cells. As mentioned above, 
some of the telomeric DNA found in APBs is extrachromosomal telomeric 
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DNA. Rapid deletion events in ALT cells may generate linear or circular 
extrachromosomal telomeric DNA. However, APBs appear to preferentially 
accumulate linear extrachromosomal telomeric DNA, suggesting that a 
function of APBs may be to sequester linear telomeric DNA so as to prevent 
them from being recognized as double strand breaks (Henson et al. 2002). 
Circular extrachromosomal telomeric DNA, also termed as t-circles, arises 
from the resolution of the t-loop at chromosomal ends and is indicative of 
frequent homologous recombination events at the t-loop (Basenko et al. 2009, 
Pickett et al. 2009, Tomaska, McEachern and Nosek 2004). The abundance 
of t-circles is also a characteristic of ALT cells. The widespread presence of t-
circles implicates it as a template for unlimited telomeric replication in ALT 
cells. 
1.6.1.4 Telomeric exchange 
The frequency of post-replicative telomeric exchanges was found to be high in 
ALT cells (Bechter, Shay and Wright 2004a). Chromosome orientation (CO) – 
FISH, instead of the conventional sister chromatid exchange (SCE) analysis, 
was used to detect such exchanges. Unfortunately, the limitation of this 
technique is such that it cannot differentiate if the telomeric exchanges are 
between sister chromatids, between different chromosomes or between a 
chromosome and extrachromosomal telomeric repeats (Muntoni and Reddel 
2005). Post-replicative exchanges involving telomeric repeats as detected by 
CO-FISH were frequently found in ALT cells and not in non-ALT cells 
(Londono-Vallejo et al. 2004, Bechter et al. 2003). Bechter et al have also 
reported that SCEs at interstitial genomic sites were not found at an increased 
frequency in ALT cells, corroborating observations that ALT cells do not 
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exhibit higher rates of general homologous recombination compared to 
telomerase-positive cells (Bechter et al. 2004a, Bechter et al. 2003). However, 
the relationship of telomeric exchanges to ALT is unclear as Bechter et al also 
reported the emergence of a survivor population of treated telomerase-
positive cells which exhibited increased telomeric exchanges and telomere 
length without displaying APBs (Bechter et al. 2004b). The reasons behind 
the increase in telomeric exchanges in ALT cells are currently uncertain. It is 
possible that proteins involved in homologous recombination are recruited to 
telomeres for their role in the ALT process and the accumulation of these 
proteins may lead to telomeric SCEs (Muntoni and Reddel 2005). However, 
SCEs are insubstantial to fully account for ALT as increases in telomere 
length via interchromosomal and extrachromosomal exchanges may require 
additional ALT-specific processes (Londono-Vallejo et al. 2004). It is 
interesting to postulate that telomeric SCEs may be the basis of the ALT 
mechanism whereby unequal telomeric exchanges results in the elongation of 
telomeres of separating chromatids without de novo synthesis of telomeric 
repeats (Bailey, Brenneman and Goodwin 2004). Thus, according to this 
hypothesis, a subpopulation of cells can continue to grow even at the expense 
of other cells that have shortened telomeres (Bailey et al. 2004). Therefore, 
unequal telomere sister chromatid exchange coupled with preferential 
segregation of chromosomes with elongated telomeres into a single daughter 
cell could have led to the formation of an ALT phenotype (Muntoni and Reddel 
2005). 
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1.6.2 Mechanisms of ALT 
While the exact mechanism of ALT has yet to be elucidated, it is certain that 
telomerase is not involved in ALT as some ALT cells do not express the RNA 
template/ TR subunit of telomerase. Instead, ALT cells display elevated levels 
of three distinct forms of telomeric recombination which are not observed in 
non-ALT cells (Cesare and Reddel 2008). The first form of telomeric 
recombination is that of homologous recombination-dependent telomere 
copying. The second form is that of post-replicative telomere exchanges and 
the third form of telomere recombination is that of t-loop junction resolution 
(Cesare and Reddel 2008, Henson et al. 2002). 
There is increasing evidence suggesting telomere recombination as the main 
mechanism of the ALT pathway. When a plasmid tag was introduced to 
telomeres, there was a corresponding increase in the number of 
chromosomes containing the plasmid tag in their telomeres as the number of 
population doublings increased (Dunham et al. 2000). The same study also 
showed that inter-telomeric recombination occurred in human ALT cancer 
cells but not in telomerase-positive cells. In addition, two studies have shown 
that while microsatellites in ALT cells appeared stable, instability at certain 
minisatellite loci that are considered recombinogenic was found (Jeyapalan et 
al. 2005, Tsutsui et al. 2003). This further point towards recombination as the 
underlying mechanism for ALT. Interestingly, Bechter et al found that the 
increased levels of telomeric recombination were not reflected at other 
locations in the genome of ALT cells, suggesting enhanced telomere-specific 
recombination (Bechter et al. 2003). 
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1.6.2.1 T-loop mediated telomere lengthening 
In addition to homologous recombination-mediated inter-telomeric copying, 
there are several proposed mechanisms for ALT-mediated elongation of 
telomere length. T-loops are lariat structures that can be found in mouse and 
human telomeres. Due to the intrinsic presence of the 3’ overhang of 
telomeres, DNA replication can be initiated at the 3’ overhang within the t-loop 
junction to bring about extensive telomere elongation. In addition, t-loops can 
also propagate the ALT pathway through the generation of circular or linear 
extrachromosomal telomeric DNA via rapid telomere shortening events. The 
extrachromosomal telomeric repeats (ECTR) could then be used as copy 
templates for telomere replication. Telomeric circles (t-circles), which are 
found in abundance in ALT cells, could serve as an indication of frequent t-
loop homologous recombination and rapid deletion events (Cesare and 
Griffith 2004). 
1.6.2.2 Linear ECTR mediated telomere lengthening 
Linear ECTR can also be generated from the excision of t-loops. Telomere 
elongation could then occur through the recombination of extrachromosomal 
telomeric DNA with chromosomal telomeres, by end-joining and/or copy 
templating (Dunham et al. 2000). However, the linear ECTR found in ALT is 
usually small and low in molecular weight. As such, they are unlikely to 
account for the large and rapid increase in telomere length as observed in 
ALT cells. The role of linear ECTR in ALT could be to sequester telomere-
binding proteins. The presence of linear ECTR in APBs suggests that it could 
be directly involved in the ALT pathway or it is a by-product of the ALT 
mechanism. 
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1.6.2.3 Rolling circle mediated telomere lengthening 
Telomere lengthening could also occur through the ‘roll and spread’ 
mechanism. This mechanism is based on the circular ECTR that is generated 
via the excision of the t-loops. Electron microscopy and 2D gel 
electrophoresis have shown the abundance of large t-circles with a size range 
of <1 kb to > 50 kb (Cesare and Griffith 2004, Wang, Smogorzewska and de 
Lange 2004). Telomeres could be extended by the rolling-circle replication 
whereby t-circles are templates and replication can occur following the 
invasion of the 3’ telomeric overhang into the t-circles. The invading 3’ 
overhang allows rolling of the t-circle and results in an extensive elongation of 
the telomere. The elongated telomere can subsequently be used as a copy 
template, thus effectively spreading its sequence to other telomeres. This is 
known as the ‘roll and spread’ mechanism (Bollmann 2007) and is able to 
account for the occurrence of extremely long telomeres due to uninterrupted 
rolling-circle recombination with an interminable template (t-circle). 
1.6.2.4 Additional ALT mechanisms 
There are some telomerase-negative human and mouse cells that exhibit 
telomere maintenance mechanisms but lack some of the hallmarks of ALT 
cells (Argilla et al. 2004, Bechter et al. 2004b, Fasching et al. 2005, Marciniak 
et al. 2005, Cerone et al. 2005). These observations suggest that there may 
be more than one ALT mechanism. 
In a study involving yeast telomerase deletion mutants, the survivors 
generated circular chromosomes through the fusion of the chromosomes that 
have lost all telomeric repeats (Nakamura, Cooper and Cech 1998). Some 
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survivors emerged with linear chromosomes containing long heterogeneous 
amplified telomeres through recombination (Nakamura et al. 1998). To date, 
no chromosome circularization has been reported in telomerase deletion 
mutants of higher eukaryotes. 
In another study using yeast, recombination-mediated telomere lengthening 
led to the emergence of two classes of telomerase null survivors (Lundblad 
and Blackburn 1993). Studies have shown that there was simultaneous 
amplification of subtelomeric and telomeric sequences in the type I class of 
telomerase null yeast survivors (Le et al. 1999, Teng et al. 2000, Teng and 
Zakian 1999). Similar to these telomerase-negative type I yeast survivors, 
Fasching et al observed a telomerase-negative SV40-immortalised WRN-
deficient human cell-line displaying a high percentage of non-telomeric 
sequences within their telomeres (Fasching et al. 2005). While these cells 
exhibited telomeric recombination, they did not display APBs typical of ALT 
(Fasching et al. 2005). It is interesting to note that nuclear foci consisting of 
telomeric DNA and DNA repair and recombination proteins such as MRE11, 
NBS1 and TRF2, but not PML or SP100, were detected in such cells 
(Fasching et al. 2005). 
The type II telomerase-negative yeast survivors exhibited amplication of only 
telomeric repeat tracts (Lundblad and Blackburn 1993). These survivors were 
postulated to have arisen from chromatid exchanges between the short 
telomeric repeats and/or through interactions with ECTR (Chen, Ijpma and 
Greider 2001, Teng et al. 2000). The telomere phenotype of these survivors is 
reminiscent to that in ALT cells (Teng and Zakian 1999). 
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Studies have also reported the emergence of another distinct telomeric 
phenotype which occurred through the loss of the exonuclease 1 protein in 
telomerase-null yeast survivors. There was loss of all telomeric repeats with 
the formation of large DNA palindromes (Maringele and Lydall 2004a, 
Maringele and Lydall 2004b). However, there are no reports of similar 
observations in telomerase negative mammalian cells and hence it is 
unknown if mammalian cells contains any similar mechanism. 
1.6.3 ALT as a possible consequence of telomere dysfunction 
The maintenance of telomere length and structure is important for the integrity 
of the genome. Dysfunctional telomeres lead to the activation of DNA damage 
response and repair pathways. It is also postulated that dysfunctional 
telomeres can bring about telomere recombination and ALT (Mathieu et al. 
2004). The deregulation in any step in homologous recombination-assisted 
telomere capping can lead to uncapped chromosome ends, rendering them 
prone to telomeric recombination (Cesare and Reddel 2008). In addition, if 
recombination-mediated capping is not properly controlled, t-loop junction 
resolution may occur, resulting in truncated telomeres and t-circles. Truncated 
telomeres are prone to inter-telomeric recombination and the t-circles 
generated can serve as rolling circle-replication templates. Deregulation of 
capping-associated recombination can also bring about strand invasion in 
trans (inter-telomeric) rather than t-loop formation in cis (intra-telomeric) and 
this encourages telomere copying (Cesare and Reddel 2008). ALT could also 
arise from a dysfunction in chromosome capping in the G2 phase of the cell 
cycle which leaves the chromosome ends exposed when homologous 
recombination is more active. The possibility that there is an ALT-like activity 
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in normal mammalian cells cannot be ruled out. Hence it is also possible that 
the ALT phenotype observed in cancer cells is reflective of the deregulation of 
such a pathway. 
1.6.4 ALT and telomerase 
Studies have shown that the absence of telomerase activity in ALT cells 
correlated with the lack of expression of TERT and the occasional loss of 
TERC (Bryan et al. 1995, Sun et al. 2005). Kilian et al reported that there 
were undetectable levels of full-length TERT transcripts due to methylation of 
hTERT CpG island in ALT cells (Kilian et al. 1997). Dessain et al then 
proceeded to show that such CpG island was unmethylated in telomerase-
negative normal cells (Dessain et al. 2000). Thus these studies have 
corroborated that it is the lack of full-length hTERT mRNA that accounts 
mainly for telomerase inactivity. Bryan et al have reported that there was 
undetectable telomerase RNA (TR), which is encoded by the TERC gene, in 
some ALT cell-lines (Bryan et al. 1997b). Such observation directly implicates 
that telomere maintenance through ALT is independent of telomerase. 
However, in ALT cells that express the TERC gene, the sequence of this gene 
is usually wild-type (Bryan et al. 1997b). 
Perrem et al demonstrated that other telomerase subunits were expressed in 
sufficient levels to support telomerase activity when the expression of 
exogenous hTERT in TR-expressing ALT cells induced telomerase activity 
(Perrem et al. 2001). It was also shown that that the exogenous expression of 
both TERT and TR in TR-negative cells also induced telomerase activity 
(Wen, Cong and Bacchetti 1998). Interestingly, the expression of exogenous 
  32
telomerase in ALT cells was found to be compatible with continued ALT 
activity, with telomerase maintaining the shortest telomeres (Cerone, 
Londono-Vallejo and Bacchetti 2001, Ford et al. 2001, Grobelny, Kulp-
McEliece and Broccoli 2001, Perrem et al. 2001). In addition, studies have 
also shown that the hallmarks of ALT, such as heterogeneous telomere length 
and presence of APBs, were not affected by the over-expression of the 
components of telomerase and its subsequent activity (Cerone et al. 2001, 
Cesare and Griffith 2004, Grobelny et al. 2001). Thus these two distinct 
methods of telomere maintenance are able to co-exist in human cells. 
Ford et al reported that the expression of exogenous telomerase in ALT cells 
led to reduced ALT activity (Ford et al. 2001). A similar observation was also 
observed in hybrids of telomerase positive and ALT cells (Katoh et al. 1998). 
While the exact mechanism for the apparent telomerase inhibition of ALT 
activity is unclear, it is possible that telomerase leads to ALT activity being 
gradually switched off when molecules involved in ALT might be competing 
with telomerase for common molecular components or for access to 
telomeres. The possibility that high levels of telomerase subunits repress ALT 
through the sequestration of molecules common to both pathways cannot be 
excluded. 
1.6.5 Existence of ALT repressor genes 
There could be repressors of ALT activity in normal cells. This hypothesis 
came from the observation that senescent hybrids of ALT and normal cells 
displayed a loss of the ALT heterogeneous telomere length phenotype 
(Perrem et al. 1999). This suggests that activation of ALT might require the 
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loss of one or more recessive mutations leading to the loss of ALT repressor 
genes (Perrem et al. 1999). Some telomerase-positive cells may also contain 
repressors of ALT activity as Perrem et al demonstrated that ALT was also 
repressed in ALT-telomerase positive hybrids (Perrem et al. 2001). It is 
possible that the hybrids can inhibit both rapid lengthening and shortening, 
bringing about a slow but progressive telomere shortening (Zhong et al. 
2007). However, Katoh et al have showed that some hybrids became active in 
ALT with telomerase being repressed, suggesting that some ALT cells may 
contain a repressor of telomerase (Katoh et al. 1998). Alternatively, it is 
possible that some telomerase-positive cells have lost the repressors for ALT 
thus resulting in ALT activity in ALT-telomerase positive hybrids. 
While ALT repressor genes are not yet identified, genetic changes such as 
the expression of SV40 or the human papillomavirus (HPV) oncogenes have 
allowed for the activation of ALT or telomerase. While such oncogenes 
extends the proliferative life span, additional genetic changes which leads to 
genetic instability and facilitates immortalization have to be acquired for the 
activation of a telomere maintenance mechanism (Reddel 2001). 
It is speculated that the p53 and Rb family of proteins may have a direct role 
in the repression of ALT activity. p53 represses homologous recombination, 
and Razak et al demonstrated that when transactivation-incompetent p53 was 
expressed in ALT cells, it inhibited DNA synthesis in these cells and not in 
telomerase-positive cells (Razak et al. 2004). For p53 to inhibit DNA synthesis 
in ALT cells, an intact specific DNA binding domain and its ability to suppress 
recombination functions are required. In a study by Seger et al, there were 
longer telomeres in Rb deficient mice compared to wild-type mice and such 
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an elongation was not accompanied with an increase in telomerase activity 
(Seger et al. 2002). This thus implicates the Rb family of proteins in the 
regulation of ALT activity, at least in mouse cells. 
It is also possible that alterations in the telomere structure may aid ALT 
activation by making it more accessible to proteins involved in recombination. 
As such, linker histones or genetic modifications could be implicated in 
telomerase-independent telomere maintenance (d'Adda di Fagagna, Teo and 
Jackson 2004). In addition, mismatch repair (MMR) proteins which have an 
important role in maintaining genomic stability, are considered as potential 
repressors of ALT (Rizki and Lundblad 2001). This is because the MMR 
machinery has an important role in inhibiting recombination particularly 
between homologous DNA sequences due to its ability to recognize 
mismatches in recombination intermediates (Rizki and Lundblad 2001). 
Further studies are required to determine how the above factors are involved 
in telomere length regulation and if they indeed have any role in inhibiting ALT 
activity. Understanding and elucidation of the repression of ALT in normal 
cells may eventually result in anticancer therapies for the restoration of such 
repression. 
1.6.6 Genes potentially involved in ALT 
It is feasible that the proteins that could be found in APBs are involved in the 
ALT mechanism as many of these proteins, such as RAD51, RAD52 and the 
MRN complex, are involved in homologous recombination and recombination-
dependent replication. The sequestration of the MRN complex proteins by 
SP100 led to telomere shortening and inhibition of APBs (Jiang et al. 2005), 
  35
strongly implicating the MRN complex in the ALT pathway. WRN and BLM, 
which are DNA helicases, are also present in APBs. The BLM helicase could 
have a function at telomeres to regulate the formation of D-loops and/or to 
resolve recombined telomeres in ALT cells (Stavropoulos et al. 2002). The 
observation that exogenous BLM led to increases in telomeric DNA 
specifically in ALT cells led to Stavropoulos et al concluding that BLM is 
actively involved in the ALT mechanism (Stavropoulos et al. 2002). WRN may 
be involved in recombination repair at telomeres and to resolve D-loops for 
the dissociation of the 3’ overhang (Opresko et al. 2004). However, there 
could be redundancy amongst the functions of helicases and thus, the role of 
helicases in the ALT pathway remain to be established. 
1.6.7 ALT in human cancer 
The presence of ALT in human cancer samples has ruled out that ALT is an 
artefact of cell culture. ALT has been detected in bone and soft tissue 
sarcomas, glioblastomas and carcinomas of the lung, kidney, adrenal, breast 
and ovary (Bryan et al. 1997a, Hakin-Smith et al. 2003, Henson et al. 2005, 
Ulaner et al. 2003). Most immortalized cancer cell lines employ only one form 
of telomere maintenance mechanism. However, in tumors, while an estimated 
85% use telomerase as a telomere maintenance method, the prevalence of 
ALT was not established (Ulaner et al. 2004, Henson et al. 2005). As such, it 
cannot be assumed that the remaining 15% of tumors are using ALT for the 
maintenance of telomeres. There remains a possibility that some cancers do 
not have a telomere maintenance mechanism (Reddel 2000, Seger et al. 
2002). While some tumors appear to use both telomerase and ALT for 
telomere maintenance (Bryan et al. 1997b, Hakin-Smith et al. 2003, Henson 
  36
et al. 2005, Ulaner et al. 2003), it is unclear if both mechanisms are 
simultaneously active or if they are active in different subpopulations of the 
tumor. 
ALT appears to be more common in tumors that originate from mesenchymal 
tissues. Sarcomas (which are of mesenchymal origin) are believed to be more 
likely to use ALT than carcinomas (which are of epithelial origin). This is 
because carcinomas are derived from epithelial cells that have fewer barriers 
to the upregulation of telomerase activity, particularly since Yasumoto et al 
reported that low levels of telomerase activity could be detected in normal 
epithelial cells (Yasumoto et al. 1996). Generally, mesenchymal cells exhibit a 
slower turnover, and this translates into lesser telomere shortening than 
epithelial tissues and may thus repress telomerase more tightly. However, 
there are certain sarcomas that utilize telomerase as the telomere 
maintenance mechanism instead of ALT possibly because the tendency 
towards telomerase utilization could be a feature of certain sarcomas 
associated with specific chromosomal translocations (Johnson and Broccoli 
2007). 
1.6.8 ALT and prognosis 
There is increasing evidence that telomerase may be providing cancer cells 
further survival advantage in addition to that of telomere length maintenance 
(Blasco 2002). In addition, ALT cells were postulated to be less malignant 
than telomerase-positive cells (Chang et al. 2003, Stewart et al. 2002). 
However, it appears that ALT leads to equally aggressive tumors, as does 
telomerase activation as studies have identified ALT as the only mechanism 
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for telomere maintenance in metastatic tumors (Sanders et al. 2004, Ulaner et 
al. 2003) and that ALT was not associated with a better prognosis (Ulaner et 
al. 2003). The lack of any telomere maintenance mechanisms correlated 
better with survival than tumor stage and response to chemotherapy. In 
addition, ALT-positive and telomerase-positive osteosarcomas presented 
similar clinical aggressiveness (Ulaner et al. 2003). 
Interestingly, the presence of ALT as the telomere maintenance mechanism in 
high-grade brain tumors, glioblastoma multiforme (GBM), correlated with a 
better prognosis (Hakin-Smith et al. 2003). Thus the presence of ALT in GBM 
corresponded strongly and significantly with survival. 
1.6.9 ALT and cancer therapy 
As mentioned above, telomerase inhibitors are considered as potential agents 
for the specific targeting of cancer cells. However, the use of telomerase 
inhibitors is predicted to exert a strong selection pressure that will lead to the 
emergence of drug-resistant survivor cells that do not employ telomerase for 
telomere maintenance. The use of telomerase inhibitors could result in drug-
resistant cancer cells that activate ALT subsequently for telomere 
maintenance. Studies have shown the emergence of survivors that arose from 
the use of telomerase inhibitors such as adriamycin on human cancer cells 
(Kim et al. 2002). Survivors displayed telomere lengthening of up to 50kb, 
telomere maintenance in the absence of APBs and an increase in telomeric 
exchanges (Kim et al. 2002, Gan et al. 2002, Bechter et al. 2004b). 
It is also expected that telomerase inhibitors will not work on ALT tumors or in 
tumors that exhibit both telomerase activity and ALT. However, when ALT 
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was repressed through the introduction of human chromosome 7 and in 
somatic cell hybrids, cellular senescence and cell death of the immortalized 
cells occurred (Nakabayashi et al. 1997, Perrem et al. 1999). Thus ALT 
presents itself as an attractive target for telomere-directed cancer therapy. 
The use of telomerase and ALT inhibitors in a combination therapy is 
expected to prevent the emergence of drug resistance. The possibility of the 
occurrence of telomere replication in normal cells at a low frequency and 
under strict regulation cannot be ruled out. The understanding of an ALT-like 
activity in normal cells will help in the elucidation of repressors of ALT and in 
the prediction of the toxicity of potential ALT inhibitors. 
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2 CHAPTER 2  OBJECTIVES 
While the occurrence of alternative lengthening of telomeres (ALT) in cancer 
is not as common as the up-regulation and activation of telomerase, it is 
nevertheless emerging as an important niche in cancer. This is especially so 
in view of the potential use of telomerase inhibitors in cancer therapeutics. 
The concern with regard to the use of telomerase inhibitors stems from the 
fact that there exists alternative methods of telomere maintenance and the 
probability of cancer cell survivors of telomerase inhibitor treatment adopting 
such alternative pathways of telomere maintenance. In addition, the use of 
telomerase inhibitors will be ineffective in cancer cells that maintain telomeres 
in a telomerase-independent mechanism. ALT appears to occur in more 
advanced tumors and the potential outcome of cancer cells in moving towards 
an ALT mechanism upon treatment with telomerase inhibitors does not bode 
well for prognosis. 
There is an increased awareness of the significance of ALT and 
consequently, enhanced research efforts. However, there exist many details 
regarding ALT that are unknown and unclear. As of present, although 
telomeric recombination is postulated to be the mechanism of ALT, the 
mechanism has not been elucidated. While the hallmarks of ALT have been 
relatively established, there remains uncertainty with regards to the actual 
purpose of APBs. To date, there has been ambivalence with regards to 
whether APBs are truly indicative of the ALT phenotype or if they are by-
products of the ALT process. It is unknown what triggers ALT and if there are 
repressors of ALT. As a result of our current lack of knowledge with regard to 
all aspects of ALT, there are no molecular targets for subjugating ALT. As 
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molecular targets for pharmacological intervention of ALT have yet to be 
identified, it is essential to further advance our knowledge of ALT and how it 
propagates in cancer cells. 
In this study, we aim to better understand the ALT process and the factors 
that are possibly involved in it. The approach taken was to determine if 
SUMOylation affects the perpetuation of ALT and if a SUMO-defective PML 
disrupts APBs and as a consequence, that of the ALT process. We also 
aimed to study how enhancing an environment for optimal SUMOylation 
affects cellular proliferation through over-expression of SUMO proteins and 
SUMO E3 ligases such as the PIAS proteins. We were interested to see if 
SUMOylation affects ALT in ways other than the SUMO-modification of PML. 
We also investigated the effects of over-expression of wild-type PML and 
coiled-coil domain deficient PML on the formation of APBs in established ALT 
cell-lines. Subsequently, we studied how APBs relate to the ALT pathway. In 
addition, we had also looked at the effects of over-expressing wild-type PML 
and coiled-coil domain deficient PML in telomerase-positive cells to 
investigate the effects of such over-expression. 
The principle objectives of this study include: 
1) Determination of the effects of PIAS proteins on the stability of tumor 
suppressor p53 and its SUMOylated form in ALT cancer cells; 
2) Determination of the effects of enhancing the global SUMOylation 
micro-environment through the over-expression of SUMO and PIAS 
proteins in ALT cancer cells; 
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3) Investigation of the effects of the transient over-expression of wild-type 
PML and coiled-coil domain deficient PML (which will probably affect 
APBs formation as it affects PML nuclear bodies formation) on APBs 
formation and cellular processes; 
4) Study of the consequences of long-term stable over-expression of wild-
type PML and coiled-coil domain deficient PML, particularly with regard 
to telomere length maintenance and hallmarks of ALT. 
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3 CHAPTER 3 MATERIALS AND METHODS 
3.1 Cell cultures 
3.1.1 Cell lines and culture conditions 
Human cancer cell lines which are known to utilize the ALT pathway such as 
JFCF-6/T.1R, IIICF-E/6.A1 (both cell lines were obtained with the courtesy of 
Prof. Roger Reddel, Children's Medical Research Institute, NSW 2145, 
Australia) and osteosarcoma-derived U2OS (ATCC) were used. Telomerase-
positive human breast cancer cell line MCF7 was also used for comparison 
purposes. 
JFCF-6/T.1R cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma) supplemented with 10% fetal bovine serum (FBS; Gibco). 
IIICF-E/6.A1 cells were cultured in Roswell Park Memorial Institute (RPMI)-
1640 medium (Gibco) supplemented with 10% FBS. 
U2OS cells were cultured in McCoy’s 5A medium (Gibco) containing 10% 
FBS and supplemented with 10% FBS, 26mM of sodium bicarbonate and 
1mM L-glutamine. 
MCF7 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 
medium (Gibco) supplemented with 10% FBS. 
All cells were maintained in an incubator at 37oC with 5% CO2 humidified 
atmosphere. 
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3.1.2 Passaging cells 
Cells were subcultured when they reached 80-100% confluence. The culture 
medium was removed and 1X PBS was used to wash the cells. 1 ml of 1X 
trypsin/EDTA (Gibco) was added and when cells were detached, medium 
containing FBS was used to disperse cell clumps through repeated pipetting. 
About two-thirds of the cell pellet was removed and the remaining cells were 
returned to culture. For cell counting, 20 μl of the cell suspension was mixed 
with 20 μl of 0.8 mM trypan blue in PBS on a piece of parafilm. The mixture 
was then transferred to a haemocytometer and at least 100 cells were 
counted. The number of cells/ml was calculated using the following formula: 
Number of cells/ml = the average count square of haemocytometer X the  
 dilution factor X 104 
3.1.3 Storing cells 
Trypsinized cells were pelleted at 1,000 rpm for 5 minutes. The supernatant 
was discarded and the cells were resuspended in fresh freezing medium 
made up of 10% dimethyl sulfoxide (DMSO; Lab-Scan Analytical Sciences) in 
culture medium containing 10% FBS. The cell suspension was then 
transferred to cryovials for overnight storage at -80oC before long-term 
storage in liquid nitrogen. 
3.2 Determination of nuclei acid concentration 
Concentration and purity of DNA was determined by measuring its optical 
density (OD) at 260 nm. One microlitre of the DNA solution was placed on the 
Nanodrop fluorospectrometer (Thermo Scientific) and the concentration of the 
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DNA was obtained in ng/μl. The ratio of the OD260/OD280 was used as a 
gauge to determine the purity of the DNA. The measurement of the quality of 
the DNA is based on the fact that the OD at 260 nm is double that at 280 nm if 
the solution contained pure DNA. Hence purity of the DNA is indicated with a 
ratio of 1.8 to 2.0. If the value of the ratio is smaller, it indicates that the DNA 
is contaminated. 
3.3 Preparation of CaCl2 competent E.Coli cells 
E. coli strain DH5α frozen stock was streaked onto an Luria-Bertani (LB) agar 
plate and incubated overnight at 37oC. A single bacterial colony was 
inoculated into 50 ml of LB medium and cultured overnight at 37oC with 
shaking at 250 rpm. Two milliliters of bacterial culture was added into 200 ml 
of prewarmed LB medium and grown to an OD590 of 0.375. The bacteria was 
aliquoted into four 50 ml prechilled, sterile polypropylene tubes and incubated 
on ice for 10 minutes. The cells were harvested by centrifugation without 
brake at 3000 rpm for 7 minutes at 4oC. Each pellet was gently resuspended 
on ice in 10 ml of ice-cold CaCl2 followed by centrifugation at 2500 rpm for 5 
minutes at 4oC. A second resuspension in 10 ml of ice-cold CaCl2 solution 
was carried out. The cells were incubated for 30 minutes on ice before 
centrifugation. Finally, each pellet was resuspended in 2 ml of ice-cold CaCl2 
solution and dispensed in 100 μl aliquots into pre-chilled sterile 1.5 ml 
microcentrifuge tubes before storing at -80oC. 
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3.4 Plasmids Amplification 
3.4.1 Transformation 
Transformation is a standard procedure of introducing plasmid DNA into 
bacteria cells for amplification. The heat-shock procedure was used for 
transformation. Briefly, approximately 100 ng of plasmid DNA was added to 
DH5α competent cells which were then incubated on ice for 20 minutes. Heat 
shock was achieved by subsequently placing the cells at 42oC for 30 seconds, 
followed by incubation on ice for two minutes. One milliliter of ice-cold (LB) 
media was added and the suspension was incubated at 37oC for one hour. As 
the plasmids encode an ampicillin resistance gene, around 50 to 150 μl of the 
suspension was plated onto an LB agar plate containing 100 μg/ml ampicillin 
and allowed to grow overnight at 37oC. Colonies were picked the following 
day and allowed to grow overnight in LB media containing 100 μg/ml 
ampicillin. The plasmids were purified with either QIAgen miniprep or midi-
prep kits. 
3.4.2 QIAgen miniprep kit 
To obtain a small volume of a pure stock of plasmids, the miniprep kit was 
used. A bacterial colony was inoculated into 3 ml of LB medium supplemented 
with the appropriate antibiotic. The inoculated bacteria were cultured at 37oC 
overnight with shaking at 250 rpm. Two mililitres of the bacteria were pelleted 
by centrifugation at 13,000 rpm for 1 minute. Plasmid extraction was carried 
out using the mini-prep kit from QIAGEN according to the manufacturers’ 
instructions. Essentially, the procedure involves alkaline lysis of the bacteria 
cells followed by adsorption of the DNA onto silica in the presence of high salt 
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buffer. DNA is then eluted in low-salt buffer or water. The plasmids used in 
this study were eluted with water and stored at 4oC or -20oC. 
3.4.3 QIAgen HiSpeed Plasmid kit 
The kit allows for an ultrapure and high yield of plasmid DNA. Briefly, bacteria 
cells were lysed and the plasmid DNA was bound to an anion-exchange resin 
in low-salt and pH conditions. Impurities were removed by a medium-salt 
wash. Plasmid DNA was then eluted in a high-salt buffer and concentrated 
and desalted by isopropanol precipitation. Thorough drying and removal of the 
isopropanol was achieved with the use of the QIA precipitator and DNA was 
finally eluted with water. The plasmids were aliquoted in small volumes and 
stored at 4oC or -20°C. 
3.5 Plasmid constructs 
3.5.1 Addition of HA tag to SENP1 
As the SENP1 sequence in the pCI Neo vector was untagged, HA sequences 
were added upstream of the SENP1 sequence in the vector to enable the 
detection and differentiation of endogenous and exogenous SENP1 (table 3-
1). 
Table 3.1 Primers for incorporation of HA sequence to SENP1 
Primer Name Sequence 
Reverse SENP1 Sal1 5’ GTCGACTCACAAGAGCTTCCGGTG 3’ 




The PCR reaction mix for the incorporation of HA sequence in front of the 
SENP1 sequence in pCI Neo vector was prepared as shown in table 3-2 with 
the conditions stated in table 3-3. 
Table 3.2 Components for PCR reaction for addition of HA sequences to 
SENP1 
Component Volume (μl) 
SENP1 plasmid 1 
Reverse SENP1 Sal1 0.5 
Forward SENP1 EcoR1 0.5 
dNTPs 0.5 
Pfu DNA polymerase 0.5 
Pfu buffer 2.5 
H2O 19.5 
Final Volume 25 
 
Table 3.3 PCR reaction conditions for inserting HA to SENP1 sequence 
Reaction Temperature (oC) Time Cycle 
Initialization 94 3 minutes  
Denaturation 94 30 seconds  
Annealing 55 30 seconds 35 
Extension 72 90 seconds  
Final extension 72 10 minutes  
Hold 4 ∞  
 
The PCR products were purified, digested with appropriate restriction 
enzymes and cloned into the desired vector. 
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3.5.2 PCR mutagenesis to generate PML KR mutants 
After establishing the positions of the three lysines in PML that can be 
SUMOylated, primers were designed for the conversion of these lysines to 
arginine. 
Table 3.4 Primers for generating PML KR mutants 
Primer Name  Sequence 
Fwd PML K65R 5’ CAGGCGGAAGCCCGATGCCCGAAGCTG 3’ 
Rev PML K65R 5’ CAGCTTCGGGCATCGGGCTTCCGCCTG 3’ 
Fwd PML K160R 5’ CAGTGGTTCCTCCGTCACGAGGCCCGG 3’ 
Rev PML K160R 5’ CCGGGCCTCGTGACGGAGGAACCACTG 3’ 
Fwd PML K490R 5’ AGGAAGGTCATCCGCATGGAGTCTGAG 3’ 
Rev PML 490R 5’ CTCAGACTCCATGCGGATGACCTTCCT 3’ 
 
Table 3.5 Components of PCR reaction for generation of PML KR 
mutants 
Component Volume (μl) 
SENP1 plasmid 1 
Primer 1 0.5 
Primer 2 0.5 
dNTPs 0.5 
Pfu Turbo enzyme 0.5 
Pfu buffer 2.5 
H2O 19.5 
Final Volume 25 
 
Table 3.6 PCR reaction conditions for generating PML KR mutants 
Reaction Temperature (oC) Time Cycle 
Initialization 95 30 seconds  
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Denaturation 95 30 seconds  
Annealing 55 1 minutes 18 
Extension 68 30 minutes  
Hold 4 ∞  
 
The PCR products were treated with DpnI to digest parental DNA prior to 
further use. 
3.5.3 Sub-cloning of HA-PML to pCI Neo vector 
Table 3.7 Primers used for the sub-cloning of HA-PML to pCI Neo vector 
Primer Name  Sequence 
PML XhoI forward 5’ CTCGAGATGGTCTATCCTTATGACGTCCCT 3’
PML EcoRI reverse 5’ GAATTCTCACCACAACGCGTTCCTCTCCCT 3’
 
Table 3.8 Components of PCR reaction for sub-cloning of HA-PML into 
pCI Neo vector 
Component Volume (μl) 
PML plasmid 1 
PML XhoI forward (10μM) 0.5 
PML EcoRI reverse (10μM) 0.5 
10 mM dNTPs 0.5 
Pfu DNA polymerase 0.5 
Pfu buffer 2.5 
H2O 19.5 
Final Volume 25 
 
Table 3.9 PCR reaction conditions for sub-cloning of HA-PML into pCI 
Neo vector 
Reaction Temperature (oC) Time Cycle 
Initialization 94 3 minutes  
Denaturation 94 30 seconds  
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Annealing 55 30 seconds 35 
Extension 72 90 seconds  
Final extension 72 10 minutes  
Hold 4 ∞  
 
The PCR products were purified, digested with appropriate restriction 
enzymes and cloned into the desired vector. 
3.5.4 Addition of FLAG tag to PML C/C- 
As there is a partial sequence of the FLAG tag in PML C/C-, the full sequence 
of FLAG was introduced. This will allow the detection of the exogenously 
introduced PML C/C-. 
Table 3.10 Primers for addition of FLAG tag to PML C/C- 
Primer Name  Sequence 
FLAG PML C/C- fwd 5’ CTCGAGATGAGCGACTACAAGGAC 3’ 
PML EcoRI reverse 5’ GAATTCTCACCACAACGCGTTCCTCTCCCT 3’ 
 
Table 3.11 Components of PCR reaction for addition of FLAG tag to PML 
C/C- 
Component Volume (μl) 
PML C/C- plasmid 1 
FLAG PML C/C- fwd (10μM) 0.5 
PML EcoRI reverse (10μM) 0.5 
10 mM dNTPs 0.5 
Pfu DNA polymerase 0.5 
Pfu buffer 2.5 
H2O 19.5 
Final Volume 25 
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Table 3.12 PCR reaction conditions for addition of FLAG tag to PML C/C- 
Reaction Temperature (oC) Time Cycle 
Initialization 94 3 minutes  
Denaturation 94 30 seconds  
Annealing 55 30 seconds 35 
Extension 72 90 seconds  
Final extension 72 10 minutes  
Hold 4 ∞  
 
The PCR products were purified, digested with appropriate restriction 
enzymes and cloned into the desired vector. 
3.6 Restriction endonuclease digestion of DNA 
The DNA plasmids were digested with the appropriate restriction enzymes for 
subsequent ligation and cloning work. The reaction mix was prepared as 
stated in table 3-13. Double digestions were carried out simultaneously as the 
buffer conditions were suitable for both enzymes used. The reaction mix was 
prepared and allowed to incubate at 37oC (or other appropriate temperature) 
for one hour. Reaction was stopped by heat inactivating the enzymes at 65oC. 
Table 3.13 Restriction digest reaction mix 
Component Volume (μl) 
10X buffer 5 
Restriction enzyme 1 1.5 
Restriction enzyme 2 1.5 
DNA 3.5 μg 
Total volume Top up to 50 μl with water 
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3.7 Agarose gel electrophoresis 
DNA was generally analyzed on a 0.8% agarose gel. 0.8 g of agarose 
(SeaKem) was dissolved in 100 ml of 1X Tris-borate-EDTA (TBE) buffer and 
microwaved until the agarose was completely dissolved. 1 μl of 10 mg/ml of 
ethidium bromide was added and the mixture was poured into a cast with a 
well comb and allowed to solidify for at least 45 minutes prior to use. Once the 
gel was set, the comb was removed and the gel was submerged in 1X TBE 
buffer in the electrophoresis tank. Samples were mixed with gel loading dye 
prior to application to the wells. Depending on experimental conditions, the 
agarose gel was ran at voltages ranging from 40 V to 100 V until the desired 
extent of separation was obtained. The nucleic acid was visualized under UV 
light. 
3.8 Purification of DNA from agarose gel 
The desired DNA product was quickly excised from the agarose gel under UV 
light and purified with QIAquick Gel extraction kit (QIAGEN). Essentially, the 
agarose gel was solubilized and DNA was adsorbed onto the silica membrane 
under high-salt conditions and impurities such as ethidium bromide and 
primers were removed, followed by low salt elution of DNA. 
3.9 DNA ligation 
T4 DNA ligase covalently links the phosphodiester bonds between the insert 
DNA and vector DNA to join the two fragments together. Ligation between 
vector and insert DNA digested with the same restriction enzymes was carried 
out overnight at 16oC with the use of T4 DNA ligase. Ligated products were 
then used for transformation in bacteria cells. 
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3.10  DNA fast prep 
DNA fast prep was done as a means to obtain DNA from bacteria for 
screening of the bacteria clones. About 1.5 ml of the bacteria culture was 
used in this fast prep procedure. About 50 μl of the fast prep lysis solution 
was used to resuspend the bacteria pellet and the mixture was placed at 
100oC for 2 minutes followed by incubation on the ice for 1 minute. The 
mixture was spun at maximum speed at room temperature for 15 minutes and 
the DNA in the supernatant was used for subsequent screening for the 
presence of insert DNA. 
3.11  Automated DNA sequencing 
DNA sequencing using the ABI PRISM Big Dye Reaction Terminator Cycle 
Sequencing Kit version 3.1 (Applied Biosystems) was performed to ensure 
that the integrity of the gene sequences and that the desired genetic 
manipulations were successful. The PCR reaction mix and conditions for DNA 
sequencing was set up as shown in table 3-14 and 3-15. A cleaning mixture 
consisting of 3M NaOAc, 95% EtOH and water was added to the sequencing 
products obtained after the PCR reaction. The mixture was vortexed and 
incubated at room temperature for 30 minutes and centrifuged at maximum 
speed for 20 minutes. The supernatant was removed and 75% EtOH was 
added and the mixture was centrifuged for 5 minutes at maximum speed. This 
was repeated twice and after the final wash and the DNA was air-dried at 
70%. The DNA sample was then reconstituted in the sequencing loading 
buffer and analyzed on an ABI PRISMTM TM 337 automated sequencer 
(Applied Biosystems). 
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Table 3.14 DNA sequencing reaction mix 
Component Volume (μl) 
DNA template (about 200 ng) 10  
Primer 3.2 
BigDye 1.5 
5x buffer 2 
Total volume Top up to 20 μl with water 
 
Table 3.15 PCR reaction conditions for DNA sequencing 
Reaction Temperature (oC) Time Cycle 
Initialization 96 1 minute  
Denaturation 96 10 seconds  
Annealing 46 5 seconds 24 
Extension 60 4 minutes  
Final extension 60 15 minutes  
Hold 4 ∞  
 
3.12  Transient transfection 
Chemical transfection was used as a means to introduce foreign DNA to 
cultured cells. Fugene 6 (Roche) and lipofectamine 2000 (Invitrogen) were 
used for transfection. The ratio of the reagents to DNA is 3:1, that is, 3 μl of 
the transfection reagent was used with every one μg of DNA. Cells used for 
transfection were seeded one day before transfection at a density such that 
they would be about 70% confluent on the day of transfection. Transfections 
were carried out according to manufacturer’s instructions. Briefly, the 
appropriate amount of transfection reagent was added into plain medium that 
does not contain FBS and this mixture was added to the DNA and allowed to 
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incubate for at least 45 minutes before its addition into the cell culture 
medium. The transfected cells were cultured for 48 hours before assaying. 
3.13  Determination of geneticin dosage 
Geneticin (G418; Gibco) was used to select cells that stably over-express the 
transfected DNA as the vectors used encode a gene that renders cells 
containing it resistant to G418. Different concentrations of geneticin was 
added every other day to the cells for about 10 to 14 days to determine the 
minimum concentration of geneticin that cause death of all the cells. The 
geneticin dosage established for JFCF-6/T.1R and MCF7 cells was 600 μg/ml 
while that for U2OS was 800 μg/ml. These dosages were used to select 
generate stably transfected cell-lines. 
3.14  Generation of stably over-expressing cell clones (stable 
transfection) 
Cells were transfected with plasmids as outlined in the transient transfection 
protocol. On day three after transfection, the culture medium was removed 
and replaced with media containing the appropriate dosage of geneticin. This 
continued for about 2-3 weeks until distinct clones were observed. The clones 
were picked up using sterile Whatman paper and allowed to amplify in 96-
wells plate. The over-expression of the proteins in the clones was verified 
through western blot analysis. The positive clones were subsequently 
expanded. 
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3.15  Cell cycle synchronization 
Cell cycle synchronization was achieved through the addition of known 
compounds commonly used to induce cell cycle arrest in specific phases of 
the cell cycle. Cells were synchronized in the Go phase by replacing the 
medium to one that does not contain FBS. Subsequently the medium was 
replaced to one that contains aphidicolin to synchronise cells in G1 phase. 
Cells that were to be synchronized in S phase were treated with hydroxyurea. 
Hoechst 33342 was used to synchronise cells in S phase while nocodazole 
was used to synchronize cells in the M phase. Cells that were synchronized in 
M phase were obtained through mitotic shake-off. As mitotic cells are 
rounded, they have fewer points of attachment and thus detach easily upon 
shaking off from the culture plate. The synchronized cells were analyzed 
through flow cytometry to confirm that the majority of the cells were indeed 
synchronized in the desired cell cycle phase. 
3.16  Preparation of whole cell extracts 
Whole cell extracts were used to obtain protein samples for western blot 
analysis. Cells were washed with 1X phosphate-buffered saline (PBS) in the 
absence or presence of N-ethylmaleimide (NEM; Sigma), the latter being 
used for preservation of SUMO-conjugated proteins. About 100 μl of lysis 
buffer containing 0.5% NP-40 (Sigma), 1mM PMSF (Sigma), 0.5mM DTT 
(Biorad), 5mM EDTA, 150mM NaCl, 50mM Tris pH8, complete Mini (Roche) 
and 20mM NEM (if required) was used to scrape cells from the culture plate. 
This process was repeated. The cell suspension was incubated at 4oC for 45 
minutes prior to spinning at maximum speed at 4oC for 30 minutes. 
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3.17 Determination of protein concentration by Bradford 
method 
The Bradford assay is a dye-binding assay based on the differential colour 
change of Coomassie Blue G dye as it binds to the protein. A standard curve 
was generated by measuring the absorbance of BSA at concentrations from 0 
to 1mg/ml (Figure 3-1). 3 μl of protein sample was diluted with 97 μl of water 
and 1 ml of GelCode Blue (Thermo Scientific) was added and the absorbance 
of the sample at 595nm was measured in a spectrophotometer. The 
concentrations of proteins were determined from the standard curve. The 








3.18  Western blot analysis 
Western blot analysis is the gold standard to detect the presence and 
expression levels of a protein. Essentially, it consists of protein separation, 
followed by transferring of the proteins onto a membrane and probing the 
membrane with antibodies. 
3.18.1 Separation of proteins by polyacrylamide gel 
electrophoresis 
The first step of western blot analysis is the separation of proteins using 
sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (SDS-
PAGE). The percentage of acrylamide used varies depending on the size of 
the proteins under investigation. In this study, 10% acrylamide gels were 
mostly used. Generally, a lower percentage gel can be used for a higher 
molecular weight protein. Protein samples were denatured at around 95oC 
prior to loading onto the gel and resolved by running in 1X SDS running buffer 
at 180 to 220V for 45 minutes or until desired distance was reached. 
3.18.2 Protein transfer 
The separated proteins on the gel were then transferred onto a nitrocellulose 
membrane (Protran). A transfer sandwich consisting of two Whatman paper, 
nitrocellulose membrane, protein gel and another two Whatman paper was 
formed and placed onto the semi-dry transfer machine. The Whatman papers 
and membrane were soaked in the transfer buffer prior to the formation of the 
sandwich. The transfer was allowed to proceed with a setting of 180mA for 
one hour. The membrane was soaked in Ponceau S (Sigma) solution for the 
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visualization of the proteins transferred onto it. 1X Tris-buffered saline Tween 
20 (TBST) was used to wash the Ponceau S stain away. 
3.18.3 Western blotting 
The membrane was then soaked in a blocking solution for 1 hour at room 
temperature. Primary antibodies were diluted accordingly with blotting 
solution. The membrane was incubated with the primary antibodies overnight 
at 4oC. The membrane was then rinsed four times with 1X TBST and 
incubated with secondary antibodies diluted in the blotting solution for one 
hour at room temperature. The membrane was rinsed 5 times with 1X TBST 
prior before being soaked with the ECL solution (Amersham) or SuperSignal 
Femto West (Thermo Scientific) for visualization of the proteins. The 
membrane was then placed in a film cassette and an x-ray film was exposed 
to the membrane. The film (Thermo Scientific) was then placed in a 
developer. The antibodies used were mouse anti-p53 (1:1000 dilution; Santa 
Cruz), mouse SUMO-1 (1:500 dilution; Zymed Laboratories), rabbit anti-
SUMO2 (1:200 dilution; Zymed Laboratories), mouse anti-PML (1:500 dilution; 
Santa Cruz), mouse anti-Mdm2 (1:500 dilution, Calbiochem) mouse anti-p21 
(1:500 dilution; Santa Cruz), mouse anti-HA (1:2000 dilution; Covance), 
mouse anti-FLAG (1:6000 dilution; Sigma) and rabbit anti-actin (1:2000 
dilution; Sigma). Secondary antibodies used were goat anti-mouse IgG-HRP 




Table 3.16 Solutions for Western blot 
Solution Concentration 
6X Lammeli sample buffer 350mM Tris-HCl pH6.8 
36% glycerol 
10% SDS 
0.01 g Bromophenol blue 
600mM DTT 
10% resolving gel 3.33 ml 30% Acrylamide/bis solution, 3.8 ml 
Tris-HCl pH8.8, 2.82 ml H2O, 50 μl 20% SDS, 
50 μl 10% APS, 25 μl TEMED 
Stacking gel 0.8 ml 30% Acrylamide/bis solution, 714 μl 
Tris-HCl pH6.8, 4.4 ml H2O, 24 μl 20% SDS, 
25 μl 10% APS, 12.5 μl TEMED 
1X SDS running buffer 25mM Tris-HCl 
0.2M Glycine 
0.1% SDS 
adjust pH to 8.3 
Transfer buffer 25mM Tris 
192mM Glycine 
20% v/v Methanol 
Adjust pH to 8.3 
5X TBS Tris pH 7.4 
770mM NaCl 
1X TBST 0.1% Tween 20 in 5X TBS 
Blocking solution Dissolve 3% non-fat milk powder and 0.2% 
Tween 20 in 5X TBS 
Blotting solution Dissolve 1% non-fat milk powder and 0.2% 
Tween 20 in 5X TBS 
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3.19  Immunoprecipitation 
Immunoprecipitation was used to detect protein-protein interactions. 
Essentially, antibodies specific to the target protein were used to pull down a 
protein which can be used for further investigation. The preparation of whole 
cell lysate for immunoprecipitation was similar to that as described above 
without the use of denaturing reagents such as DTT. Prior to addition of 
antibodies to the protein samples, the antibodies were incubated with protein 
A/G–agarose beads (Zymed Laboratories) for at least 4 hours at 4oC. The 
antibodies-beads complexes were washed with the non-denaturing lysis 
buffer and then added to protein samples for overnight incubation at 4oC. The 
immunoprecipitated products were spun at 1000 rpm for 2 minutes and 
washed twice with ice-cold wash buffer consisting of Tween 20, Tris pH 8, 
NaCl and EDTA. For the final wash, ice-cold 1X PBS was used and one-third 
of the immunoprecipitated products were used for verification of the process 
while two-thirds was used for subsequent investigation. NEM was added in all 
solutions for preservation of SUMO-conjugated proteins. The presence of 
SDS in the loading dye and the high temperature used for denaturation of the 
proteins prior to loading on the gel led to dissociation of the proteins from the 
beads. The western blot protocol was then performed as stated above. 
3.20  Immunofluorescence 
About 10,000 cells were seeded on coverslips in 6-wells plates and allowed to 
attach overnight. For transient transfection, cells were transfected on 
coverslips and harvested 48 hours later. Cells were washed with 1X PBS and 
then fixed with 4% paraformaldehyde (PFA) at room temperature for 10 
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minutes. After three washes with 1X PBS, the cells were permeabilised with 
0.2% Triton-X100 in PBS for 5 minutes. After a 30 minutes incubation with the 
blocking buffer containing 5% BSA in 0.2% Triton-X100 in PBS, the cells were 
simultaneously incubated with two primary antibodies diluted in 3% BSA for 
one hour at room temperature. After three washes with 1X PBS, simultaneous 
incubation with secondary antibodies at room temperature in the dark for one 
hour was performed. Subsequent washes were also conducted in the dark. 
The coverslips were sufficiently dried prior to mounting them onto slides 
containing Vectashield mounting media with DAPI (Vector laboratories). 
Slides were stored at 4oC in the dark until analysis. Primary antibodies used 
were mouse anti-PML (1:100 dilution; Santa Cruz), goat anti-TRF2 (1:100 
dilution; Santa Cruz), mouse anti-HA (1:1000 dilution; Covance), mouse anti-
FLAG (1:1000 dilution; Sigma) and rabbit anti-SP100 (1:100 dilution; Santa 
Cruz). Secondary antibodies used were Texas-red rabbit anti-mouse (1:250 
dilution; Molecular probes) and FITC rabbit anti-goat (1:250; Vector 
Laboratories). 
3.21  Confocal microscopy analysis 
Fluorescent images were captured through confocal microscopy (Olympus 
Fluoview FV1000). Images were captured at the XY plane and at 100X 
magnification. Images were processed and analyzed with the Olympus FV10-
ASW1.3 Viewer. 
3.22  Crystal violet cell viability assay 
Crystal violet assay was employed as a means to determine the viability of 
cells. Crystal violet stains only live cells and is hence an indicator of cellular 
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viability. For transient transfection experiments, 0.05 x 106 cells were seeded 
onto 6 wells plates and cells were harvested 48 hours after transfection. For 
stably transfected cells, 0.1 x 106 cells were seeded and allowed to attach 
overnight. Cells were then washed two times with 1X PBS and the crystal 
violet solution was added to the cells and incubated at 37oC for 15 minutes. 
Subsequently, the crystal violet solution was removed and cells were washed 
twice with 1X PBS. 1% SDS in PBS was added to dissolve the cells and the 
absorbance of the samples at 595nm was measured with a 
spectrophotometer (Bio-Tek Instruments). 
Table 3.17 Crystal violet solution 
Component  Volume (ml)/ Weight (mg) 
40% Formaldehyde 875 ml 
NaCl  125 mg 
100% ethanol 50 ml 
Crystal Violet powder 750 mg 
 
3.23  Cell cycle analysis by propidium iodide staining 
Propidium iodide stains DNA and it was used together with fluorescence-
activated cell sorting (FACS) to determine the phase of the cell cycle a cell is 
in. The DNA content of a cell changes depending on the stage of the cell 
cycle it is in. Cells undergoing apoptosis are known to be in the sub-G1 phase 
while cells with normal amount (N) of DNA content are in the G1 phase. Cells 
that have double the amount (2N) of DNA content are in the G2/M phase. 
Cells that have DNA content between N and 2N are in the S phase whereby 
DNA is being replicated. Cells were trypsinized and washed with 1X PBS 
twice. Cells were then fixed with 70% ice-cold ethanol and incubated at -20oC 
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for at least 2 hours. Subsequently, the ethanol was removed and cells were 
washed with 1X PBS and stained with a propidium iodide solution containing 
RNase and Triton X-100 for at about 15 minutes at room temperature. Cells 
were filtered before use in the flow cytometry machine. The data was 
analyzed with the WinMDI software. 
3.24  Colony formation assay 
Colony formation assay is a cell survival assay based on the ability of a single 
cell to grow into a colony. This assay tests every cell in the population for its 
ability to undergo unlimited proliferation. 1000 cells were counted and seeded 
onto 100 mm culture dishes and allowed to grow for 10 to 14 days. Culture 
media was changed every other day until the cells were harvested. After 
washing with 1X PBS, crystal violet solution was used to stain the cells. The 
plates were air-dried after repeated washing with 1X PBS. Images of the 
plates were then taken and colonies were counted. 
3.25  Terminal Restriction Fragment analysis 
The terminal restriction fragment (TRF) analysis is a commonly used method 
to determine telomere length. Here, a TeloTAGGG Telomere Length Assay kit 
from Roche was used. Briefly, genomic DNA obtained was digested with RsaI 
and HinfI, leaving sub-telomeric and telomeric DNA. The digested DNA was 
then separated on a 0.8% agarose gel and transferred onto a positively 
charged membrane by Southern blotting. The membrane was subsequently 
incubated with a telomere specific probe which is labeled with digoxigenin 
(DIG). A DIG-specific antibody that is coupled with alkaline phosphatase was 
then added to the membrane. The telomeric probes were visualized through 
  65
the addition of CDP-Star, a chemiluminescent substrate of alkaline 
phosphatase. The average telomere length was determined by comparisons 
with the molecular weight standard. 
3.25.1 Preparation of DNA from cells 
Cells were trypsinized and DNA was extracted using the DNeasy Blood and 
Tissue kit (QIAGEN). Essentially cells were directly lysed with proteinase K 
and conditions were adjusted to optimized DNA binding and DNA was bound 
to the DNeasy membrane while contaminants passed through. Contaminants 
and enzyme inhibitors were removed in wash steps and DNA was eluted with 
a low-salt buffer and ready for use. 
3.25.2 Restriction endonuclease digestion of DNA 
DNA was digested with Fastdigest RsaI and HindfI enzymes prepared as 
shown in table 3-16. The reaction mix was placed in a 37oC water bath for 10 
minutes prior to loading into the agarose gel. 
Table 3.18 Reaction mix of RE digest of genomic DNA 
Components  Volume (μl) 
RsaI 1 
HinfI 1 
Genomic DNA 1-2 μg 
Fastdigest buffer 2 
Total volume Top up to 20 μl with water 
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3.25.3 DNA separation by agarose gel electrophoresis 
A 0.8% agarose gel was used for the separation of the digested genomic 
DNA. The gel was resolved at 60V for 4 to 6 hours. The gel was visualized 
after the end of the run to ensure the separation of the DNA. The DNA gel 
was then acidified and neutralized before it was used for southern blotting. 
3.25.4 Southern blotting 
3.25.4.1 Transferring of DNA to nylon membrane 
The Whatman paper and nylon membrane were soaked with 20X sodium 
chloride - sodium citrate (SSC) buffer. A sponge of the appropriate size was 
thoroughly soaked with 20X SSC and placed in a container filled with 20X 
SSC. A sandwich consisting of two Whatman paper, the DNA gel, the 
membrane and two Whatman paper was formed on top of the sponge. Saran 
wrap was used to cover the sandwich and the container to prevent 
evaporation of the 20X SSC buffer. A razor blade was used to remove the 
saran wrap surrounding the sandwich, exposing it to enable paper towels to 
be placed over it. Weights were then placed over the paper towels to allow 
southern blot to take place over night through capillary action. After overnight 
transfer, the DNA on the membrane was cross-linked with UV and the gel was 
checked for complete transfer of DNA under UV light. 
3.25.4.2 Pre-hybridization, hybridization with probe and washing of 
blot 
The membrane was then incubated with the pre-hybridization solution at 42oC 
for 1 hour. The telomeric probe was added for a further incubation of 3 hours 
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at 42oC. Subsequently, the membrane was washed with various wash buffers 
under stringent conditions. 
3.25.4.3 Detection 
Anti-DIG antibodies were then added and chemiluminescence could be 
detected after the addition of the substrate CDP-Star. The average telomere 
length was then measured with the use of a densitometer to compare the 
signals against that of the molecular weight markers. 
Table 3.19 Solutions required for Southern blot and TRF analysis 
Solution Concentration 
HCl solution 0.8% HCl solution 
Denaturation solution 0.5M NaOH 
1.5M NaCl 
Neutralization solution 0.45M Tris pH 7.4 
2.7M NaCl 
Stringent wash buffer I 2X SSC 
1% SDS 
Stringent wash buffer II 0.2X SSC 
1% SDS 
Washing buffer 1X washing buffer 
Blocking solution 1X blocking solution 
0.9X maleic acid 
Anti-DIG-AP working solution 1 ul of anti-DIG-AP  
1X blocking solution 
0.9X maleic acid 
Detection buffer 1X detection buffer 
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3.26  Metaphase chromosomes preparation 
For visualization of telomere length, metaphase chromosomes were prepared. 
The addition of colcemid at 0.1 μg/ml to cultured cells was used to enhance 
the population of cells in metaphase. Cells were trypsinized following 
overnight treatment with colcemid. Prewarmed KCl was added as a source of 
hypotonic solution which caused the cells to swell so that they burst open 
when dropped onto slides. After 10 minutes incubation with KCl at 37oC, the 
cells were spun down at 800 rpm for 8 minutes. After removal of the KCl, a 
fixative containing methanol and acetic acid in a 3:1 ratio was added and this 
process was repeated. The cell suspension was taken up by Pasteur pipettes 
and cells were dropped onto slides in a drop-wise manner. Slides were 
viewed under light microscope to ensure proper metaphase spreads were 
obtained and then dried prior to subsequent use. Remaining cells were stored 
at -20oC for future use. 
3.27  Fluorescence in situ hybridization 
The metaphase spreads on the slides were first rehydrated with 1X PBS and 
then fixed with 4% formaldehyde. After three washes with 1X PBS, the slides 
were rinsed with water containing HCl. Pepsin at 1 mg/ml was added to the 
slides and allowed to incubate in 37oC for 3 minutes. Subsequently, the cells 
were placed in 4% formaldehyde and after a series of washing with 1X PBS, 
cells were dehydrated in increasing concentrations of ethanol. After the slides 
were air dried, they were covered with the hybridization mix. The slides were 
placed in an oven of 80oC for 3 minutes and were hybridized in a humidified 
chamber at room temperature for 2 hours in the dark. After a series of 
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washing, another serial dehydration was done. When slides were dried, 
Vectashield mounting medium containing DAPI was used to mount coverslips 
onto the slides. Slides were kept at 4oC in the dark before examination under 
a fluorescent microscope. 
3.28  Telomerase activity assay (TRAP) 
The TRAPeze XL (Chemicon) kit was used for measurement of telomerase 
activity. This assay is a semi-quantitative assay for the measurement of 
telomerase activity through the addition of fluorescent telomeric sequences 
onto telomeres. Cells containing higher telomerase activities will have a 
higher readout in terms of the total product generated (TPG). The first step 
involves lysis of the cell pellet with CHAPS lysis buffer and about 1.5 ng of 
proteins were used for the PCR reactions subsequently. The contents of the 
completed PCR products were transferred to a black 96-wells plate and 150 
μl of TRAP buffer consisting of 10mM Tris pH 7.4, 0.15M NaCl and 2mM 
MgCl2 was added to it. The sulphodamine and fluorescein fluorescent 
intensity were obtained and the TPG was calculated. 
Table 3.20 PCR components of TRAP PCR 
Component Volume (μl) 
5X TRAPeze reaction mix 10 
Taq polymerase 0.4 
Protein lysate 1.5 μg 
Total volume Top up to 50 μl with water 
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Table 3.21 PCR reaction conditions for TRAP PCR 
Reaction Temperature (oC) Time Cycle 
Incubation 30 30 minutes  
Denaturation 94 30 seconds  
Annealing 59 30 seconds 36 
Extension 72 1 minute  
Final extension 72 10 minutes  
Incubation 55 25 minutes  
Hold 4 ∞  
 
3.29  Bioinformatics and Biostatistics 
Database searches were carried out using National Center for Biotechnology 
Information (NCBI). Student’s t-test was done to determine the statistical 




4 CHAPTER 4   RESULTS 
4.1 SUMOylation of p53 
4.1.1 Different global SUMO-1 and SUMO-2 conjugation patterns in 
ALT and non-ALT cancer cell lines 
The global SUMOylation pattern detectable by both SUMO-1 and SUMO-2 
antibodies in ALT cell lines, IIICF-E/6.A1 and JFCF-6/T.1R, and in 
telomerase-positive MCF7 cells, was first studied (Figure 4-1 and 4-2). N-
ethylmaleimide, an agent that preserves SUMO-conjugated proteins, was 
used to enable the identification of SUMO-conjugated proteins. NEM inhibits 
isopeptidases, preventing them from acting on the isopeptide bond between 
the SUMO protein and its target protein. Cell lysates were harvested in the 
presence or absence of NEM. An antibody-reactive protein band observed in 
the NEM-positive lysate, but not in the NEM-negative lysate, indicates that 
such band is the SUMO-conjugated form of the protein. Similar patterns of 
global SUMOylation among the different cell lines were observed. However, 
the intensity of the SUMO1 antibodies reactive bands appeared more intense 
in the ALT cell lines. The levels of SUMO-1 conjugated proteins were also 
higher than of SUMO-2 modified proteins. Correspondingly, free SUMO-2 was 
more easily detectable than free SUMO-1. Another interesting observation is 
that the levels of free SUMO-2, as observed in cells that were harvested in the 
absence of NEM, were high in ALT cells compared to undetectable levels in 





Figure 4.1 Global SUMOylation status of cancer cells (SUMO1). 
ALT cells (IIICF-E/6.A1 and JFCF-6/T.1R) presented a greater degree global 
SUMOylation than non-ALT cells. Endogenous proteins were harvested in the 
presence or absence of NEM. Bands present in cell lysates harvested in the 
presence of NEM but disappeared in lysates harvested in the absence of 
NEM represent the SUMOylated species. Blots were probed with the 












Figure 4.2 Global SUMOylation status of cancer cells (SUMO2). 
The intensity of SUMOylation differed in different cell lines, with IIICF-E/6.A1 
cells showing the least amount of SUMO-2 conjugated proteins. Endogenous 
proteins were harvested in the presence or absence of NEM. Bands present 
in cell lysates harvested in the presence of NEM but disappeared in lysates 
harvested in the absence of NEM represent the SUMOylated species. Blots 









4.1.2 SUMO-p53 is detected in JFCF-6/T.1R cells and not in MCF7 
cells 
Subsequently, proteins that have important roles in carcinogenesis and whose 
functions are affected by SUMOylation were considered for further 
investigation. After intensive literature review, tumor suppressor p53 was 
decided as the main protein of interest in this study. p53 is an important tumor 
suppressor whose function is lost in about 50% of human tumors. p53 has 
been shown to be modifiable by SUMO and that SUMOylated p53 has 
demonstrated enhanced anti-tumorigenic properties (Melchior and Hengst 
2002). Endogenous p53 in telomerase-positive MCF7 cells and ALT positive 
JFCF-6/T.1R cells was studied in a bid to determine its presence and the 
expression levels of its SUMO-conjugated counterpart. 
The immunoblot probed with p53 antibodies showed that p53 was detected in 
both the cell types (Figure 4-3). In MCF7 cells, there were multiple higher 
molecular weight bands, which were not present in the cell lysate harvested 
without NEM, above the p53 protein. In JFCF-6/T.1R cells, an additional band 
above the p53 protein, at approximately 66 kDa, was detected. The 
verification of these higher molecular weight bands as SUMO-modified p53 
was next carried out. 
Immunoprecipitation of p53 followed by western blotting with anti-SUMO-1 
antibodies in both MCF7 and JFCF-6/T.1R cells was performed (Figure 4-4). 
While the higher molecular weight band at approximately 66 kDa was verified 
to be SUMO-p53 in JFCF-6/T.1R cells, no SUMO-p53 was detected in MCF7 
cells. As NEM can preserve both SUMOylated and ubiquitinated proteins, it 
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was suspected that the higher molecular weight proteins in MCF7 cells are 
ubiquitinated p53 instead of SUMOylated p53. To substantiate this claim, 
MCF7 cells were treated with MG132, a known proteasome inhibitor, at a 
concentration of 5μM for six hours. The use of MG132 leads to an 
accumulation of ubiquitinated proteins as they are not removed by the 
proteasome system. As shown in figure 4-4, the use of MG132 indeed 
preserved the higher molecular weight proteins above p53. Hence p53 is 
SUMOylated in JFCF-6/T.1R cells while ubiquitinated in MCF7 cells. 
 
Figure 4.3 p53 is present in both MCF7 and JFCF-6/T.1R cells and 
appears to be SUMO-modified. 
Endogenous proteins were harvested in the presence or absence of NEM. A) 
Multiple higher molecular weight species present in MCF7 cell lysate 
harvested with NEM were detected, presumably representing SUMOylated 
p53. B) A distinct band at 66 kDa which is probably indicative of SUMO-










Figure 4.4 p53 is SUMOylated in JFCF-6/T.1R cells and ubiquitinated in 
MCF7 cells. 
Endogenous p53 was immunoprecipitated with anti-p53 antibodies and the 
immunoprecipitated proteins were probed with anti-SUMO-1 antibodies. A) i) 
Western blot analysis of immunoprecipitated p53 did not reveal any 
SUMOylated p53 in MCF7 cells. ii) Treatment with MG132 preserved 
ubiquitinated-p53 in MCF7 cells. Cells were harvested 6 hrs after MG132 
(5μM) treatment. B) Western blot analysis of immunoprecipitated p53 
demonstrated the presence of SUMO-p53 in JFCF-6/T.1R cells. Blots were 
probed with the indicated antibodies. 
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4.1.2.1 De-SUMOylation of p53 is achieved through SUMO-specific 
protease SENP1 
To further validate that p53 is SUMOylated in JFCF-6/T.1R cells, SENP1 was 
over-expressed and SUMO-p53 levels was reviewed. SENP1 is a SUMO-
specific protease and it has been shown to de-conjugate SUMO from its 
target proteins (Di Bacco and Gill 2006, Yates et al. 2008). While the over-
expression of SENP1 in MCF7 cells did not affect the ubiquitinated levels of 
p53 regardless of the amounts introduced, SENP1 reduced the proportion of 
SUMO-p53 in JFCF-6/T.1R cells (Figure 4-5). This reduction brought about by 
SENP1 occurred in a dose-dependent manner. 
 
Figure 4.5 De-SUMOylation of p53 in JFCF-6/T.1R cells is achieved by 
SENP1. 
(A) SENP1 does not de-ubiquitinate p53 in MCF7 cells. (B) SENP1 de-
SUMOylates p53 in JFCF-6/T.1R cells. Fugene 6 was used for transfection 
and HA-SENP1 was used in increasing concentration from 1 μg to 4 μg. 100 
μg of proteins were obtained 48 hours after transfection and separated on 
10% polyacrylamide gels. Proteins were detected through western blotting. 
SENP1 is tagged with HA and placed under the control of the CMV promoter 
in the pIRES-EGFP vector. Empty pIRES-EGFP vector as used as negative 
control. Actin was used as a loading control. Blots were probed with the 
indicated antibodies.  
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4.1.2.2 PIAS proteins increase the proportion of SUMO-p53 in JFCF-
6/T.1R cells 
Just as the family of SENP proteins result in SUMO de-conjugation, the 
SUMO E3 ligases have been demonstrated to bring about an increase in the 
proportion of SUMOylated proteins. In this study, PIAS proteins, a family of 
SUMO E3 ligases, were transiently over-expressed, in both MCF7 and JFCF-
6/T.1R cells (Figure 4-6). Four members of the PIAS family, namely PIAS1, 
PIASY, PIASXα and PIASxβ, were introduced. As can be seen in figure 4-6, 
the over-expression of PIAS proteins, regardless of which member, did not 
affect the ubiquitinated levels of p53 in MCF7 cells. However, in JFCF-6/T.1R 
cells, the over-expression of the PIAS proteins led to an increase in the levels 
of SUMO-p53, with PIASY bringing about the least increment. 
 
 
Figure 4.6 PIAS proteins increase the proportion of SUMOylated p53 in 
JFCF-6/T.1R cells. 
Cells were transiently transfected with different members of the PIAS family of 
SUMO E3 ligases in A) breast cancer cell line MCF7 and B) ALT positive cell 
line JFCF-6/T.1R. Blots were probed with the indicated antibodies. Actin was 
used as a loading control.  
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4.1.3 PIASY is the most stably over-expressed member among the 
PIAS family 
The stability of transiently over-expressed PIAS proteins was studied to 
determine the member best to be used for subsequent experiments. Equal 
amounts of plasmids encoding FLAG-tagged PIAS proteins were transfected 
into MCF7 and JFCF-6/T.1R cells (Figure 4-7). In MCF7 cells, PIASY was 
easily detected while PIAS1, PIASXα and PIASXβ were not detected. In 
JFCF-6/T.1R cells, PIAS1, PIASY and PIASXα were easily detected while 
PIASXβ was not detected. It is interesting to note that PIASY has the highest 
expression levels in both cell lines. 
 
Figure 4.7 PIASY is the most stably over-expressed among the PIAS 
family. 
Equal concentration of plasmids encoding different PIAS proteins were used 
for transfection into A) MCF7 and B) JFCF-6/T.1R cells. All PIAS proteins 
introduced were tagged with FLAG. N.S indicates non-specific binding of the 
antibodies. Blots were probed with the indicated antibodies. 
 
4.1.4 Over-expression of p53 in JFCF-6/T.1R cells barely affects 
SUMOylated p53 levels 
This study then proceeded to establish if enhancing the microenvironment for 
SUMOylation influences the degree of SUMO-modification of p53 in JFCF-
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6/T.1R cells. p53, SUMO1 and PIASY were over-expressed, individually and 
in combination, in a bid to create an environment more favorable for SUMO 
modification of p53 (Figure 4-8). The over-expression of p53 in JFCF-6/T.1R 
cells did not affect the basal levels of p53 detected. The over-expression of 
SUMO1 and PIASY singly or in combination with p53 also did not change the 
basal levels of p53. However, the co-transfection of p53 with SUMO1 or 
PIASY appears to increase the levels of SUMO-p53 slightly. 
 
Figure 4.8 Co-expression of p53, SUMO1 and PIASY minimally increases 
the proportion of SUMO-p53 in JFCF-6/T.R cells. 
Plasmids encoding SUMO1, p53 and PIASY were over-expressed in equal 
amounts individually and co-transfected in a bid to determine if these proteins 
will enhance the SUMOylation of p53. Blots were probed with the indicated 
antibodies. 
 
4.1.5 Stability of over-expressed p53 in MCF7 cells is affected by 
SUMO and PIAS 
In MCF7 cells, the transient expression of either SUMO1 or PIASY did not 
affect the levels of endogenous p53 and ubiquitinated p53 (Figure 4-9). 
However, the introduction of p53 into MCF7 cells led to an increase in its 
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levels. This was expected as there would be a larger pool of p53 after 
transfection, thus enabling enhanced detection Interestingly, the levels of 
ubiquitinated p53 increased following transfection of p53 with SUMO1 or 
PIASY. However, the co-expression of all three proteins, p53, SUMO1, and 
PIASY did not result in the same phenomenon. . The lysate for non-
transfected cells harvested in the absence of NEM was included to 
demonstrate the effectiveness of NEM in the preservation of 
SUMOylated/ubiquitinated proteins. 
 
Figure 4.9 Over-expression of p53 in MCF7 cells leads to an increase in 
ubiquitinated p53. 
Plasmids encoding SUMO1, p53 and PIASY were over-expressed in equal 
amounts individually and co-transfected in a bid to determine if these proteins 
will affect the stability of p53 and its ubiquitinated counterparts in MCF7 cells. 
Blots were probed with the indicated antibodies. 
4.1.6 PIAS affects the stability of over-expressed p53 
Thus far, SUMO-1 and PIASY appears to be affecting the stability of 
exogenous p53 in MCF7 and not in JFCF-6/T.1R cells. To determine if PIAS 
proteins do affect the stability of p53, plasmids encoding wild-type p53 were 
transfected into HCT116 p53-null cells. p53 was co-transfected with equal 
amounts of PIAS1, PIASY, PIASXα and PIASXβ (Figure 4-10). Transfection 
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of p53 alone did not lead to its high expression. However, enhanced levels of 
p53 were observed with co-transfection of p53 with PIAS proteins. It is striking 
that the levels of p53 vary with the over-expression of different PIAS proteins. 
The levels of p53 are higher in PIAS1 and PIASY transfected cells than in 
PIASXβ and PIASXα transfected cells. Thus the over-expression of the PIAS 
proteins could have led to an induced expression or stabilization of the 
exogenous p53 proteins. 
 
Figure 4.10 Levels of p53 were enhanced with the over-expression of 
PIAS1 and PIASY. 
Co-transfection of p53 with the same amount of plasmids encoding different 
PIAS led to varying degree of stability of p53 in HCT116 p53 null cells. Blots 
were probed with the indicated antibodies. Actin was used as a loading 
control.  
4.1.7 SUMO1 and PIAS stabilizes over-expressed p53 further 
As PIAS1 and PIASY stabilized p53 more than PIASXα and PIASXβ, PIAS1 
and PIASY were used for co-expression with SUMO-1 and p53. The co-
expression of p53 with both SUMO-1 and PIAS proteins enhanced the 
expression levels of p53 (Figure 4-11). The co-expression of SUMO1 and 
PIASY with p53 exhibited the most distinct increment. 
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Figure 4.11 SUMO1 and PIAS stabilizes p53 further. 
The inclusion of SUMO1 in the co-transfection enhanced p53’s stability further 
in HCT116 p53 null cells. Cells were transfected with the indicated plasmids 
and blots were probed with the indicated antibodies. Actin was used as a 
loading control.  
 
4.1.7.1 SUMO1 increases the proportion of SUMO-p53 significantly 
As shown in figure 4-11, SUMO1 and PIAS proteins stabilize the levels of 
exogenous p53. The higher levels of p53 detected indicate that there is a 
larger pool of substrate for post-translational modifications of the protein. As 
SUMOylation is a key form of post-translational modification for regulating the 
roles and functions of proteins, it is postulated that the increased levels of p53 
will be SUMO-modified. HCT116 p53-null cells transfected with p53, SUMO1 
and certain PIAS proteins were harvested with NEM, an agent which 
preserves SUMO-conjugated proteins (Figure 4-12). Consistent with the 
previous results (Figure 4-11), the levels of unmodified p53 were higher with 
the co-transfection of p53 with SUMO1 or PIAS proteins. In addition, the over-
expression of SUMO1 led distinctly higher levels of SUMO-p53. However, 
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while PIAS1 brought about an increase in the proportion of SUMO-p53, 
PIASY did not lead to enhanced SUMO-p53 levels. The co-transfection of 
PIAS1 and SUMO1 together with p53 resulted in a higher amount of SUMO-
p53 than that of transfection of PIAS1 alone. While PIASY alone did not 
increase the levels of SUMO-p53, the co-transfection with SUMO1 and PIASY 
up-regulated the levels of SUMO-modified p53. 
 
Figure 4.12 Levels of SUMOylated p53 is affected by SUMO1 and PIAS. 
Equal amounts of plasmids encoding the indicated proteins were used for 
transfection as indicated. NEM was present in all cell lysates to preserve 
SUMO-conjugated p53. Blots were probed with the indicated antibodies. Actin 
was used as a loading control.  
 
4.2 Effects of SUMO-p53 
4.2.1 SUMO-p53 and cell viability 
The study continued with the aim of looking at the effects of over-expression 
of p53, SUMO1 and PIAS proteins on cellular proliferation. As the over-
expression of wild-type p53 can cause anti-tumorigenic effects such as cell 
death, the study proceeded to investigate how over-expression of p53 in 
combination with components involved in SUMOylation affects cellular 
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viability. The over-expression of p53, SUMO1, PIAS1 and PIASY singly in 
MCF7 cells led to a slight increase in viability of the cells (Figure 4-13). 
Interestingly, the co-expression of p53 with SUMO1 led to a very slight 
decrease in the viability of MCF7 cells. It is also interesting to note that the co-
transfection of SUMO1 with either PIAS1 or PIASY affected cell viability 
differently. While PIAS1 increased cell viability when co-expressed with 
SUMO1, PIASY reduced cell viability and both sets of data are statistically 
significant. However, the addition of p53 into the SUMO1 and PIASY 
combination abolished the anti-proliferative effect observed with the latter two.  
The over-expression of p53, SUMO1, PIAS1 and PIASY in JFCF-6/T.1R cells 
brought about a similar cell viability pattern as that seen in MCF7 cells. While 
the co-transfection of SUMO1 with p53 did not lead to a decrease in cell 
viability, the co-transfection of p53 and SUMO1 with PIAS1 or PIASY led to a 






Figure 4.13 Crystal violet cell viability assay indicates that the over-
expression of the indicated plasmids individually enhances viability 
while reducing viability in combination. 
A) Over-expression of p53, SUMO1 and PIAS marginally reduced cell viability 
in MCF7 cells. B) Over-expression of p53 and SUMO1 with either PIAS1 or 
PIASY consistently reduced viability of JFCF-6/T.1R cells. Crystal violet assay 
was done 48 hours after transfection of the plasmids encoding wild-type p53, 
SUMO1, PIAS1 and PIASY. At least three independent experiments were 
done and data presented are the average values. Student’s t-test was 




4.2.2 SUMO-p53 and cell cycle progression 
As cell proliferation and cell cycle progression are closely correlated, the cell 
cycle profiles of transiently transfected cells were analyzed. Consistent with 
the cell viability data on p53 and SUMO1 causing a reduced viability in MCF7 
cells (Figure 4-13A), the cell cycle profile analysis showed an increase in the 
sub-G1 population for cells transfected with p53 and SUMO1 (Figure 4-14).  
Interestingly, the co-expression of p53, SUMO1 and PIASY in MCF7 cells led 
to a sustained enhanced sub-G1 population which was not reflected in the cell 
viability assay. 
Similar to the crystal violet assay results, over-expression of p53 in JFCF-
6/T.1R cells did not bring about cell death. It appears that JFCF-6/T.1R cells 
co-transfected with p53, SUMO1 and PIASY have a slight increase in G1 
phase of the cell cycle (Figure 4-14). 
The effects of over-expressing p53 in combination with certain components of 
the SUMO machinery in a p53-null cell line were also studied. In figure 4-14, 
in all combinations of transfection, except that of PCI Neo, there is an 
increase in the population of cells in the sub-G1 phase with a corresponding 
decrease in the G1 phase and an increase in the G2/M phase of the cell 
cycle. Interestingly, the over-expression of p53 with SUMO-1 and PIASY 





Figure 4.14 Cell cycle profiles of propidium iodide stained cells were 
analyzed by flow cytometry. 
A) Over-expression of SUMO1 in MCF7 cells led to a S-phase arrest. B) Co-
expression of p53 with PIASY increased the fraction of apoptotic cells in 
JFCF-6/T.1R cells. C) Co-expression of p53, SUMO1 and PIASY in HCT116 
p53 null cells elevated the apoptotic cell population. Cells were stained with 
propidium iodide 24 hours after transfection and analysed with flow cytometry. 
At least three independent experiments were done and data presented are 
the average values. Student’s t-test was conducted to obtain the p value. * 
indicates p<0.05. 
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4.3 Factors that affect SUMOylation 
4.3.1 Arsenite reduces global SUMOylation as well that of p53 in 
ALT cells 
As the over-expression of p53 with components of the SUMO machinery 
showed that the consequences differ greatly according to cell types, the study 
shifted to focus on factors that affect SUMOylation. As SUMOylation has been 
shown to impact greatly on cellular functions by affecting protein-protein 
interactions and protein localization, this study aims to investigate 
environmental factors that could affect SUMOylation. 
SUMOylation has been shown to be affected by many factors including 
oxidative stress. In this study, arsenite was used as a source to induce 
oxidative stress. Environmental concentrations of arsenite at 1.5 μg/ml and 3 
μg/ml were used to investigate the consequences of arsenite exposure on 
SUMOylation. It is interesting to note that arsenite does not affect the global 
SUMOylation levels in MCF7 cells while dramatically reducing that in the ALT 
cell lines (Figure 4-15). 
As global SUMOylation in ALT cells was dramatically affected by arsenite, the 
SUMOylation levels of p53 were also studied. In tandem with the reduced 
global SUMOylation observed in JFCF-6/T.1R cells, the levels of SUMO-p53 
were also significantly diminished (Figure 4-16). The levels of SUMO-p53 
declined with increasing concentrations of arsenite. While general 
ubiquitination levels were not investigated, the ubiquitination of p53 in MCF7 
was investigated and interestingly, the addition of arsenite also reduced the 
ubiquitination of p53 and such reduction was also dose-dependent. The 
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downstream effectors of p53 were also studied. Both concentrations of 
arsenite enhanced the levels of Mdm2 (Figure 4-17). Moreover, a higher 




Figure 4.15 Arsenite reduces global SUMOylation in ALT cancer cells. 
Cells were treated with 1.5 μg/ml and 3.0 μg/ml of arsenite and endogenous 
proteins were harvested in the presence of NEM. A) Arsenite did not affect 
global SUMOylation levels in MCF7 cells. B) Higher concentration of arsenite 
abolished SUMOylation in JFCF-6/T.1R cells. C) Arsenite drastically 
diminished global SUMOylation in IIICF-E/6.A1 cells. D) Effects of arsenite on 
SUMOylation were greatly reduced in U2OS. Blots were probed with anti-
SUMO1 antibodies. Actin was used as a loading control.  
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Figure 4.16 Arsenite reduces post-translationally modified p53. 
Cells were treated with 1.5 μg/ml and 3.0 μg/ml of arsenite and endogenous 
proteins were harvested in the presence of NEM. A) Ubiquitination of p53 in 
MCF7 cells was reduced by arsenite treatment. B) Arsenite reduced 
SUMOylation of p53 in JFCF-6/T.1R cells. Blots were probed with the 
indicated antibodies. Actin was used as a loading control. 
 
 
Figure 4.17 Arsenite treatment up-regulates the expression of effectors 
downstream of p53 in JFCF-6/T.1R cells. 
Cells were treated with 1.5 μg/ml and 3.0 μg/ml of arsenite. A) A lower dose of 
arsenite increased the expression of Mdm2 distinctly. B) A higher dose of 
arsenite induced the expression of p21. Blots were probed with the indicated 
antibodies. Actin was used as a loading control. 
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4.3.2 Proportion of SUMO-p53 in JFCF-6/T.1R cells varies in 
different phases of the cell cycle 
This study also explored the possibility that levels of SUMOylation changes 
according to the stage of cell cycle the cells are in. In this study, cells were 
synchronized in different phases of the cell cycle through the use of 
established compounds that were commonly used to enhance the proportion 
of cells in the desired phase. Essentially, cells were serum starved for at least 
30 hours prior to the addition of any compounds. This step was crucial in 
ensuring that most of the cells entered and remained in the G0 phase until a 
stimulus, that is fetal bovine serum (FBS), was added to allow for cell cycle 
progression. Thus, the majority of the cells would exit and enter G1 phase in 
tandem, allowing a more accurate cell cycle movement of the entire cell 
population. After cells have been serum starved for at least 30 hours, drug 
compounds were then introduced into fresh culture medium containing FBS. 
To obtain a population of cells in the G0 phase, cells were harvested after 
they have been serum starved for 30 hours. Aphidicolin was used to enhance 
cells in the G1 phase while hydroxyurea was used to obtain cells in the S 
phase. G2 cells were enhanced with Hoechst 33342 while cells in the M 
phase were amplified with nocodazole. To boost the proportion of cells 
synchronized in the M phase, mitotic shake-off was performed on nocodazole 
treated cells. This could only be done for cells in the M phase as such cells 
have a rounded morphology, and are thus less strongly attached to the 
surface of culture dishes, allowing them to be shaken off into the culture 
media. 
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Propidium iodide was used to stain the DNA of the harvested cells and cells 
were analyzed with a florescence activated cell sorting (FACS) flow cytometry 
machine. FACS analysis of the synchronized cells was done to ensure that 
the majority of the cells were indeed synchronized in the desired phase. As 
seen in figure 4-18, JFCF-6/T.1R cells responded relatively well to the 
compounds used for synchronization. There appears to be no difference in 
the cell cycle profiles between the DMSO control cells, the G0 and G1 phase 
arrested cells. The use of hydroxyurea, Hoechst 33342 and nocodazole 
effectively synchronized majority of the cells in S, G2 and M phase of the cell 
cycle respectively. Contrastingly, MCF7 cells were not easily synchronized 
into the desired cell cycle phases (Figure 4-21). Most of the compounds used 
did not appear to synchronize majority of the cells into the desired phases 
except for nocodazole, which enriched cells in the M phase. 
Although the levels of global SUMOylation did not change drastically in cells 
synchronized in different phases of the cell cycle (Figure 4-19), there appears 
to be a slight reduction in the SUMOylation levels of G1, S and G2 phase 
synchronized cells. Interestingly, while no great variations were observed in 
global SUMOylation levels in JFCF-6/T.1R cells, there were distinct 
differences in the proportion of SUMO-p53. Levels of SUMO-p53 were 
enhanced in G0 and M phase synchronized cells. Subsequently, p21, a 
downstream effector of p53, was studied. p21 is an important cell cycle 
regulatory protein and primarily prevents cell cycle progression by arresting 
cells in the G1 phase. As seen in figure 4-19, an increase in p21 expression 
corresponds to an increase in the proportion of SUMO-p53 in the G0 phase. 
Such an increase in the levels of p21 was not observed with enhanced levels 
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of SUMO-p53 in the M phase. The increase in p21 expression could be 
maintained until the S phase, whereby the expression returned to basal levels 
thereafter. It is also fascinating that there was no detection of Mdm2 in all the 
phases except for the M phase where there was a distinctly high expression 
of Mdm2. There was a slight up-regulation of p53 in the S phase synchronized 
MCF7 cells, which led to a corresponding increase in p21 that was 
sustainable till the M phase (Figure 4-22). Similarly, there was an increase in 
the Mdm2 levels in the M phase synchronized cells, although the increase 
was not as striking as that observed in JFCF-6/T.1R cells. 
The state of the cells after their release from synchrony was also investigated. 
This was crucial to ensure that no major anomaly occurred during the 
synchronization process that could have resulted in false positive results. 
After cells have been treated for synchronization for the indicated duration, 
there was replacement of the medium with fresh culture media containing 
FBS. As seen in figure 4-20 and 4-23, following their release from synchrony, 
both JFCF-6/T.1R and MCF7 cells were viable and able to continue to 




Figure 4.18 JFCF-6/T.1R cells were synchronised in each phase of the 
cell cycle. 
A) Cell cycle histograms depicting the majority of the cell population in the 
synchronised phase. (i) DMSO control (ii) G0 phase (Serum starved) (iii) G1 
phase (aphidicolin) (iv) S phase (hydroxyurea) (v) G2 phase (Hoechst 33342) 
(vi) M phase (nocodazole). DMSO was used as a vehicular control. Drugs 
used to synchronised cells were indicated in the brackets. B) Graphical 
representation of cell cycle profiles of synchronised JFCF-6/T.1R cells. Cells 
were stained with propidium iodide and analysed with fluorescence activated 







Figure 4.19 SUMO-p53 is enhanced in G0 and M phase of the cell cycle 
of JFCF-6/T.1R cells. 
Western blot analysis was performed on cell cycle synchronised JFCF-6/T.1R 
cells. Endogenous proteins were harvested in the presence of NEM. DMSO 
was used as a vehicular control. Serum starvation was used to synchronise 
cells in G0; Aphidicolin was used to synchronise cells in G1 phase; 
Hydroxyurea was used to synchronise cells in S phase; Hoechst 33342 was 
used to synchronise cells in G2 phase and nocodazole was used to 
synchronise cells in M phase of the cell cycle. Blots were probed with the 





Figure 4.20 JFCF-6/T.1R cells are still viable and able to progress 
through the cell cycle after release from synchrony. 
A) Cell cycle histograms depicting the progression of cells through the cell 
cycle following release from synchrony. (i) DMSO control (ii) G0 phase 
(Serum starved) (iii) G1 phase (aphidicolin) (iv) S phase (hydroxyurea) (v) G2 
phase (Hoechst 33342) (vi) M phase (nocodazole). DMSO was used as a 
vehicular control. Drugs used to synchronise cells were indicated in the 
brackets. B) Graphical representation of the cell cycle profiles of JFCF-6/T.1R 
cells released from synchrony. Cells were stained with propidium iodide and 





Figure 4.21 MCF7 cells are not easily synchronised into each phase of 
the cell cycle. 
A) Cell cycle histograms depicting the spread of the cells in the cell cycle. (i) 
DMSO control (ii) G0 phase (Serum starved) (iii) G1 phase (aphidicolin) (iv) S 
phase (hydroxyurea) (v) G2 phase (Hoechst 33342) (vi) M phase 
(nocodazole). DMSO was used as a vehicular control. Drugs used to 
synchronised cells were indicated in the brackets. B) Graphical representation 
of cell cycle profiles of supposedly synchronised MCF7 cells. Cells were 
stained with propidium iodide and analysed with fluorescence activated cell 







Figure 4.22 p53 and p21 are stabilised in S, G2 and M phase of the cell 
cycle in MCF7 cells. 
Western blot was performed on MCF7 synchronised cells. Endogenous 
proteins were harvested in the presence of NEM. DMSO was used as a 
vehicular control. Serum starvation was used to synchronise cells in G0; 
Aphidicolin was used to synchronise cells in G1 phase; Hydroxyurea was 
used to synchronise cells in S phase; Hoechst 33342 was used to 
synchronise cells in G2 phase and nocodazole was used to synchronise cells 
in M phase of the cell cycle. Blots were probed with the indicated antibodies. 





Figure 4.23 MCF7 cells are still viable and able to progress through the 
cell cycle after release from synchrony. 
A) Cell cycle histograms depicting the progression of cells through the cell 
cycle following release. (i) DMSO control (ii) G0 phase (Serum starved) (iii) 
G1 phase (aphidicolin) (iv) S phase (hydroxyurea) (v) G2 phase (Hoechst 
33342) (vi) M phase (nocodazole). DMSO was used as a vehicular control. 
Drugs used to synchronised cells were indicated in the brackets. B) Graphical 
representation of cell cycle profiles of MCF7 cells released from synchrony. 
Cells were stained with propidium iodide and analysed with fluorescence 
activated cell sorting (FACS) flow cytometry. 
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4.4 PML in cancer 
4.4.1 Lysine160 is important for SUMOylation of PML and the 
coiled-coil domain is required for SUMOylation 
This study moved on to investigate the role of SUMOylated PML in APB 
formation in ALT cells. Here, plasmids encoding SUMO-defective PML as well 
as PML lacking the coiled-coil domain were used to study how PML that are 
deficient in SUMOylation affects APB formation. 
There are three established SUMO attachment sites in PML; at K65, K160 
and K490. Mutation of lysine to arginine at these sites was performed to 
generate SUMO-deficient PML to determine if they affect SUMOylation of 
PML and the formation of APBs in ALT cells. These PML KR mutants were 
over-expressed in JFCF-6/T.1R cells (Figure 4-24) and the cell lysates were 
obtained in the presence or absence of NEM. The SUMO conjugates of wild-
type PML, K65R and K490R mutants were detected. However, the SUMO 
conjugate of the K160R mutant was not detected. Although the K65/160R 
double mutant displayed SUMOylated PML, the degree of SUMOylation 
appeared to be less intense than that of the K65R single mutant. The 
K65/490R double mutant continued to show a relatively strong extent of 
SUMOylation. Interestingly, the K160/490R double mutant did not display any 
SUMOylated PML conjugates. As expected, no SUMOylated conjugates of 
the triple KR mutants were detected. SUMO-conjugate of wild-type PML but 
not of the coiled-coil domain deficient PML was detected in JFCF-6/T.1R, 
U2OS and MCF7 cells (Figure 4-25). The presence of SUMO-PML was 
verified with immunoprecipitation followed by western blot (Figure 4-26). As 
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the transfected PML is tagged with HA, PML was immunoprecipitated with 
anti-HA antibodies. The immunoprecipitated products were then probed  with 
SUMO1 antibodies to detect SUMO-PML. The higher molecular weight band 
detected in the PML transfected lysate obtained in the presence of NEM 
represent the SUMOylated species of PML. As SUMO modification confers an 
additional molecular weight of about 20 kDa to its substrate, SUMO-PML has 




Figure 4.24 K160 appears to be an important site for SUMOylation. 
Single mutant K160R, double mutant K160/490R and triple mutant were not 
SUMOylated. Cells were transfected with the indicated plasmids and 
harvested in the presence or absence of NEM. The triple mutant has 
mutations at all three SUMO lysine sites. All PML constructs are HA-tagged. 











Figure 4.25 PML C/C- mutant is not SUMOylated. 
Cells were transfected with the indicated plasmids and proteins were 
harvested in the presence or absence of NEM. Wild-type PML was 
SUMOylated but the coiled-coil deletion mutant was not in A) JFCF-6/T.1R, B) 
U2OS and C) MCF7 cells. Blots were probed with the indicated antibodies. 










Figure 4.26 SUMO-PML is established to be to be the higher molecular 
weight specie at around 97 kDa in JFCF-6/T.1R cells. 
Cells were transfected with the indicated plasmids and lysates were harvested 
in the presence or absence of NEM. A) PML was immunoprecipitated with 
PML antibodies and the immunoprecipitated product was analysed with 
western blot and probed with SUMO1 antibodies. B) One-third of the IP 
product was probed with HA antibodies to establish the success of 
immunoprecipitation. C) Western blot analysis of the cell lysate indicated the 
presence of PML and SUMO-PML in JFCF-6/T.1R cells. Blots were probed 
with the indicated antibodies. 
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4.4.2 Transiently transfected PML KR mutants continue to form 
APBs but not the coiled-coil domain deletion mutant 
Wild-type PML and its KR mutants were transiently transfected into JFCF-
6/T.1R and U2OS ALT cells (Figure 4-27 and 4-28). In both ALT cell lines, 
endogenous APBs, defined by the co-localization of PML with TRF2, were 
detected in PCI Neo transfected cells. The single, double and, interestingly, 
the triple PML mutants also formed APBs. 
The PML coiled-coil domain deleted mutant, henceforth referred as PML C/C-, 
was over-expressed in both ALT cell lines and non-ALT cell lines (Figure 4-
29). Endogenous APBs were detected in both JFCF-6/T.1R and U2OS cells 
but not in MCF7 cells. The over-expression of wild-type PML in all three cell-
lines led to nuclear bodies that were distinctly bigger in size than the 
endogenous ones. APBs were observed in JFCF-6/T.1R and U2OS cells with 
















Figure 4.27 All PML KR mutants are able to form APBs in JFCF-6/T.1R 
cells. 
Cells were transiently transfected with (A) PCI Neo (B) PML (C) K65R (D) 
K160R (E) K490R (F) K65/160R (G) K65/490R (H) K160/490 (I) triple KR 
mutants. Wild-type PML and KR mutants were tagged with HA. The 
antibodies used for visualisation were indicated as above. Arrows indicate 
detection of APBs, as defined by the co-localisation of PML with TRF2. 














Figure 4.28 All PML KR mutants are able to form APBs in U2OS cells. 
Cells were transiently transfected with (A) PCI Neo (B) PML (C) K65R (D) 
K160R (E) K490R (F) K65/160R (G) K65/490R (H) K160/490 (I) triple KR 
mutants. Wild-type PML and KR mutants were tagged with HA. The 
antibodies used for visualisation were indicated as above. Arrows indicate 
detection of APBs, as defined by the co-localisation of PML with TRF2. 


















Figure 4.29 PML C/C- does not form any distinct nuclear bodies. 
A) HA-PML, but not FLAG-PML C/C-, formed APBs in JFCF-6/T.1R cells. (B) 
HA-PML, but not FLAG-PML C/C-, formed APBs in U2OS cells. (C) No APBs 
were detected in MCF7 cells. Over-expressed HA-PML formed PML nuclear 
bodies while FLAG-PML C/C- did not form any distinct nuclear bodies. Cells 
were transfected with (i) PCI Neo  (ii) HA-PML (iii) FLAG-PML C/C-. Arrows 
indicate detection of APBs. Antibodies used for visualisation were indicated as 


















4.4.3 Transient over-expression of PML and PML C/C- enhances 
the viability of ALT cells 
The effects of the over-expression of wild-type PML and PML C/C- on cell 
viability were subsequently investigated to determine if the reported tumor 
suppressive activity of PML is functional in these three cancer cells lines. 
Over-expression of these proteins for 48 and 72 hours brought about an 
increase in the viability of JFCF-6/T.1R and U2OS cells but not of MCF7 cells 
(Figure 4-30 and 4-31). The effects of PML and PML C/C- on cell viability in 










Figure 4.30 Transient over-expression of wild-type PML and PML C/C- in 
ALT cells increased their viability at 48 hours. 
PML and PML C/C- enhanced the viability of (A) JFCF-6/T.1R cells and (B) 
U2OS cells but not in (C) MCF7 cells. Indicated plasmids were used for 
transient transfection in the cells and crystal violet cell viability assay was 
performed 48 hours after transfection. At least three independent experiments 
were performed. Data presented is the mean values and error bars indicate 






Figure 4.31 Transient over-expression of wild-type PML and PML C/C- in 
ALT cells led to their increase in viability after 72 hours. 
PML and PML C/C- enhanced the viability of (A) JFCF-6/T.1R cells and (B) 
U2OS cells but not in (C) MCF7 cells. Cells were transiently transfected with 
the indicated plasmids and crystal violet assay was performed 72 hours after 
transfection. At least three independent experiments were performed and 
mean values were presented. 
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4.4.4 Transient over-expression of PML and PML C/C- increases 
the population of ALT cells in G2/M phase of the cell cycle 
The cell cycle profiles of the cancer cells were studied 48 hours after transient 
transfection. The PML and PML C/C- transfected JFCF-6/T.1R cells exhibited 
an increase in the population of cells in G2/M phase of the cell cycle (Figure 
4-32A). The cell cycle profiles of PML and PML C/C- transfected U2OS cells 
showed a slight reduction in the sub-G1 population which was accompanied 
by a modest increase in the G1 population. There were no distinct differences 
in the cell cycle profiles of transfected MCF7 cells except that PML 
transfected MCF7 cells exhibited a reduced population of sub-G1 cells. 
Contrary to that in JFCF-6/T.1R cells, the reduction of MCF7 cells in the sub-
G1 phase corresponded with an increase in G1 phase instead of G2/M. 
In contrast to the cell cycle profiles of JFCF-6/T.1R cells 48 hours after 
transfection, the over-expression of PML and PML C/C- for 72 hours led to a 
decrease in the G1 population (Figure 4-33). The cell cycle profiles of U2OS 
and MCF7 cells did not display any significant changes from that of the empty 













Figure 4.32 Cell cycle profiles of cancer cells at 48 hours after 
transfection. 
Cells were transiently transfected with (i) PCI Neo, (ii) PML and (iii) PML C/C-
and cell cycle analysis was performed 48 hours after transfection through 
propidium iodide staining and flow cytometry. A) There was an increase in the 
G2/M phase of the cell cycle of JFCF-6/T.1R cells 48 hours after transfection 
with PML and PML C/C-. a) Graphical representation of cell cycle profile of 
JFCF-6/T.1R cells. B) There was a slight increase in the G2/M population of 
U2OS cells transfected with PML C/C-. b) Graphical representation of the cell 
cycle profile of U2OS cells. C) There was no distinct differences in the cell 
cycle profile of MCF7 cells at 48 hours after transfection. c) Graphical 













Figure 4.33 Cell cycle profiles of cancer cells at 72 hours after 
transfection. 
transfection. 
Cells were transiently transfected with (i) PCI Neo, (ii) PML and (iii) PML C/C-
and cell cycle analysis was performed 72 hours after transfection through 
propidium iodide staining and flow cytometry. There were no significant 
changes in the cell cycle profiles of (A) JFCF-6/T.1R, (B) U2OS and (C) 
MCF7 72 hours after transfection. (a), (b) and (c) are graphical representation 









4.4.5 U2OS and MCF7 clones of stably over-expressed PML and 
PML C/C- were generated 
As transient transfection of plasmids does not lead to a permanent over-
expression of proteins, the stable transfection of wild-type PML and PML C/C-
was carried out. The stable over-expression of PML and PML C/C- was 
established in all three cancer cell lines (Figure 4-34). For each stably over-
expressed protein in each cell type, two clones were obtained. The clones 
amplified were those that expressed the highest levels of proteins. The PCI 
Neo stably transfected clones are empty vector controls to be used as 
negative controls for subsequent experiments. It is striking that PML stably 
transfected JFCF-6/T.1R cells were not viable while the permanent over-






Figure 4.34 Stable over-expression of PML and PML C/C- in the cancer 
cell lines. 
Two clones of each over-expressed protein were obtained for each cell type 
using G418 resistance as the selection marker. The PML stably transfected 
JFCF-6/T.1R cells were not viable although that of MCF7 and U2OS were. 
Clones expressing high levels of the over-expressed proteins were chosen for 
subsequent investigation. PCI Neo stably transfected clones were used as 
empty vector controls. PML is tagged with HA and PML C/C- is tagged with 
FLAG. Blots were probed with the indicated antibodies. 
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4.4.6 Stably over-expressed PML C/C- does not form APBs in ALT 
cells 
As shown above, PML C/C- does not form APBs in ALT cells when transiently 
over-expressed (Figure 4-29). In the long-term investigation, the ability of wild-
type PML to continue to form APBs and of PML C/C- to continue to inhibit 
APBs formation when stably over-expressed was investigated. Endogenous 
APBs were detected in JFCF-6/T.1R and U2OS PCI Neo stably transfected 
clones (Figure 4-35 and 4-36). Sp100 is a nuclear antigen which is a major 
component of PML nuclear bodies. As Sp100 is established to be critical for 
the formation of PML nuclear bodies (Everett et al. 1999, Ishov et al. 1999), 
we then studied if Sp100 is present in the APBs in ALT cells and if PML C/C- 
affects the distribution of Sp100 (if any). This would provide additional 
information with regard to the constituents of APBs in ALT cells and if the 
absence of the coiled-coil domain in PML will affect the nuclear distribution of 
Sp100 if it is present in APBs. As observed in figure 4-35 and 4-36, Sp100 
foci were detected in both ALT cell lines and co-localized with PML. As 
mentioned above, no clones stably over-expressing wild-type PML could be 
established in the JFCF-6/T.1R cell line. In JFCF-6/T.1R PML C/C- clones, 
Sp100 foci were observed even though PML C/C- could not form distinct 
nuclear bodies. The same observation was obtained in U2OS C/C- stably 









Figure 4.35 PML C/C- does not form APBs in JFCF-6/T.1R cells even 
when stably over-expressed. 
(A) (i) Endogenous APBs were detected in JFCF-6/T.1R PCI Neo STC10 
clone. (ii) Sp100 co-localised with PML in JFCF-6/T.1R PCI Neo STC10 
clone. APBs are not detected in JFCF-6/T.1R C/C- (B)(i) STC7 and (C)(i) 
STC20 clones. Sp100 foci formation was not affected by the over-expression 
of PML C/C- in JFCF-6/T.1R C/C- (B)(ii) STC7 and (C)(ii) STC20 clones. 
Arrowheads indicate APBs while roundheads indicate co-localization of PML 
with SP100. The antibodies used for visualization were indicated as above. 



















Figure 4.36 PML C/C- does not form APBs in U2OS cells even when 
stably over-expressed. 
Endogenous APBs were detected in U2OS PCI Neo (A)(i) STC6 and (B)(i) 
STC8 clones. SP100 co-localised with PML in U2OS PCI Neo (A)(ii) STC6 
and (B)(ii) STC8 clones. APBs were detected in U2OS PML (C)(i) STC20 and 
(D)(i) STC21 clones. SP100 co-localised with HA-PML in U2OS PML (C)(ii) 
STC20 and (D)(ii) STC21 clones. APBs were not formed with stable over-
expression of PML C/C- in U2OS PML C/C- (E)(i) STC20 and (F)(i) STC22 
clones. SP100 foci formation was not affected by the over-expression of PML 
C/C- in U2OS PML C/C- (E)(ii) STC20 and (F)(ii) STC22 clones. Wild-type 
PML is HA-tagged while PML C/C- is FLAG-tagged. Arrowheads indicate 
APBs while roundheads indicate co-localization of PML with SP100. The 
antibodies used for visualization were indicated as above. Images were 
captured at 100x magnification with confocal microscopy. 
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4.4.6.1 Stable over-expression of PML in MCF7 cells leads to APBs 
formation 
As expected, no APBs were found in PCI Neo stably transfected MCF7 
(Figure 4-37). However, PML nuclear bodies were routinely detected. It 
should be noted that Sp100 and TRF2 were not easily detected in MCF7 
cells. In MCF7 PML clones, there was detection of PML foci that were 
distinctly larger than those found in PCI Neo transfected clones. Interestingly, 
a few PML foci co-localized with TRF2 to form APBs in the MCF7 PML STC10 
clone but not in the PML STC7 clone. Over-expressed PML in the stably 
transfected clones co-localized with Sp100. Similar to observations in the ALT 

















Figure 4.37 APBs can be detected in MCF7 PML stably over-expressed 
clones. 
APBs were not present in MCF7 PCI Neo (A)(i) STC1 and (B)(i) STC4 clones. 
Co-localisation of PML with Sp100 was detected in MCF7 PCI Neo (A)(ii) 
STC1 and (B)(ii) STC4 clones. Stably over-expressed wild-type PML formed 
distinct foci and colocalised with TRF2 to form APBs in MCF7 PML (C)(i) 
STC7 and (D)(i) STC10 clones. Wild-type PML co-localised with Sp100 in 
MCF7 PML (C)(ii) STC7 and (D)(ii) STC10 clones. PML C/C- did not form 
APBs when over-expressed stably in MCF7 C/C- (E)(i) STC7 and (F)(i) 
STC22 clones. No co-localization of C/C- and Sp100 was observed in MCF7 
C/C- (E)(ii) STC7 and (F)(ii) STC22 clones. Wild-type PML is HA-tagged while 
PML C/C- is FLAG-tagged. Arrowheads indicate APBs while roundheads 
indicate co-localization of PML with Sp100. The antibodies used for 






4.4.7 Wild-type PML and PML C/C- ALT clones have a slower 
population doubling time 
The effects of the stably over-expressed proteins on population doubling time 
were studied subsequently. The population doubling time of the clones were 
tracked for 20 passages with approximately 72 hours between each passage. 
As seen in figure 4-38A, the population doubling time, in terms of hours per 
population doubling, of JFCF-6/T.1R PML C/C- clones were higher than that 
of the PCI Neo clone. While the JFCF-6/T.1R PML C/C- clones demonstrated 
different population doubling times throughout 20 passages, the trend 
exhibited was the same. 
Similarly, U2OS PML and PML C/C- clones also displayed higher population 
doubling time compared to their PCI Neo counterparts (Figure 4-38B), 
demonstrating that a longer time is required for the doubling of the cells. The 
U2OS PML clones consistently displayed a higher population doubling time. 
4.4.7.1 MCF7 PML clones grow faster than PCI Neo clones 
The MCF7 PML clones exhibited a reduced population doubling time 
compared to the PCI Neo clones (Figure 4-38C), suggesting that the cells are 
growing at a faster rate. The PML C/C- clones varied in their population 
doubling times. While the doubling time of the MCF7 PML C/C- STC7 clone 
fluctuated throughout 20 passages, the doubling time of the PML C/C- STC22 











Figure 4.38 Wild-type PML and PML C/C- ALT clones exhibit a slower 
population doubling time. 
Cells were seeded at a known density and cell numbers were counted at 
every 72 hours at every passage up to the 20th passage using the trypan blue 
exclusion method. A) PML C/C- JFCF-6/T.1R clones displayed a slower 
population doubling rate than the PCI Neo clones. B) Wild-type PML U2OS 
clones have a slower population doubling rate than the PML C/C- clones. (i) 
and (ii) are representative of two different sets of U2OS clones. C) MCF7 PML 
C/C- clones have a slower population doubling rate than the wild-type PML 
clones. (i) and (ii) represent two sets of different MCF7 clones. 
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4.4.8 Wild-type PML inhibits the clonogenicity of U2OS cells 
To validate the population doubling results, colony formation assay of the 
clones was performed. Consistent with the population doubling data, the 
U2OS PML clones displayed a significant reduction in the number of colonies 
formed (Figure 4-39). The proliferation of the U2OS PML STC21 clone was 
strikingly slower than the U2OS PML STC20 clone (Figure 4-38). In addition 
to the reduction in the number of colonies formed, the size of the colonies 
formed by the U2OS PML clones was also notably smaller than that formed 
by the PCI Neo and PML C/C- clones. 
While the U2OS PML C/C- clones have a higher number of colonies 
compared to the PML clones, it formed fewer colonies than the PCI Neo 
clones. There were no observable changes in the sizes of the colonies formed 
by the PML C/C- clones compared to that by the empty vector control. 
4.4.8.1 Wild-type PML might reduce the clonogenicity of MCF7 cells 
While the proliferation of the MCF7 PML clones exhibited an increase 
compared to that of the PCI Neo clones, the colony forming ability of the PML 
clones appeared to be diminished (Figure 4-39). There was a significant 
reduction in the number of colonies formed in the PML clones but the sizes of 
the colonies formed did not seem to have changed. Instead, it appears that 
the occurrence of bigger colonies in PML clone was higher than that in the 
PCI Neo clones. The MCF7 PML C/C- clone formed fewer colonies than the 
PCI Neo clones but more than that by the PML clone. The sizes of the 











Figure 4.39 U2OS PML clones have a reduced clonogenic capacity. 
Cells were seeded and maintained for 10-14 days before staining with crystal 
violet for visualization. Colony formation assay of A) (i) U2OS PCI Neo STC6 
clone (ii) U2OS PML STC20 clone (iii) U2OS PML C/C- STC20 clone. B) (i) 
U2OS PCI Neo STC8 clone (ii) U2OS PML STC21 clone (iii) U2OS PML C/C- 
STC22 clone. C) (i) MCF7 PCI Neo STC1 clone (ii) MCF7 PML STC7 clone 
(iii) MCF7 PML C/C- STC7 clone. D) (i) MCF7 PCI Neo STC4 clone (ii) MCF7 
PML STC10 clone (iii) MCF7 PML C/C- STC22 clone. E) Bar chart displaying 
percentage of colonies obtained in (i) U2OS and (ii) MCF7 clones. ** indicates 
p<0.01. 
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4.4.9 Higher proportion of cells in sub-G1 and G2/M phase of the 
cell cycle in U2OS PML clones 
As proliferation and cell cycle are closely related, the cell cycle profiles of the 
U2OS clones were tracked for 20 population doublings. The cell cycle profiles 
of the clones at every 5 passages are displayed (Figure 4-40). The U2OS 
PML clones exhibited an increase in the population of cells in the sub-G1 
phase, indicating the presence of more apoptotic cells. Additionally, there is 
also an increase in the proportion of U2OS PML cells in the G2/M phase of 
the cell cycle. In tandem with the increase of cells in the sub-G1 and G2/M 
phases, there was a reduction of U2OS PML cells in the G1 phase. 
The U2OS PML C/C- clones exhibited a similar profile as that of the PML 
clones but to a lesser extent. This means that while the PML C/C- clones 
exhibits an arrest in the G2/M phase, the degree of arrest is lower than that 
observed in the PML clones. Thus there are more cells in the G1 phase in the 
PML C/C- clones than in the PML clones. It is also interesting to note that 
there were no significant changes in the sub-G1 population of the PML C/C- 
clones; the proportion of the apoptotic cells was similar or even lower than 

















Figure 4.40 Cell cycle profile analyses of U2OS clones at every five 
passages until passage 20. 
Cell cycle profiles of the cells were analysed at every 5th passage up to 
passage 20. Cells were stained with propidium iodide and anakysed with flow 
cytometry. A) Cell cycle profile of the first set of U2OS clones comprising of 
PCI Neo STC6, PML STC20 and PML C/C- STC20. (a) Graphical 
representation of cell cycle profiles of the clones. B) Cell cycle profile of the 
second set of U2OS clones comprising of PCI Neo STC8, PML STC21 and 
PML C/C- STC22. (b) Graphical representation of the cell cycle profiles of the 
clones. (i) indicates clones at passage 1; (ii) indicates clones at passage 5; 
(iii) indicates clones at passage 10; (iv) indicates clones at passage 15; (v) 
indicates clones at passage 20. 
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4.4.9.1 S and G2/M phase cells are enhanced in MCF7 PML clones 
The cell cycle profiles of MCF7 clones at every 5 passages up to passage 20 
were also obtained (Figure 4-41). The cell cycle profiles of MCF7 clones 
differed from that of the U2OS clones. The MCF7 PML clones showed an 
enhanced proportion of cells in both S and G2/M phase of the cell cycle. The 
MCF7 PML C/C- clones also showed a similar increase in the population of 



























Figure 4.41 Cell cycle profile analyses of MCF7 clones at every five 
passages until passage 20. 
Cell cycle profiles of the cells were analysed at every 5th passage up to 
passage 20. Cells were stained with propidium iodide and anakysed with flow 
cytometry. A) Cell cycle profiles of the first set of MCF7 clones comprising of 
PCI Neo STC1, PML STC7 and PML C/C- STC7. (a) Graphical representation 
of cell cycle profiles of clones. B) Cell cycle profile of second set of MCF7 
clones comprising of PCI Neo STC4, PML STC10 and PML C/C- STC22. (b) 
Graphical representation of cell cycle profiles of clones. (i) indicates clones at 
passage1; (ii) indicates clones at passage 5; (iii) indicates clones at passage 












4.4.10 Wild-type PML increases telomere length slightly while 
PML C/C- reduces telomere length in U2OS cells 
One of the main objectives of this study is to determine if the over-expression 
of wild-type PML will enhance the ALT pathway and if the over-expression of 
PML C/C- will disrupt the ALT mechanism. Here, the continued maintenance 
or elongation of telomeres is seen as the main phenotype for the propagation 
of the ALT pathway. The telomere length of the U2OS clones was analyzed at 
every five passages up to the 20th passage. The basal telomere length in 
U2OS is very long as can be seen in the U2OS PCI Neo clones (Figure 4-42). 
In both U2OS PML clones, there was a slight increase in the mean telomere 
length and such an increase can be sustained up to 20 passages. In the 
U2OS PML C/C- clones, there was a decrease in the average telomere length 







Figure 4.42 Wild-type PML increases telomere length slightly while PML 
C/C- reduces telomere length in U2OS clones. 
Terminal restriction fragment analysis by Southern blot was used to determine 
telomere length of the cells at every 5 passage up to passage 20. A) (i) 
Southern blot analysis of U2OS PCI Neo STC6, PML STC20, PML C/C- 
STC20. (ii) Graphical representation of telomere length of clones. B) (i) 
Southern blot analysis of U2OS PCI Neo STC8, PML STC21 and PML C/C- 
STC22. (ii) Graphical representation of telomere length of clones. Bars 
indicate mean telomere length as detected and measured by densitometer. 
 
  146
4.4.10.1 MCF7 PML and PML C/C- clones exhibit ALT-like telomere 
phenotype 
Similarly, the telomere length of MCF7 PML and PML C/C- clones was also 
analyzed for every five passages up to passage 20. The basal telomere 
length of MCF7 was not expected to be as long as that seen in ALT cell-lines 
and indeed, the mean basal telomere length of MCF7 is around 2 to 4 kb 
(Figure 4-43). Surprisingly, the telomere length of the MCF7 PML STC10 
clone was significantly longer than the PCI Neo clone. Interestingly, for both 
PML C/C- clones, the telomere length was dramatically increased. While the 
telomere length in PML C/C- STC7 clone displayed a relatively consistent 
elongated telomere, there was a gradual increase in the telomere length over 
20 passages of the PML C/C- STC10 clone. Another fascinating observation 
was the continued presence of basal telomeres in addition to the elongated 







Figure 4.43 MCF7 PML STC10 clone exhibits very long telomeres which 
are typical of the ALT phenotype. 
Terminal restriction fragment analysis by Southern blot was used to determine 
telomere length of the cells at every 5 passage up to passage 20. A) (i) 
Southern blot analysis of MCF7 PCI Neo STC1,PML STC7 and PML C/C- 
STC7 clones. (ii) Graphical representation of telomere length of MCF7 PCI 
Neo STC1, PML STC7 and PML C/C- STC7 clones. B) (i) Southern blot 
analysis of MCF7 PCI Neo STC4, PML STC10 and PML C/C- STC22 clones. 
(ii) Graphical representation of telomere length of MCF7 PCI Neo STC4, PML 
STC10 and PML C/C- STC22 clones. Bars indicate mean telomere length as 
detected and measured by densitometer. 
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4.4.11 Telomere lengthening and accumulation of MCF7 clones 
exhibiting ALT-like telomere phenotype 
Fluorescence in situ hybridization (FISH) using a fluorescent telomeric probe 
was performed to validate the southern blot analysis of telomere length. 
Essentially, cells were treated with colcemid for about six hours to enhance 
the proportion of cells in metaphase. Metaphase chromosomes from these 
cells were then prepared for the subsequent FISH experiment. The ISIS 
software was used to analyze and generate telomere length data. The 
telomere intensity obtained is indicative of telomere length. As can be seen in 
figure 4-44, the telomere intensity shifted to the right for the MCF7 PML 






Figure 4.44 Telomere fluorescence intensity of MCF7 PML clone shifted 
to the right. 
Telomere length was measured using the ISIS analysis software after 
fluorescence in situ hybridization with Cy3 telomeric probe. Telomere intensity 
and frequency of (i) MCF7 PCI STC4 (ii) MCF7 PML STC10 (iii) MCF7 PML 
C/C- STC22 clones were obtained.  
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4.4.12 MCF7 PML STC10 clone has a much lower telomerase 
activity 
As the ALT pathway appeared to be activated in MCF7 PML and PML C/C- 
clones, the telomerase activity of the clones was studied to determine if such 
an ALT-like pathway affected telomerase activity. Telomerase activity was 
measured by the TRAP assay and the total product generated (TPG) is an 
indicator of telomerase activity. Interestingly, while the MCF7 PML clone 
(STC10) displayed greatly reduced telomerase activity, the other MCF7 PML 
clone (STC7) demonstrated a dramatic increase in telomerase activity. This 
observation as a differential response of the cells towards long-term over-
expression of wild-type PML could have altered the telomere maintenance 
mechanisms in the MCF7 cells (further discussion in subsequent chapter).  








Figure 4.45 Telomerase activity of MCF7 PML C/C- clones is dramatically 
increased. 
A) Telomerase activity of MCF7 PCI Neo STC1, PML STC7 and PML C/C- 
STC7 clones. B) Telomerase activity of MCF7 PCI Neo STC4, PML STC10 
and PML C/C- STC22 clones. A possible change in the telomere maintenance 
mechanism in the MCF7 PML STC10 clone might have occurred with the 
stable over-expression of the wild-type PML protein. The change in the 
predominant telomere maintenance mechanism probably led to a suppression 
of telomerase activity in the MCF7 PML STC10 clone. Telomerase activities 
are represented in terms of percentage of the total product generated (TPG) 
as measured by the TRAP assay. *** indicates p<0.005. 
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4.4.13 MCF7 clones displaying ALT-like phenotypes are more 
sensitive to doxorubicin 
Doxorubicin is an anthracycline which works by intercalating DNA and is 
employed in cancer therapy for osteosarcomas. Tamoxifen is an antagonist of 
estrogen receptor and is used for estrogen receptor-positive breast cancers in 
breast cancer therapy. Doxorubicin was used in our study to evaluate the 
effects it might have on the ALT-positive U2OS osteosarcoma cells and on 
the MCF7 cells which appeared to exhibit an ALT phenotype. As osteoblasts 
have been shown to express endogenous estrogen receptors (Eriksen et al, 
1988), tamoxifen was also used in our study to study any possible effects it 
might have on both MCF7 and U2OS cells. Thereby, in this study, the effects 
of these established clinical drugs, tamoxifen and doxorubicin, on U2OS 
osteosarcomas as well as MCF7 breast cancer cells that display apparent 
ALT phenotypes were investigated. It is expected that there are differences in 
viability in ALT cells, telomerase-positive MCF7 and MCF7 cells exhibiting 
ALT phenotypes towards the anti-cancer drugs. As shown in figure 4-46, 
U2OS was more sensitive to 1μM of doxorubicin than to 10μM of tamoxifen. It 
is intriguing that the over-expression of PML C/C- in U2OS led to a slight 
increase in sensitivity to doxorubicin. MCF7 also exhibited a similar enhanced 
sensitivity to doxorubicin than to tamoxifen (Figure 4-47). It is interesting to 
note that the MCF7 clones that distinctly exhibit an ALT-like telomere 
phenotype, i.e. MCF7 PML STC10 and PML C/C- STC22, displayed a slight 




Figure 4.46 U2OS clones exhibit greater sensitivity to doxorubicin than 
to tamoxifen. 
Cells were treated with indicated doses of the drugs for 24 hours. A) Cell 
viability of U2OS PCI Neo STC6, PML STC20 and PML C/C- STC20 clones. 
B) Cell viability of U2OS PCI No STC8, PML STC21 and PML C/C- STC22. 
Cell viability was measured by crystal violet assay. At least three independent 




Figure 4.47 MCF7 clones exhibit greater sensitivity to doxorubicin than 
to tamoxifen. 
Cell viability was measured using the crystal violet assay. Cells were treated 
with indicated doses of the drugs for 24 hours. A) Cell viability of MCF7 PCI 
Neo STC1, PML STC7, PML C/C- STC7 clones. B) Cell viability of MCF7 PCI 
Neo STC4, PML STC10 and PML C/C- STC22 clones. At least three 
independent experiments were performed. *** indicates p<0.005. 
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5 CHAPTER 5   DISCUSSION 
5.1 SUMOylation of p53 
5.1.1 Different global SUMO-1 and SUMO-2 conjugation patterns in 
ALT and non-ALT cell lines 
The differences in the intensity of SUMOylation pattern in different cell types 
are representative of the extent of SUMOylation, whereby a higher intensity is 
indicative of more abundant SUMO-conjugated proteins. Our results indicate 
that while there is a certain degree of similarity in the global SUMOylation 
patterns, the extent of SUMOylation by SUMO-1 and SUMO-2 varies across 
different cell types. The observation of more SUMO-1 conjugated proteins 
than the SUMO-2 counterparts may reflect the finding that the majority of 
SUMO-1 is conjugated to substrates while free SUMO-2 and SUMO-3 readily 
attaches to substrates during cellular stress response (Di Bacco and Gill 
2006). The presence of higher levels of free SUMO-2 in ALT cells could be 
reflective of the different cell types. It should also be noted that the SUMO-
reactive bands as detected by western blots are usually of high molecular 
weight, suggesting that SUMO-modified proteins probably aggregate and form 
supramolecular protein complexes. 
5.1.2 SUMO-p53 is detected in JFCF-6/T.1R and not in MCF7 cells 
The modification of a protein by SUMO leads to an increase in its molecular 
weight by approximately 10 to 20 kDa. The multiple bands above the p53 
protein seen in MCF7 cells might not all be SUMO-p53, although it is possible 
that one of these bands could be SUMO-p53. In JFCF-6/T.1R cells, one band 
at approximately 66 kDa could be SUMO-p53 as its molecular weight 
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corresponds to that of SUMO-conjugated p53 (between 63 to 73 kDa). 
Immunoprecipitation followed by western blot analysis verified the presence of 
SUMO-p53 in JFCF-6/T.1R cells. 
The fact that p53 is differentially modified post-translationally implies strongly 
that such modifications can affect and control its anti-tumorigenic functions. In 
MCF7 cells where there is wild-type p53 (Gartel, Feliciano and Tyner 2003), it 
is possible that the ubiquitination and subsequent degradation of the protein 
via the 26S proteasome system is a mechanism through which these cancer 
cells counteract against the anti-proliferative property of p53. In JFCF-6/T.1R 
cells, while p53 is present, it is currently unknown if it encodes any mutations. 
The presence of SUMO-p53 in JFCF-6/T.1R cells corroborates the knowledge 
that a protein could be differently modified post-translationally in different cell 
types, giving rise to varying cellular functions and consequences. 
5.1.2.1 De-SUMOylation of p53 is achieved through SUMO-specific 
protease SENP1 
Ubiquitinated p53 in MCF7 cells was unaffected by the over-expression of 
SENP1 while SUMO-p53 levels decreased with its expression. This verifies 
the specificity of SENP towards SUMOylated substrates. Although higher 
concentrations of SENP1 reduced the levels of SUMO-p53 significantly in 
JFCF-6/T.1R cells, there appears to be a basal level of SUMO-p53 that is 
unaffected by SENP1. As there are several members in the SENP family, it is 
possible that another member of the family also mediates the SUMO de-
conjugation of p53 in JFCF-6/T.1R cells, in addition to SENP1. 
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5.1.2.2 PIAS proteins increase the proportion of SUMO-p53 in JFCF-
6/T.1R cells 
SUMOylation is highly dynamic and at any point in time, SUMOylated proteins 
are observed as a result of the equilibrium between concurrent SUMO 
conjugation and de-conjugation. The SUMO E3 ligase activity of PIAS 
enhanced the SUMOylation of p53 in JFCF-6/T.1R cells while having no 
effects on ubiquitinated p53, demonstrating their specificity for the SUMO 
pathway. In this study, contrary to reports that PIASY enhanced the levels of 
SUMO-p53 (Bischof et al. 2006), PIASY was shown to bring about the least 
increment in SUMO-p53 among the PIAS proteins. It is possible that the same 
PIAS protein have different effects in enhancing the levels of SUMO-p53 in 
different cell types. 
5.1.3 PIASY is the most stably over-expressed member among the 
PIAS family 
Different cell types might allow for the expression of exogenous proteins at 
dissimilar levels and this probably accounts for the disparity in the expression 
of PIAS1, PIASXα and PIASXβ in both the cell lines. Inefficiency in 
transfection has been ruled out for such diverse expression as transfection 
efficiency had been optimized early in the project and transfection reagents 
and conditions were kept constant. From these over-expression experiments, 
it appears that PIASY is more stable than the other PIAS members when 
over-expressed in vitro. As PIASY also enhanced the levels of SUMO-p53, it 
was chosen as the SUMO E3 ligase to be used for subsequent experiments. 
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5.1.4 Over-expression of p53 in JFCF-6/T.1R cells barely affects 
SUMOylated p53 levels 
Surprisingly, the over-expression of p53 did not lead to its enhanced detection 
in JFCF-6/T.1R cells, suggesting that exogenous p53 does not contribute 
significantly to the pools of endogenous p53 that is detected by western blot 
analysis. It is possible that in JFCF-6/T.1R cells, the levels of SUMO-modified 
p53 are at an optimal level, thus the introduction of either SUMO1 or PIASY 
led to a minimal increment in the proportion of SUMO-p53. It is also likely that 
the slight increase in the levels of SUMOylated p53 resulted from the 
exogenous p53 introduced as such increment was observed only with the 
transfection of p53 with SUMO1 and PIASY. This also implies that minimal 
SUMOylation of p53 is occurring in JFCF-6/T.1R cells. 
5.1.5 Stability of over-expressed p53 in MCF7 cells is affected by 
SUMO and PIAS 
It appears that SUMO1 or PIASY when over-expressed alone does not affect 
the endogenous levels of p53 and its ubiquitinated counterparts. This 
suggests that the levels of p53 and ubiquitinated-p53 are probably at steady 
state and are not easily affected by exogenous proteins. The increase in 
ubiquitinated p53 is probably due to the over-expression of p53 whereby the 
increased levels of total p53 triggered enhanced ubiquitin modification as a 
way to counteract the tumor suppressive actions of exogenous p53, and thus 
to allow tumorigenic pathways to continue unperturbed. This suggests that the 
microenvironment in MCF7 cells favors tumorigenic processes. Observations 
from this experiment also indicate the possibility that components involved in 
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the SUMOylation process can affect the stability of p53 in MCF7 cells 
whereby SUMO-1 and PIASY are enhancing its stability. 
5.1.6 PIAS affects the stability of over-expressed p53 
Our results show that different PIAS proteins have dissimilar effects in 
stabilizing exogenous p53 in a p53-null background. The observation of 
PIASY stabilizing p53 correlates with earlier reports that show PIASY as a 
good SUMO E3 ligase for p53, which also enhanced its tumor suppressive 
activities (Bischof et al. 2006). Thus it is highly probable that PIAS proteins 
may exert its p53-stabilizing effects on exogenous p53 than on endogenous 
p53. 
5.1.7 SUMO1 and PIAS stabilizes over-expressed p53 further 
Our results show that SUMO-1, together with PIAS1 and PIASY, can enhance 
the stability of over-expressed p53. Thus the addition of components in the 
SUMOylation machinery can enhance the stability of exogenous p53 in a p53-
null background. 
5.1.7.1 SUMO1 increases the proportion of SUMO-p53 significantly 
The over-expression of SUMO-1 with p53 shows that SUMO-1 is able to 
stabilize p53 and at the same time, it is sufficient to induce SUMOylation of 
p53. This implies that the basal levels of proteins involved in SUMOylation are 
sufficient for SUMO modification of its substrates. It appears that while PIASY 
stabilizes p53, it does not further enhance the SUMO-modification of p53 by 
itself alone. Compared to the SUMO-enhancing ability of PIAS1, it appears 
that the SUMO E3 ligase activity of PIASY remains low even when placed in 
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an environment that favors SUMOylation. These observations are in contrast 
to the data published by Bischof et al (2006) whereby it was shown that 
PIASY stimulated SUMOylation of p53, leading to p53-dependent senescence 
and apoptosis. The opposing effects of PIASY stimulation of p53’s 
modification by SUMO are probably due to cell type specificity, whereby 
different cell types contrast in the SUMO modification of p53 according to their 
cellular status. 
5.2 Effects of SUMO-p53 
5.2.1 SUMO-p53 and cell viability 
It appears that over-expression of p53, SUMO-1, PIAS1 or PIASY did not 
affect the cell viability in MCF7 cells. In MCF7 cells, the over-expression of 
both p53 and SUMO-1 did not lead to an increase in cell viability. This 
suggests that exogenous p53 may be exerting its anti-proliferative effects in 
MCF7 cells. However, co-expression of p53 with either PIAS1 or PIASY did 
not bring about a similar anti-proliferative effect in MCF7 cells. It is possible 
that the enhanced stability conferred to exogenous p53 proteins by the PIAS 
protein led to its rapid ubiquitination (Figure 4-9) and degradation by the 26S 
proteasome system and as a result, the anti-proliferative effects of p53 were 
not observed. PIASY could contain anti-proliferative activity on top of its 
SUMO E3 ligase activity, which may be further enhanced by the presence of 
SUMO1, thus leading to a slight decrease in cell viability. It is possible that the 
effectiveness of wild-type p53 is limited by the microenvironment within MCF7 
cells which does not encourage the anti-tumorigenic effects of p53, as can be 
seen from the increased ubiquitinated p53 levels with the over-expression of 
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p53 (Figure 4-9). It is thereby suggested that MCF7 cells could possibly be 
more sensitive to the presence of wild-type p53 particularly when it is present 
with other factors that could enhance its anti-proliferative effects and such 
sensitivity could allow the cancer cells to maintain its tumor-promoting 
microenvironment. 
Similarly, the over-expression of p53, SUMO-1, PIAS1 or PIASY did not affect 
cell viability of JFCF-6/T.1R cells. However, the over-expression of p53 and 
SUMO-1 with either PIAS1 or PIASY led to a slight decrease in cell viability. 
While the transfection of these three proteins led to a very slight increase in 
SUMOylated p53 (Figure 4-8), perhaps such small increment in the proportion 
of SUMO-p53 was sufficient to affect cell viability negatively. This observation 
is consistent with reports of SUMOylated p53 being to better enable cellular 
senescence and cell death (Melchior and Hengst 2002, Stehmeier and Muller 
2009, Watson and Irwin 2006, Yates et al. 2008). It is thus conceivable that if 
p53 can be better SUMOylated in JFCF-6/T.1R cells, the viability of these 
cancer cells will decrease significantly accordingly. On the other hand, it is 
possible that the JFCF-6/T.1R cells microenvironment strictly maintains the 
level of SUMOylation of p53 so as to retain its high proliferative trait. These 
results also suggest that even though, at any time, there is a small fraction of 
SUMOylated proteins, the effects of such modified proteins are sufficiently 
effective to induce changes in the cell. 
5.2.2 SUMO-p53 and cell cycle progression 
As mentioned above, SUMO has a variety of functions, one of which is to 
enhance or diminish protein stability via the mediation of protein-protein 
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interactions. Thus in MCF7 cells, SUMO-1 and PIASY are possibly stabilizing 
exogenous p53, allowing it to exert its pro-apoptotic functions. However, as 
mentioned previously, the microenvironment in MCF7 cells is likely to be one 
that promotes the rapid degradation of p53, thus strongly limiting the growth 
inhibitory effects of exogenous p53. The over-expression of p53 with or 
without components involved in the SUMOylation pathway in JFCF-6/T.1R 
cells did not appear to increase the proportion of cells in the sub-G1 
population. Interestingly, it appears that the over-expression of p53 with 
SUMO-1 and PIASY led to a slight increase in the G1 population, implicating 
p53 in the cell cycle arrest observed at the G1 phase. This explains the 
reduction in viability as observed in the cell viability assay whereby cells that 
were arrested did not continue to proliferate and this is reflected as a 
reduction in the proliferation capacity of the cells. It seems that in JFCF-
6/T.1R cells, p53 does not cause cell death, as it appears to be doing so in 
MCF7 cells, but rather, it results in cell cycle arrest. This implies that wild-type 
p53, when over-expressed in different cell types, do not necessarily exert the 
same effects. Instead p53 is subjected to the regulatory mechanisms that are 
in place in different cell types.  In HCT116 p53-null cells, the over-expression 
of p53 with SUMO-1 and PIASY led to an enhanced sub-G1 population. This 
suggests that these HCT116 cells remain sensitive to p53 and that p53 can 
continue its function as a cell death effector in these p53-null cells. 
The degree of cell death observed from the cell cycle assay sometimes does 
not correlate with that seen in the cell viability assay. It is thus possible that 
some cells were in the early stages of apoptosis and hence were detected as 
  164
viable cells in the crystal violet assay but apoptotic cells in FACS analysis 
using propidium iodide. 
Thus exogenous p53 is able to exert its anti-tumorigenic effects in causing cell 
death and cell cycle arrest. However, different microenvironments produce 
varying results from such over-expression. While SUMOylated p53 was 
detected in both JFCF-6/T.1R and HCT116 cells, there appears to be a 
difference in its levels and functions. Again, this indicates that the context in 
which p53 over-expression and modification are critical in controlling and 
determining its functions. This thus cautions against the viewing of mutated 
p53 as one of the main obstacle to overcome in cancer progression and of 
wild-type p53 to be employed in cancer therapy without a thorough 
understanding of its cellular activities and post-translational modifications in 
major cancer cell types. 
5.3 Factors that affect SUMOylation 
5.3.1 Arsenite reduces global SUMOylation as well that of p53 in 
ALT cells 
The reduction in global SUMOylation levels in the ALT cells was 
concentration-dependent, whereby a higher concentration of arsenite led to a 
greater reduction in SUMOylation levels. Although the global SUMOylation 
levels in U2OS cells was the least affected among the ALT cell lines, it is 
conceivable that an even higher concentration of arsenite can abolish 
SUMOylation in U2OS cells as seen in the other two ALT cell lines. It is 
interesting to note that the use of arsenite did not affect global SUMOylation 
levels in MCF7 cells at all. Instead arsenite reduced the levels of ubiquitinated 
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p53. It is plausible that the reduction of ubiquitinated p53 allows MCF7 cells to 
respond positively towards the oxidative stress induced by arsenite. It is thus 
speculated that SUMOylation in ALT cell lines is more susceptible to oxidative 
stress than that in telomerase-positive cell lines. It is also tempting to 
speculate that the effects of arsenite in affecting SUMOylation could be 
specific towards ALT cells and not in telomerase-positive cells. However, 
more telomerase-positive and ALT cell types have to be used to draw a 
definite conclusion. 
Corresponding to the reduction in global SUMOylation, there was a reduction 
in the levels of SUMO-p53. It appears that the loss of SUMO-modification of 
p53 leads to an increase in its transcriptional activity, leading to an increased 
expression of its downstream effectors in JFCF-6/T.1R cells. However, the 
extent of the loss of SUM0-p53 appears to influence the up-regulation of 
specific downstream effectors. A slight reduction of SUMO-p53 up-regulated 
Mdm2 while a more extensive loss of SUMOylated p53 up-regulated p21 in 
JFCF-6/T.1R cells. The up-regulation of Mdm2 could be in response to the 
reduction of SUMO-p53 levels, especially if SUMOylation is used as a means 
to regulate the activity of p53 and thus the equilibrium of the feedback loop 
between p53 and Mdm2. As arsenite is toxic, the up-regulation of p21 in 
response to higher arsenite concentrations could be part of a normal cellular 
response to stress. It is also noted that arsenite did not affect the levels of 
unmodified p53 in both MCF7 and JFCF-6/T.1R cells. This implies that the up-
regulation of downstream effectors of p53 in JFCF-6/T.1R cells is probably 
due to changes in post-translational modifications of the protein. From these 
experiments, it seems that SUMO modification of p53 suppresses its 
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transcriptional activity and de-SUMOylation of p53 by arsenite restores such 
activity. Thus SUMOylation is probably a mechanism employed by JFCF-
6/T.1R cells to negatively control the activity and functions of p53. 
5.3.2 Proportion of SUMO-p53 in JFCF-6/T.1R cells varies in 
different phases of the cell cycle 
The observation that MCF7 cells did not respond well to agents established to 
induce synchrony suggests that the cell cycle process in MCF7 is highly 
deregulated such that it does not respond to signals that would halt cell cycle 
progression under normal circumstances, thereby conferring MCF7 cells a 
proliferative advantage that is important in cancer cells. 
Interestingly, higher levels of SUMO-p53 corresponded with an increase in the 
levels of its downstream proteins such as Mdm2 and p21. This contrasted 
with the results obtained when JFCF-6/T.1R cells were treated with arsenite 
whereby a reduction of SUMO-p53 brought about an increase in its 
downstream proteins (Figure 4-17). p21 is a cyclin-dependent kinase inhibitor 
and is a cell cycle regulator in both G1 and S phase. The increase in the 
expression of p21 in the G1 and S phase synchronized JFCF-6/T.1R cells 
could be reflective of the function of the protein. The low levels of SUMO-p53 
in G2 phase synchronized cells could have enhanced transcriptional activity 
which led to a dramatic increase in Mdm2 levels that is thus reflected in M 
phase synchronized cells. Thus the high levels of Mdm2 observed in M phase 
synchronized cells could be due to a delayed effect of reduced SUMO-p53 
levels in S phase synchronized cells. Alternatively, it is possible that the 
enhanced levels of SUMO-p53 increased the transcriptional activity of p53, 
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leading to higher levels of Mdm2. In this case, this implies that the effects of 
SUMOylation on p53 under stress (in the case of arsenite treatment) differ 
significantly from p53 under other cellular conditions. 
5.4 PML in cancer 
5.4.1 Lysine160 is important for SUMOylation of PML and the 
coiled-coil domain is required for SUMOylation 
As mentioned above, PML is critical for the formation of APBs as it is one of 
the core components. It is unclear if all the components required for the 
formation and maintenance of APBs are identical as that for PML nuclear 
bodies. The SUMOylation of PML is required for the formation of PML nuclear 
bodies and in this study, the question of whether the SUMOylation of PML is 
also required for the formation of APBs is addressed. 
There are three established lysine SUMOylation sites in PML and they are 
located at Lys65, Lys160 and Lys 490. For this study, seven plasmids 
containing mutations of lysine to arginine at these three positions were 
generated singly and in various combinations. Hence there are three plasmids 
encoding a single mutation at each SUMO site, three plasmids encoding 
double mutations with various combinations at two sites and one plasmid 
encoding mutations at all three lysine sites. In addition to these seven 
plasmids, there is another plasmid that encodes the PML protein which lacks 
the coiled-coil domain. The coiled-coil domain in PML is crucial for the 
nucleation process, which is the start of the nuclear bodies formation process. 
The coiled-coil domain is also important for the attachment of the SUMO E2 
conjugating enzyme Ubc9 to PML for SUMOylation of the protein (Hodges et 
  168
al. 1998). It has been shown that in the absence of the coiled-coil domain, 
PML is unable to form PML nuclear bodies (Hodges et al. 1998, Jensen, 
Shiels and Freemont 2001). 
Interestingly, while the SUMO counterparts of both K65R and K490R mutants 
were detected, the SUMO conjugate of the K160R mutant was not detected. 
This suggests K160 to be a critical site for SUMOylation of the PML protein. In 
addition, the K65/160R double mutant displayed a reduction in its 
SUMOylation, implying that the inability of K160R to be SUMOylated affects 
the extent of SUMO modification at K65. The K65/490R double mutant 
continued to show a relatively strong extent of SUMOylation, implying that the 
presence of a functional K160 is sufficient for adequate SUMOylation. It is 
also noted that the K160/490R double mutant is not SUMOylated and this 
suggests that the SUMOylation at K490 is dependent on K160. Thus it 
appears that the ability of K160 to be SUMOylated affects the SUMOylation of 
the other two lysine residues. The absence of any SUMO modified PML 
mutant lacking the coiled-coil domain is consistent with various reports on the 
requirement of the coiled-coil domain in PML for SUMOylation of the protein. 
5.4.2 Transiently transfected PML KR mutants continue to form 
APBs but not the coiled-coil domain deletion mutant 
One of the main objectives of this study is to determine which PML SUMO-
defective mutant does not lead to APBs formation and to further investigate its 
role in the ALT process of telomere maintenance. Hence, after the verification 
of PML mutants that cannot be SUMOylated, the effects of the mutants on the 
formation of APBs were investigated. 
  169
The observation of APBs formation with the KR mutants implies that 
SUMOylation of PML at the three established SUMO lysine sites is not 
required for the formation of APBs. It has also been shown that the PML triple 
KR mutant is able to form PML nuclear bodies (Shen et al. 2006). It is 
conceivable that the triple KR mutant remains able to form APBs because of 
the presence of the SUMO-binding motif. The SUMO binding motif is able to 
bind to all members of the SUMO family. Shen et al. (Shen et al. 2006) 
showed that the deletion of the SUMO binding motif does not lead to the 
formation of PML nuclear bodies. Hence it is highly likely that the presence of 
the SUMO binding motif is able to compensate for the loss of the SUMO 
lysine sites and continue to form APBs. 
It should be noted that APBs are found in only 5-10% of the cells and that 
other PML nuclear bodies that are not APBs were also observed. It is 
interesting to note that TRF2 was easily detectable in the ALT cells but not in 
MCF7. In all three cell lines, PML C/C- did not form any distinct nuclear bodies 
and this agrees with earlier findings (Hodges et al. 1998, Jensen et al. 2001). 
The formation of nuclear bodies in the absence of SUMO modified PML (KR 
mutants) suggests that SUMOylation of PML is not absolutely essential for the 
formation of APBs as long as PML is able to initiate the nucleation process for 
nuclear bodies formation. 
Thus among the SUMO defective PML mutants used in this study, only PML 
C/C- prevents the formation of distinct APBs. Hence, PML C/C- was used in 
subsequent experiments to study how it might affect the ALT pathway through 
the disruption of APBs formation. 
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5.4.3 Transiently over-expression of PML and PML C/C- enhances 
the viability of ALT cells 
As PML was reported to have tumor suppressive effects, its over-expression 
was expected to reduce the viability of cancer cells. It was thus an 
unexpected observation for PML to result in an increase in the viability of the 
ALT cancer cells. It is interesting that 72 hours of over-expression of PML 
C/C- in MCF7 cells led to a slight reduction in its viability. This suggests that a 
longer term of over-expression of PML and PML C/C- might be required for its 
tumor suppressive effects to manifest in MCF7 cells. However, in the ALT 
cells, there appears to be no tumor suppressive functions of transiently over-
expressed PML and PML C/C-. 
5.4.4 Transient over-expression of PML and PML C/C- increases 
the population of ALT cells in G2/M phase of the cell cycle 
The PML and PML C/C- transfected JFCF-6/T.1R cells exhibited an increase 
in the population of cells in G2/M phase of the cell cycle, leading to a 
reduction in the sub-G1 population (Figure 4-32A). This correlates with the 
observation of higher viability of PML and PML C/C- transfected JFCF-6/T.1R 
cells (Figure 4-30). It appears that the arrested cells at the G2/M phase were 
prevented from cell death, and this contributed to the increase in cellular 
viability. Similarly, there was a slight reduction in the proportion of U2OS cells 
in the sub-G1 phase of the cell cycle with a modest increase in the G1 
population (Figure 4-31B). Thus the arrest of cells in a particular phase of the 
cell cycle led to an increase in the viability of cells. The reduction in the sub-
G1 phase of the PML transfected MCF7 cells did not, however, reflect in its 
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enhanced viability. It is plausible that the transient over-expression of PML 
and PML C/C- is insufficient to alter the cell cycle kinetics and hence that of 
viability of MCF7 cells. 
The over-expression of PML and PML C/C- in JFCF-6/T.1R cells for different 
duration led to different changes in cell cycle profiles. The G2/M arrest 
observed at 48 hours was not sustained and reflected at 72 hours. Thus the 
duration of the over-expression of the proteins might be an important 
determinant in the final outcome observed. 
It is interesting to note that the cell cycle profiles of the cells at 48 hours after 
transfection were not maintained at 72 hours. It is conceivable that the effects 
of the over-expressed proteins may have tapered by the time the cells were 
harvested at 72 hours after transfection due to gradual degradation of the 
protein. 
5.4.5 U2OS and MCF7 clones of stably over-expressed PML and 
PML C/C- were generated 
The primary objective of this study is to determine how the over-expression of 
PML and PML C/C- affects the ALT process and one of the key phenotypes 
under investigation is that of telomere length. As mentioned above, 100 to 200 
base pairs are lost from telomeres with each successive round of replication 
(Harley et al. 1990, Shay and Wright 2000). Therefore for any obvious 
changes in telomere length to be observed, long-term cell culture is required. 
Hence stable transfection, which allows long-term over-expression of the 
proteins, was determined to be the best way to proceed. Intriguingly, JFCF-
6/T.1R cells stably over-expressing wild-type PML were not viable. As PML 
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exhibits tumor suppressive activities, it is possible that in the event of its over-
expression in JFCF-6/T.1R cells permanently, its anti-proliferative activities 
prevented the propagation of the cells. As U2OS and MCF7 clones were able 
to grow while over-expressing PML stably, it is probable that the tumor 
suppressive effects of PML do not affect these two cell lines as much as it did 
in JFCF-6/T.1R cells. The implication of this is that U2OS and MCF7 cells are 
probably more tumorigenic in nature than JFCF-6/T.1R cells whereby the cell 
death pathways are more de-regulated and the survival pathways are strongly 
and highly enforced. 
5.4.6 Stably over-expressed PML C/C- does not form APBs in ALT 
cells 
As expected, endogenous APBs are present in ALT cells. Interestingly, not all 
of the PML foci co-localized with TRF2 to form APBs, suggesting the 
presence of non-APBs PML nuclear bodies within ALT cells. In addition, not 
all Sp100 foci co-localize with PML. This implies that the formation of some 
PML foci in ALT cells can occur independently of Sp100. Thus Sp100 is not a 
requirement for the formation of PML nuclear bodies. The observation of 
Sp100 foci in PML C/C- clones suggests that the formation of SP100 into 
distinct foci is independent of the coiled-coil domain of PML and that of the 
PML protein. 
5.4.6.1 Stable over-expression of PML in MCF7 cells leads to APBs 
formation 
PML nuclear bodies were readily detected in MCF7 cells but these nuclear 
bodies did not co-localize with TRF2 to form APBs. Currently, there are no 
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published reports on APBs being formed in telomerase positive cells; hence 
our observation of APBs formation in MCF7 PML clone is a novel finding. It 
would be interesting to explore any changes and differences in the telomere 
length of the MCF7 PML clones. It is tempting to suggest that the observation 
of APBs in MCF7 PML STC10 could be due the onset of an ALT-like pathway 
in these cells. Similar to the observations in the ALT cells, not all the foci of 
over-expressed PML in MCF7 cells co-localized with Sp100, showing that 
Sp100 is not a prerequisite for the formation of PML nuclear bodies. Our 
immunofluorescence data showed that even when PML C/C- is over-
expressed permanently, it does not form distinct nuclear bodies in the cancer 
cell lines. In the ALT cell lines, TRF2 and Sp100 were readily observed as 
distinct foci but in MCF7 cells, the detection of these two proteins was difficult 
and when detected, weak fluorescence was usually obtained. The difficulty in 
the detection of these two protein, particularly that of TRF2, could be a 
characteristic of non-ALT cells. 
5.4.7 Wild-type PML and PML C/C- ALT clones have a slower 
population doubling rate 
A higher population doubling rate means that a longer time is required for the 
cell division, implying that the proliferation rate of a cell has been reduced. 
The increased population doubling rate of the JFCF-6/T.1R C/C- cells indicate 
that the over-expression of PML C/C- slowed down the growth rate of the 
cells. It is particularly fascinating that the U2OS PML clones have much 
slower population doubling rates. This suggests that PML could be exerting its 
tumor suppressive effects, mainly anti-proliferative, in the stably transfected 
U2OS clones. This data further supports the hypothesis that over-expression 
  174
of wild-type PML in JFCF-6/T.1R cells leads to cell death due to its anti-
proliferative effects, resulting in the absence of viable JFCF-6/T.1R PML 
clones. U2OS and JFCF-6/T.1R cells are intrinsically different and U2OS, 
probably being less sensitive to the tumor suppressive effects of PML, 
underwent slow growth instead of cell death. In addition, this experiment 
showed that the anti-proliferative effects of PML in ALT cells manifests when 
over-expressed for a longer period as such effects were not observed with 
transient over-expression of PML in the same cells. 
5.4.7.1 MCF7 PML clones grow faster than PCI Neo clones 
In MCF7 cells, it appears that the tumor suppressive properties of PML did not 
manifest even when over-expressed for a long period. The over-expression of 
PML brought about enhanced proliferation of MCF7 cells, suggesting a 
possibility of over-expressed PML activating a pathway in MCF7 cells that 
may confer upon it with further survival advantage. It appears that wild-type 
PML functions differently when over-expressed in ALT cells and telomerase-
positive MCF7 cells, with ALT cells being more sensitive to the anti-
proliferative effects of PML. 
5.4.8 Wild-type PML inhibits the clonogenicity of U2OS cells 
Our data shows that PML C/C- affects the clonogenicity in U2OS but to a 
lesser extent compared that induced by wild-type PML. The data obtained 
from the colony formation assays correlates with the population doubling rates 
of the U2OS clones. Clones that exhibited a higher population doubling rate, 
in terms of hours per doubling, do not form a high number of colonies and the 
sizes of the colonies formed were smaller. 
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5.4.8.1 Wild-type PML might reduce the clonogenicity of MCF7 cells 
Interestingly, while over-expression of wild-type PML led to a reduction in the 
number of MCF7 colonies formed, the sizes of the colonies formed were not 
affected. The possibility of PML being able to facilitate the formation of 
colonies that are larger in size implies that it is enhancing the growth and 
clonogenicity of cells. As clonogenicity is a hallmark of cancer, PML might be, 
as mentioned above, activating pathways that confer more tumorigenic 
properties onto MCF7 cells. The results of the colony formation assay 
supported the observations of the population doubling assay. 
5.4.9 Higher proportion of cells in sub-G1 and G2/M phase of the 
cell cycle in U2OS PML clones 
Cell cycle profiles imply that the reduced clonogenicity of U2OS PML clones 
(Figure 4-39) could be due to a combination of cells dying and arresting in the 
G2/M phase of the cell cycle. The reduction of cells in the G1 phase of the cell 
cycle indicates that there are lesser cells that could potentially undergo 
cellular synthesis and cells that continue to cycle become stuck in the G2/M 
phase, resulting in a slow population growth. 
Hence wild-type PML is able to exert its tumor suppressive effects in U2OS by 
causing cell death and cell cycle arrest primarily at the G2/M phase of the cell 
cycle. However, the PML C/C- is able to only induce cell cycle arrest and not 
cell death. Thus the coiled-coil domain of PML is essential for full functionality 
of the protein to induce apoptosis. 
In these long-term over-expression studies of PML and PML C/C-, it can be 
seen that the phenotypic tumor suppressive effects of wild-type PML manifest 
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following longer durations of expression in the U2OS ALT cells. This 
conclusion was obtained from comparing the cell proliferation results and cell 
cycle profiles of the cells after transient transfection and stable over-
expression whereby the former exhibited an increased proliferation and no 
changes in cell cycle profile. The stable over-expression of the proteins, 
however, led to observations that brought about similar conclusions regarding 
the functions of the over-expressed proteins. In addition, it appears that JFCF-
6/T.1R cells appear more sensitive than U2OS cells to the over-expression of 
PML and PML C/C-. This can be seen from the transient over-expression of 
PML and PML C/C- in JFCF-6/T.1R cells which led to G2/M arrest, and the 
inability of wild-type PML clones to survive. These suggest that the JFCF-
6/T.1R cells could not survive the anti-tumorigenic effects of stably over-
expressed PML. 
5.4.9.1 S and G2/M phase cells are enhanced in MCF7 PML clones 
Our observations are consistent with the population doubling results, which 
indicate that PML brought about a slight increase in the proliferation of MCF7 
cells. The increment of MCF7 cells stably over-expressing PML in the S 
phase suggests that there is enhanced DNA synthesis occurring. The rise in 
the number of cells in the S phase could have led to a subsequent increase in 
the proportion of cells that enter the G2/M phase of the cell cycle. As APBs 
have been suggested as a storage depot for telomeric DNA and thus a 
location for telomeric recombination, it is likely that the APBs observed in the 
MCF7 PML clones are performing a similar function as that in ALT cells. 
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5.4.10 Wild-type PML increases telomere length slightly while PML 
C/C- reduces telomere length in U2OS cells 
Our observations validated our hypothesis that the introduction of wild-type 
PML can help propagate the ALT pathway through enhancing the formation of 
APBs and that the over-expression of PML C/C- affects ALT via the 
prevention of formation of APBs. It is highly possible that the cell cycle arrest 
induced by wild-type PML prevented it from effectively boosting the ALT 
pathway as ALT occurs through telomeric recombination which takes places 
mainly in the S phase of the cell cycle. With the occurrence of cell cycle arrest 
at G2/M phase, cells that might have undergone telomeric recombination do 
not continue to progress through and complete the cycle, thus resulting in a 
diminished effect of PML on ALT. It is also possible that telomere 
maintenance and elongation in the ALT cells are at its optimal and thus the 
over-expression of wild-type PML did not bring about drastic increase in 
telomere length. The inability of the coiled-coil domain deficient PML to form 
APBs validates APBs to be essential for the propagation of the ALT pathway. 
Thus, the permanent deficiency in APBs formation with the long-term over-
expression of PML C/C- led to telomere shortening. However, as such 
telomere shortening is progressive as it is observed only after several rounds 
of telomere shortening (whereby 100-200 base pairs are lost with each 
successive round of replication), transient over-expression of PML C/C- 
probably does not result in immediate degeneration of the ALT pathway. It 
also remains possible that endogenous PML, which remains able to form 
APBs, continue to sustain the ALT pathway although its support towards the 
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pathway could be reduced or affected by the stable over-expression of PML 
C/C-. 
5.4.10.1 MCF7 PML and PML C/C- clones exhibit ALT-like telomere 
phenotype 
Surprisingly, the telomere length of the MCF7 PML STC10 clone was 
significantly longer than that of the PCI Neo clone. It appears that there was 
rapid telomere elongation in this PML clone with a concurrent loss of basal 
telomeres. It is also conceivable that the telomeres in MCF7 PML C/C- clones 
have undergone rapid elongation. However the elongation in the PML C/C- 
STC22 appears to be progressive and increases with further passaging of the 
cells. Interestingly, there is preservation of basal length telomeres with on-
going rapid telomere elongation. Such rapid elongation of telomere length in 
both MCF7 PML and PML C/C- clones are reminiscent of the telomere length 
phenotype observed in ALT cells even though the mean length of the 
elongated telomeres in MCF7 PML and PML C/C- clones are not as long as 
that seen in the U2OS cells. 
The observations of ALT-like telomeres in MCF7 PML and PML C/C- clones 
suggest the occurrence of an on-going alternative pathway of telomere 
maintenance in these clones. While telomerase can lengthen telomeres 
gradually and progressively with each round of DNA replication, it cannot 
account for the rapid increment (in terms of kilobases) in telomere length. 
Besides, telomerase generally acts to maintain rather than to elongate 
telomeres. In addition, as APBs were detected in MCF7 PML clones (Figure 
4-37), it is probable that the ALT pathway has been activated in telomerase-
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positive MCF7 with the stable over-expression of PML. As basal lengths of 
telomeres were detected in the PML C/C- STC22 clone, it is possible that 
rapid telomere elongation by ALT and telomerase mediated telomere 
maintenance are on going concurrently. In this clone, it is possible that 
telomerase is maintaining telomeres at the basal length while ALT is activated 
for rapid telomere elongation. Such phenomenon has also been observed in 
hybrids of telomerase positive and ALT cells (Bryan and Reddel 1997, 
Grobelny, Kulp-McEliece and Broccoli 2001). 
The probable activation of the ALT pathway in the MCF7 PML clone could 
account for the faster population doubling rate of the cells (Figure 4-38). As 
ALT is usually found in more advanced tumors, the activation of ALT in MCF7 
PML clones could further advance the proliferation of the cells. Additionally, 
the increased proportion of MCF7 cells stably over-expressing PML in the S 
phase of the cell cycle (Figure 4-41) could be an indicator for an increase in 
DNA replication, probably that of telomeric recombination and synthesis. The 
occurrence of ALT in PML C/C- could probably co-exist with telomerase 
activation to simultaneously elongate and maintain telomeres. It is possible 
that the lack of the coiled-coil domain in PML prevented a complete 
inducement of the ALT pathway as the main mechanism for telomeric 
maintenance, possibly due to the lack of APBs formation. This suggests that 
while APBs might not be absolutely critical for the ALT pathway, but its 
presence and function could ensure the complete dominance of the pathway. 
Once again, the telomere phenotypes displayed with stable over-expression 
of wild-type PML and PML C/C- were distinct between the ALT and MCF7 
cells. The over-expression of wild-type PML increased telomere length slightly 
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in U2OS cells while PML C/C- reduced telomere length. Over-expression of 
the same proteins in MCF7 cells led to a dramatic increase in telomere length. 
Thus in cell lines utilizing different telomere maintenance mechanisms, the 
over-expression of PML and PML C/C- differs to probably allow for the 
mechanisms that best enhance cell survival to dominate. 
5.4.11 Telomere lengthening and accumulation of MCF7 clones 
exhibiting ALT-like telomere phenotype 
As revealed by QFISH, there was an accumulation of long telomeres in MCF7 
PML STC10 and PML C/C- STC22 clones suggesting that the lengths of 
telomeres in these two clones are higher than that in the MCF7 PCI Neo 
clone. The histogram for the PML STC10 clone showed that the frequency of 
short telomeres has reduced while that for the longer telomeres has 
increased. However, the frequency of elongated telomeres did not reflect its 
detection according to southern blot analysis. This is possible due to the 
presence of a wide heterogeneous population of long telomeres in the MCF7 
PML STC10 clone, whereby very short and long telomeres could be 
observed. It is possible that the southern blot analysis is not sensitive enough 
to detect the presence of very short telomeres in the MCF7 PML STC10 
clone. Besides, indicating an increase in the frequency of longer telomeres, 
the histogram for the PML C/C- STC22 clone also showed the continued 
occurrence of the shorter telomeres. This is consistent with the southern blot 
analysis data (Figure 4-43) which demonstrated the presence of basal length 
telomeres as well as rapidly elongated telomeres. The histogram is also 
consistent with the observation of a gradual increment of telomere lengths in 
the MCF7 PML C/C- STC22 clone. 
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5.4.12 MCF7 PML STC10 clone has a much lower telomerase 
activity 
Telomerase activity was measured to determine if it contributes to the 
dramatic increase in telomere length. Telomerase activity was found to be 
greatly reduced in the MCF7 PML STC10 clone, and thus it could not account 
for the amplified telomere length observed (Figure 4-43). This further validates 
the activation of another pathway of telomere maintenance, probably that of 
the ALT pathway. It is possible that the over-expression of PML led to the 
activation of ALT in MCF7 cells, and this suppressed telomerase activity so as 
to allow for ALT dominance in telomere maintenance. In the MCF7 PML STC7 
clone, wherein no APBs and heterogeneous telomere length was observed, 
the increase in telomerase activity could be in response to the over-
expression of PML. The impressive augmentation of telomerase activity in this 
clone could have resulted in the prevention and suppression of ALT activity. 
The dominance of one telomere maintenance pathway over the other has 
been well documented in telomerase and ALT cell hybrids (Cerone, Londono-
Vallejo and Bacchetti 2001). Hence it is conceivable that in the MCF7 PML 
STC7 clone, up-regulation of telomerase in response to the over-expression 
of PML resulted in telomerase exerting its dominance. However, in the MCF7 
PML STC10 clone, the over-expression of PML allowed for the activation and 
assertion of the ALT pathway over telomerase. 
In the MCF7 PML C/C-clone, it appears that there is activation of both ALT 
and telomerase to bring about telomere elongation and maintenance. Indeed, 
the telomerase activity of PML C/C- clones was increased to a great extent 
and such an increase could be a result of competition with the ALT pathway 
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induced. Hence while the PML C/C- mutant could not establish ALT to be the 
dominant pathway of telomere maintenance, it allowed the co-existence of 
both pathways to maintain telomeres as observed in some TERT over-
expression studies in ALT cells (Ford et al. 2001, Perrem et al. 2001). 
However, it remains a possibility for one pathway to exert dominance over the 
other eventually. 
5.4.13 MCF7 clones displaying ALT-like phenotypes are more 
sensitive to doxorubicin 
From these cell viability assays, it can be concluded that doxorubicin is a 
better chemotherapeutic drug of choice than tamoxifen for the cell types used 
in this study. In U2OS cells, the over-expression of PML C/C- resulted a slight 
reduction in cellular viability upon treatment with doxorubicin. It is likely that 
the over-expression of PML C/C- in ALT cells disrupts the ALT pathway and 
this in turn affects the viability of ALT cells. Thus, the ability of PML C/C- to 
negatively affect cell viability suggests that targeting the ALT pathway could 
be an effective means in cancer therapy. The occurrence of the ALT pathway 
only in ALT cancer cells renders the targeting of the pathway highly specific. 
Interestingly, tamoxifen does not appear to affect the viability of the MCF7 
PML C/C- clones. In the MCF7 clones that display a distinct ALT-like telomere 
phenotype, there appears to be an enhanced sensitivity to doxorubicin. The 
possibility that the occurrence of an ALT-like phenotype in MCF7 renders 
them more sensitive to doxorubicin cannot be ruled out. It is also fascinating 
to note that the presence of long telomeres with high telomerase activity 
(MCF7 PML C/C- STC22 clone) renders the cells more sensitive to 
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doxorubicin than the occurrence of long telomeres alone (MCF7 PML STC10 
clone). It is tempting to speculate that a long telomere phenotype renders the 
cells more susceptible to doxorubicin while long telomeres combined with high 
telomerase activity enhance such susceptibility further. It is also conceivable 
that the inability of PML C/C- to form APBs is a contributing factor in the 
enhanced sensitivity of the cells to doxorubicin. 
This experiment shows that the sensitivity of the ALT cells towards 
doxorubicin is affected with interference to the ALT pathway, and this could be 
due to the disruption of APBs. In such a case, APBs could possibly have a 
protective role in ALT cells. In addition, telomerase-positive cells, which 
exhibit an ALT-like phenotype, varied in their responses towards 
chemotherapeutic drugs and such responses are seemingly dependent on the 
degree of telomerase activity in the cells. 
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6 CHAPTER 6   CONCLUSION 
Tumor suppressor protein p53 can be modified post-translationally by both 
SUMO and ubiquitin. The type of post-translation modification appears to be 
cell-type dependent. We have shown that p53 is predominantly SUMO-
modified in JFCF-6/T.1R, an ALT cell line, while it is ubiquitinated in MCF7 
cells. Components involved in the SUMO process can affect the stability of 
proteins. PIAS and SUMO-1 does affect the stability of both endogenous and 
exogenous p53, and also enhance the SUMO modification of p53. PIAS and 
SUMO-1 are specific towards SUMO processes and do not affect other similar 
forms of post-translational modifications such as ubiquitination. Over-
expressed p53 in cancer cell lines exerts tumor suppressive effects such as 
cell cycle arrest and cell death but such effects appear to be greatly controlled 
and limited by post-translational modifications. 
Oxidative stress affects SUMO modifications. In this study, we have shown 
that arsenite, a known inducer of oxidative stress, affects SUMOylation in ALT 
cells and not in telomerase positive cells. The corresponding reduction of 
SUMO-p53 in ALT cells resulted in transcriptional activation of p53. Thus, 
under conditions of stress, de-SUMOylation of p53 leads to its functional 
activation. However, under physiological conditions, the SUMO modification of 
p53 resulted in its transcriptional activation. Therefore, the cellular conditions 
appear to be critical in determining the activities of SUMO-p53. 
There are three lysine sites available for SUMOylation in the PML protein. The 
lysine at position 160 appears to be a critical site for complete SUMO 
modification of the PML protein. However, SUMO modification of the PML 
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protein is not critical for the formation of APBs in ALT cells. Rather, the coiled-
coil domain is required for the formation of APBs, even though the coiled-coil 
domain deficient PML cannot be modified by SUMO. The inability of the PML 
C/C- mutant to form APBs is maintained when over-expressed stably. 
PML exerts some anti-tumorigenic activities. However, such functions were 
not distinctly reflected with its transient over-expression. When over-
expressed stably in ALT cells, PML brought about a slower rate of population 
doubling. While the stable over-expression of PML C/C- also resulted in a 
slower population doubling rate of the ALT cells, the extent of slow growth 
was not as dramatic as that brought about by PML stable over-expression. 
There are no endogenous APBs detected in MCF7 cells as it is telomerase-
positive cell-line and does not present other known pathways of telomere 
maintenance. Interestingly, stable over-expression of PML led to observations 
of APBs in MCF7 cells. In MCF7 cells, PML does not exert its tumor 
suppressive activities. Instead, stably over-expressed PML led to a slightly 
enhanced rate of population doubling. 
There was a slight telomere lengthening in U2OS cells with the stable over-
expression of PML and a slight telomere shortening following stable over-
expression of PML C/C-. Over-expression of PML in MCF7 cells resulted in an 
impressive increase in telomere length. The stable over-expression of PML 
C/C- in MCF7 cells also enhanced telomere length with maintenance of basal 
telomere lengths. Telomerase activity was reduced with stable over-
expression of PML and increased with that of PML C/C-. Thus the display of 
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ALT-like morphological hallmarks in MCF7 cells suggests a switch in its 
telomere maintenance mechanism. 
Both U2OS and MCF7 cells are more sensitive towards doxorubicin than to 
tamoxifen. The stable over-expression of PML C/C- in U2OS cells might 
contribute to the enhanced sensitivity to doxorubicin via its disruption of the 
APBs. The MCF7 cells that displayed ALT-like phenotypes are more 
susceptible to doxorubicin. Levels of telomerase activity and the ability for 
APBs formation could be factors that contribute to sensitivity to doxorubicin. 
Thus, in this study, it is shown, for the first time, that the over-expression of 
PML and PML C/C- in telomerase positive cells can culminate in the 
occurrence of ALT-like phenotypes in these cells. This expands the current 




7 CHAPTER 7   Future Directions 
The over-expression of PML in telomerase positive MCF7 cells leading to 
ALT-like phenotypes suggests that the ALT mechanism is dormant and can 
be activated in non-ALT cells. To validate if ALT can indeed be activated in 
telomerase positive cells by the over-expression of PML, more telomerase 
positive cell-lines should be used. As it is possible that very low levels of 
telomeric exchanges may be present in normal cells, it is worthwhile to over-
express PML in normal cells to check if such an over-expression increases 
the rate of telomeric exchange, ultimately leading to elongated telomeres. 
To elucidate the mechanism of how PML induces ALT-like phenotypes in 
telomerase positive cells, studies on more clones stably expressing PML will 
be required. The use of more PML mutants, in addition to the PML C/C- 
mutant, will be helpful in determining the required domains for the activation of 
ALT and the telomere phenotypes generated by various mutants. Extensive 
interaction studies will have to be done to determine the main molecular 
players. Interaction studies of PML and its mutants with telomere associated 
proteins, such as TRF1 and TRF2, and known components of APBs are likely 
to shed light on how different PML mutants interact differently to bring about 
distinct ALT-like phenotype. 
Endogenous PML in telomerase positive cells could have a role in 
determining the consequences of over-expressed PML and PML mutants. A 
screen for the type of endogenous PML isoform and any mutations it might 
encode will be useful in ascertaining the type of isoform and mutations that 
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could predispose the cell to the activation of ALT with the over-expression of 
PML. 
Understanding the means of ALT activation in telomerase positive cells will 
contribute significantly to the current knowledge of ALT activation and 
mechanism. In addition, the elucidation of how telomerase positive cells can 
activate ALT will be important and helpful in the understanding of the 
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